<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="1188"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="731" label="Small molecule therapeutic"/><FilterOption id="585" count="579" label="Oral formulation"/><FilterOption id="648" count="466" label="Intravenous formulation"/><FilterOption id="761" count="432" label="Biological therapeutic"/><FilterOption id="595" count="407" label="Tablet formulation"/><FilterOption id="740" count="390" label="Infusion"/><FilterOption id="586" count="281" label="Capsule formulation"/><FilterOption id="751" count="271" label="Film coating"/><FilterOption id="746" count="266" label="Solution"/><FilterOption id="573" count="248" label="Immunoglobulin-G"/><FilterOption id="898" count="232" label="Formulation powder"/><FilterOption id="750" count="199" label="Freeze drying"/><FilterOption id="647" count="191" label="Subcutaneous formulation"/><FilterOption id="85" count="182" label="Protein recombinant"/><FilterOption id="169" count="166" label="Monoclonal antibody humanized"/><FilterOption id="1263" count="131" label="Immuno-oncology"/><FilterOption id="1652" count="95" label="Prodrug"/><FilterOption id="1647" count="87" label="Natural product"/><FilterOption id="594" count="84" label="Oral suspension formulation"/><FilterOption id="593" count="82" label="Oral liquid formulation"/><FilterOption id="168" count="81" label="Monoclonal antibody human"/><FilterOption id="80" count="70" label="Peptide"/><FilterOption id="175" count="68" label="Drug combination"/><FilterOption id="766" count="56" label="Parenteral formulation unspecified"/><FilterOption id="805" count="50" label="Daily dosing"/><FilterOption id="166" count="47" label="Chimeric monoclonal antibody"/><FilterOption id="902" count="47" label="Orally disintegrating tablet"/><FilterOption id="589" count="45" label="Sustained release formulation"/><FilterOption id="745" count="44" label="Suspension"/><FilterOption id="651" count="43" label="Intramuscular formulation"/><FilterOption id="180" count="41" label="Antibody fragment"/><FilterOption id="743" count="38" label="Granule"/><FilterOption id="630" count="34" label="Stereochemistry"/><FilterOption id="667" count="33" label="Peptidomimetic"/><FilterOption id="894" count="30" label="Liquid formulation"/><FilterOption id="596" count="29" label="Injectable formulation"/><FilterOption id="701" count="26" label="Nucleoside synthesis"/><FilterOption id="66" count="25" label="Antibiotic"/><FilterOption id="171" count="25" label="Monoclonal antibody conjugated"/><FilterOption id="603" count="25" label="Systemic formulation unspecified"/><FilterOption id="680" count="23" label="Buccal formulation systemic"/><FilterOption id="660" count="23" label="Oral sustained release formulation"/><FilterOption id="742" count="23" label="Pellet"/><FilterOption id="852" count="22" label="Intravesical formulation"/><FilterOption id="1646" count="21" label="Injectable controlled release formulation"/><FilterOption id="348" count="20" label="PEGylated formulation"/><FilterOption id="599" count="19" label="Nanoparticle formulation injectable"/><FilterOption id="84" count="19" label="Protein fusion"/><FilterOption id="90" count="19" label="Steroid"/><FilterOption id="641" count="18" label="Controlled release formulation"/><FilterOption id="74" count="18" label="Glycoprotein"/><FilterOption id="102" count="18" label="Nucleotide and derivatives"/><FilterOption id="127" count="17" label="Cell culture"/><FilterOption id="128" count="16" label="Cell culture technique"/><FilterOption id="723" count="16" label="Drug coating"/><FilterOption id="112" count="15" label="DNA technology"/><FilterOption id="598" count="15" label="Liposome formulation injectable"/><FilterOption id="649" count="14" label="Intraperitoneal formulation"/><FilterOption id="207" count="14" label="Protein conjugated"/><FilterOption id="1164" count="12" label="Antibody drug conjugate"/><FilterOption id="616" count="12" label="Inhalant formulation"/><FilterOption id="611" count="10" label="Dermatological formulation"/><FilterOption id="756" count="10" label="Pharmaceutical carrier"/><FilterOption id="851" count="9" label="Intradermal formulation"/><FilterOption id="569" count="9" label="Oligonucleotide antisense"/><FilterOption id="620" count="9" label="Ophthalmic formulation"/><FilterOption id="776" count="9" label="Oral gel formulation"/><FilterOption id="349" count="8" label="Lipid"/><FilterOption id="753" count="8" label="Microparticle formulation"/><FilterOption id="103" count="8" label="Oligonucleotide"/><FilterOption id="208" count="8" label="Protein conjugation"/><FilterOption id="558" count="8" label="Transdermal formulation"/><FilterOption id="654" count="7" label="Intrathecal formulation"/><FilterOption id="267" count="7" label="Multivalent antibody"/><FilterOption id="662" count="7" label="Quick release formulation"/><FilterOption id="537" count="6" label="Chimeric antibody"/><FilterOption id="1669" count="6" label="Emulsion formulation"/><FilterOption id="731" count="6" label="Imaging"/><FilterOption id="51" count="6" label="Monoclonal antibody"/><FilterOption id="159" count="6" label="Oligosaccharide"/><FilterOption id="617" count="5" label="Aerosol formulation inhalant"/><FilterOption id="857" count="5" label="Allogenic stem cell therapy"/><FilterOption id="612" count="5" label="Emulsion dermatological"/><FilterOption id="652" count="5" label="Intra-articular formulation"/><FilterOption id="347" count="5" label="Intratumoral formulation"/><FilterOption id="764" count="5" label="Local formulation unspecified"/><FilterOption id="236" count="5" label="Macrolide"/><FilterOption id="167" count="5" label="Monoclonal antibody murine"/><FilterOption id="559" count="5" label="Oral controlled release formulation"/><FilterOption id="661" count="5" label="Oral quick release formulation"/><FilterOption id="135" count="5" label="T-lymphocyte"/><FilterOption id="62" count="5" label="Virus recombinant"/><FilterOption id="878" count="4" label="Adipose stem cell therapy"/><FilterOption id="216" count="4" label="Antibody conjugated"/><FilterOption id="582" count="4" label="Antibody polyclonal"/><FilterOption id="570" count="4" label="Cell therapy"/><FilterOption id="1247" count="4" label="Chimeric antigen receptor T cell therapy"/><FilterOption id="590" count="4" label="Enteric coated formulation"/><FilterOption id="864" count="4" label="Mesenchymal stem cell therapy"/><FilterOption id="170" count="4" label="Multivalent monoclonal antibody"/></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="159" count="51" label="HIV-1 infection"/><FilterOption id="1828" count="47" label="Multiple myeloma"/><FilterOption id="2399" count="45" label="Adenocarcinoma"/><FilterOption id="3657" count="42" label="Metastatic breast cancer"/><FilterOption id="158" count="39" label="HIV infection"/><FilterOption id="3665" count="36" label="Metastatic non small cell lung cancer"/><FilterOption id="1069" count="34" label="Metastasis"/><FilterOption id="1731" count="28" label="Acute myelogenous leukemia"/><FilterOption id="49" count="28" label="Breast tumor"/><FilterOption id="3257" count="26" label="Stage IV melanoma"/><FilterOption id="3246" count="23" label="Hormone refractory prostate cancer"/><FilterOption id="1771" count="22" label="Transitional cell carcinoma"/><FilterOption id="307" count="21" label="Squamous cell carcinoma"/><FilterOption id="3713" count="20" label="Advanced solid tumor"/><FilterOption id="1734" count="19" label="Chronic lymphocytic leukemia"/><FilterOption id="4250" count="19" label="Metastatic renal cell carcinoma"/><FilterOption id="255" count="19" label="Parkinsons disease"/><FilterOption id="1749" count="18" label="Diffuse large B-cell lymphoma"/><FilterOption id="3658" count="18" label="Metastatic colorectal cancer"/><FilterOption id="14" count="17" label="Alzheimers disease"/><FilterOption id="70" count="17" label="Liver cirrhosis"/><FilterOption id="1542" count="16" label="Atrial fibrillation"/><FilterOption id="3510" count="16" label="Pulmonary artery hypertension"/><FilterOption id="337" count="16" label="Ulcerative colitis"/><FilterOption id="80" count="15" label="Coronary artery disease"/><FilterOption id="84" count="15" label="Crohns disease"/><FilterOption id="1745" count="15" label="Follicle center lymphoma"/><FilterOption id="1272" count="15" label="Myelodysplastic syndrome"/><FilterOption id="224" count="15" label="Myocardial infarction"/><FilterOption id="153" count="14" label="Hepatitis C virus infection"/><FilterOption id="1767" count="13" label="Hepatocellular carcinoma"/><FilterOption id="55" count="12" label="Cardiac failure"/><FilterOption id="1185" count="12" label="Chronic obstructive pulmonary disease"/><FilterOption id="836" count="12" label="Insulin dependent diabetes"/><FilterOption id="319" count="12" label="Non-Hodgkin lymphoma"/><FilterOption id="3256" count="12" label="Stage III melanoma"/><FilterOption id="2243" count="11" label="Fallopian tube cancer"/><FilterOption id="799" count="11" label="Ovary tumor"/><FilterOption id="3083" count="11" label="Peritoneal tumor"/><FilterOption id="17" count="10" label="Anemia"/><FilterOption id="552" count="10" label="Bleeding"/><FilterOption id="3676" count="10" label="Ischemic stroke"/><FilterOption id="3666" count="10" label="Metastatic stomach cancer"/><FilterOption id="20" count="10" label="Pain"/><FilterOption id="1867" count="10" label="Pulmonary hypertension"/><FilterOption id="1728" count="9" label="Acute lymphoblastic leukemia"/><FilterOption id="2454" count="9" label="Glioblastoma"/><FilterOption id="3466" count="9" label="Metastatic bladder cancer"/><FilterOption id="3667" count="9" label="Metastatic esophageal cancer"/><FilterOption id="3866" count="9" label="Metastatic ovary cancer"/><FilterOption id="3669" count="9" label="Metastatic pancreas cancer"/><FilterOption id="3664" count="9" label="Metastatic prostate cancer"/><FilterOption id="213" count="9" label="Multiple sclerosis"/><FilterOption id="2637" count="9" label="Non-alcoholic steatohepatitis"/><FilterOption id="837" count="9" label="Non-insulin dependent diabetes"/><FilterOption id="316" count="8" label="B-cell lymphoma"/><FilterOption id="1765" count="8" label="Cholangiocarcinoma"/><FilterOption id="3771" count="8" label="Idiopathic pulmonary fibrosis"/><FilterOption id="3673" count="8" label="Metastatic head and neck cancer"/><FilterOption id="318" count="8" label="Systemic lupus erythematosus"/><FilterOption id="427" count="8" label="Uterine cervix tumor"/><FilterOption id="23" count="7" label="Angina"/><FilterOption id="31" count="7" label="Asthma"/><FilterOption id="152" count="7" label="Hepatitis B virus infection"/><FilterOption id="161" count="7" label="Hodgkins disease"/><FilterOption id="2989" count="7" label="Kidney transplant rejection"/><FilterOption id="203" count="7" label="Lymphoma"/><FilterOption id="3239" count="7" label="Portal hypertension"/><FilterOption id="1995" count="7" label="Primary biliary cholangitis"/><FilterOption id="299" count="7" label="Schizophrenia"/><FilterOption id="3859" count="6" label="Abdominal aortic aneurysm"/><FilterOption id="3258" count="6" label="Acute coronary syndrome"/><FilterOption id="760" count="6" label="Brain tumor"/><FilterOption id="1735" count="6" label="Chronic myelocytic leukemia"/><FilterOption id="1705" count="6" label="Endometrioid carcinoma"/><FilterOption id="205" count="6" label="Melanoma"/><FilterOption id="1262" count="6" label="Non-small-cell lung cancer"/><FilterOption id="245" count="6" label="Osteoarthritis"/><FilterOption id="291" count="6" label="Rheumatoid arthritis"/><FilterOption id="1261" count="6" label="Small-cell lung cancer"/><FilterOption id="3678" count="6" label="Urethral cancer"/><FilterOption id="3492" count="5" label="AL amyloidosis"/><FilterOption id="1729" count="5" label="B-cell acute lymphoblastic leukemia"/><FilterOption id="3919" count="5" label="Chronic liver failure"/><FilterOption id="89" count="5" label="Cytomegalovirus infection"/><FilterOption id="2212" count="5" label="Hepatorenal syndrome"/><FilterOption id="2318" count="5" label="Liver fibrosis"/><FilterOption id="2273" count="5" label="Oligodendroglioma"/><FilterOption id="330" count="5" label="Restenosis"/><FilterOption id="3395" count="4" label="Acute liver failure"/><FilterOption id="29" count="4" label="Aspergillus infection"/><FilterOption id="1102" count="4" label="Atopic dermatitis"/><FilterOption id="2380" count="4" label="Bladder cancer"/><FilterOption id="2432" count="4" label="Bronchiectasis"/><FilterOption id="1308" count="4" label="Candida infection"/><FilterOption id="616" count="4" label="Graft versus host disease"/><FilterOption id="178" count="4" label="Hypertension"/><FilterOption id="3198" count="4" label="Larynx tumor"/><FilterOption id="2983" count="4" label="Liver transplantation"/><FilterOption id="3235" count="4" label="Merkel cell carcinoma"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="9247" count="49" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="9218" count="47" label="HIV infection - Assessment of Immune Response"/><FilterOption id="7879" count="45" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="7908" count="41" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7538" count="41" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="8712" count="40" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9215" count="40" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="9213" count="40" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="8078" count="39" label="Leukemia - Assessment of adverse events"/><FilterOption id="8719" count="37" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7547" count="37" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8489" count="36" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8713" count="34" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8481" count="32" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7563" count="32" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7569" count="32" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7354" count="32" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="8721" count="30" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8998" count="30" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8077" count="30" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="7360" count="30" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7367" count="29" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="42921" count="29" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="7680" count="28" label="Lymphoma - Assessment of adverse events"/><FilterOption id="7611" count="27" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="7679" count="26" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="6919" count="26" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="8720" count="25" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8738" count="25" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="9246" count="25" label="HIV infection - Assessment of Safety and Tolerability"/><FilterOption id="9212" count="25" label="HIV infection - Assessment of Viral Load"/><FilterOption id="7909" count="25" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7898" count="24" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="9242" count="23" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="8505" count="23" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="9153" count="23" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7027" count="23" label="Melanoma - Assessment of adverse events"/><FilterOption id="7489" count="23" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"/><FilterOption id="8722" count="22" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="8109" count="22" label="Leukemia - Assessment of Mortality/Death Rates"/><FilterOption id="7373" count="22" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8996" count="21" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="7907" count="21" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8140" count="21" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="8639" count="21" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="6924" count="21" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6940" count="21" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="7372" count="21" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="9238" count="20" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="7558" count="20" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7488" count="20" label="Multiple myeloma - Assessment of Safety and Tolerability"/><FilterOption id="11717" count="19" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="8640" count="19" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7564" count="19" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7049" count="19" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="10540" count="19" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"/><FilterOption id="8725" count="18" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="2622" count="18" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="7393" count="18" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="43670" count="18" label="Other gastrointestinal disease - Assessment of adverse events"/><FilterOption id="7045" count="18" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="10545" count="18" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8714" count="17" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="8744" count="17" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="8754" count="17" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="7916" count="17" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="9415" count="17" label="Lymphoma - Assessment of Disease Progression"/><FilterOption id="2492" count="16" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="9272" count="16" label="HIV infection - Assessment of Mortality/Death Rates"/><FilterOption id="9255" count="16" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="8147" count="16" label="Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease"/><FilterOption id="7395" count="16" label="Multiple myeloma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="43526" count="16" label="Other gastrointestinal disease - Clinical Assessments"/><FilterOption id="25660" count="16" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"/><FilterOption id="11728" count="15" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8430" count="15" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="2703" count="15" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="7921" count="15" label="Leukemia - Assessment of Disease Relapse/Recurrence"/><FilterOption id="7891" count="15" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9300" count="15" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="43393" count="15" label="Other gastrointestinal disease - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="10828" count="15" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="15212" count="15" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="11722" count="14" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11773" count="14" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8999" count="14" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8759" count="14" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8163" count="14" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="2621" count="14" label="Coronary artery disease - Assessment of Mortality/Death Rates"/><FilterOption id="7394" count="14" label="Multiple myeloma - Assessment of Disease Progression"/><FilterOption id="25708" count="14" label="Pulmonary artery hypertension - Assessment of Safety and Tolerability - Assessment of adverse effects"/><FilterOption id="15287" count="14" label="Solid tumor - Assessment of adverse events"/><FilterOption id="2410" count="13" label="Alzheimers disease - Assessment of Safety and Tolerability"/><FilterOption id="17356" count="13" label="Anemia - Assessment of adverse events"/><FilterOption id="11735" count="13" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="2619" count="13" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"/><FilterOption id="6863" count="13" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="9197" count="13" label="HIV infection - Assessment of virological response - Assessment of virological failure"/><FilterOption id="9195" count="13" label="HIV infection - Assessment of virological response"/><FilterOption id="7906" count="13" label="Leukemia - Assessment of Response Rates (RR)"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="10"><FilterOption id="L" count="716" label="Launched"/><FilterOption id="C3" count="109" label="Phase 3 Clinical"/><FilterOption id="C2" count="100" label="Phase 2 Clinical"/><FilterOption id="DX" count="60" label="Discontinued"/><FilterOption id="R" count="19" label="Registered"/><FilterOption id="NDR" count="15" label="No Development Reported"/><FilterOption id="C1" count="15" label="Phase 1 Clinical"/><FilterOption id="PR" count="11" label="Pre-registration"/><FilterOption id="DR" count="6" label="Discovery"/><FilterOption id="W" count="4" label="Withdrawn"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="1039423" count="109" label="Hospital Clinic of Barcelona"/><FilterOption id="19446" count="82" label="Roche Holding AG"/><FilterOption id="26178" count="67" label="F Hoffmann-La Roche AG"/><FilterOption id="18767" count="58" label="Pfizer Inc"/><FilterOption id="1038736" count="42" label="PETHEMA Foundation"/><FilterOption id="16450" count="34" label="Gilead Sciences Inc"/><FilterOption id="15331" count="31" label="Celgene Corp"/><FilterOption id="14881" count="28" label="Boehringer Ingelheim International GmbH"/><FilterOption id="15414" count="20" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1067538" count="18" label="Janssen Research &amp; Development LLC"/><FilterOption id="19453" count="16" label="Genentech Inc"/><FilterOption id="1059823" count="16" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="1053612" count="15" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="1091809" count="15" label="Janssen-Cilag International NV (BE)"/><FilterOption id="1042061" count="15" label="Spanish Breast Cancer Research Group"/><FilterOption id="23780" count="14" label="Actelion Ltd"/><FilterOption id="27847" count="14" label="Boston Scientific Corp"/><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="1042371" count="12" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="22546" count="11" label="Boehringer Ingelheim GmbH"/><FilterOption id="14455" count="10" label="Bayer AG"/><FilterOption id="1017513" count="10" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="28611" count="9" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="15065" count="9" label="Bristol-Myers Squibb Co"/><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="1020322" count="8" label="Daiichi Sankyo Inc"/><FilterOption id="1052299" count="8" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="21991" count="8" label="Takeda Oncology"/><FilterOption id="22554" count="7" label="Boehringer Ingelheim BV"/><FilterOption id="22586" count="7" label="Boehringer Ingelheim Corp"/><FilterOption id="1103352" count="7" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="22563" count="7" label="Boehringer Ingelheim Ltd"/><FilterOption id="17810" count="7" label="Eli Lilly &amp; Co"/><FilterOption id="1051470" count="7" label="Fundacio Clinic Per A La Recerca Biomedica"/><FilterOption id="1039086" count="7" label="Germans Trias i Pujol Hospital"/><FilterOption id="1122528" count="7" label="SCS Boehringer Ingelheim Comm.V"/><FilterOption id="1009440" count="6" label="Intercept Pharmaceuticals Inc"/><FilterOption id="17259" count="6" label="Ipsen"/><FilterOption id="19063" count="6" label="Pharmacyclics Inc"/><FilterOption id="1045513" count="6" label="Spanish Lung Cancer Group"/><FilterOption id="22598" count="6" label="Unilfarma Lda"/><FilterOption id="1013295" count="5" label="Astellas Pharma Inc"/><FilterOption id="22549" count="5" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="22556" count="5" label="Boehringer Ingelheim France SARL"/><FilterOption id="1042252" count="5" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="1003065" count="5" label="Hospital Vall D'Hebron"/><FilterOption id="1090417" count="5" label="Roche Singapore Pte Ltd"/><FilterOption id="25439" count="5" label="United Therapeutics Corp"/><FilterOption id="13601" count="4" label="Abbott Laboratories"/><FilterOption id="1063251" count="4" label="BeiGene Co Ltd"/><FilterOption id="1005244" count="4" label="Biogen Inc"/><FilterOption id="31522" count="4" label="BIOTRONIK SE &amp; Co"/><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"/><FilterOption id="22560" count="4" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="1056497" count="4" label="CETLAM Group"/><FilterOption id="1035512" count="4" label="EMD Serono Inc"/><FilterOption id="1046331" count="4" label="Fundacion SEIMC-GESIDA"/><FilterOption id="1040940" count="4" label="Hospital Universitari de Bellvitge"/><FilterOption id="1017771" count="4" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="17437" count="4" label="Johnson &amp; Johnson Sdn Bhd"/><FilterOption id="1091820" count="4" label="Roche China Co Ltd"/><FilterOption id="24652" count="4" label="Shire plc"/><FilterOption id="1073757" count="4" label="Spanish Society of Cardiology"/><FilterOption id="1076372" count="4" label="Stryker Neurovascular"/><FilterOption id="29151" count="4" label="Universitair Medisch Centrum Utrecht"/><FilterOption id="14109" count="3" label="Amgen Inc"/><FilterOption id="24968" count="3" label="Arena Pharmaceuticals Inc"/><FilterOption id="14296" count="3" label="ARIAD Pharmaceuticals Inc"/><FilterOption id="1148005" count="3" label="BeiGene USA, Inc"/><FilterOption id="22545" count="3" label="Boehringer Ingelheim AB"/><FilterOption id="22555" count="3" label="Boehringer Ingelheim Ellas AE"/><FilterOption id="1067616" count="3" label="Clinica Universidad de Navarra"/><FilterOption id="19620" count="3" label="Eisai Inc"/><FilterOption id="14913" count="3" label="Eisai Ltd"/><FilterOption id="1046616" count="3" label="European Organization for Research and Treatment of Cancer"/><FilterOption id="16581" count="3" label="Grifols SA"/><FilterOption id="1089015" count="3" label="Grupo Espanol Multidisciplinar de Melanoma"/><FilterOption id="1056260" count="3" label="Grupo Espanol de Investigacion en Cancer de Ovario"/><FilterOption id="1056537" count="3" label="Grupo Espanol de Linfoma y Trasplante de Medula Osea"/><FilterOption id="17002" count="3" label="Human Genome Sciences Inc"/><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1073881" count="3" label="Lymphoma Academic Research Organisation"/><FilterOption id="18101" count="3" label="Merck KGaA"/><FilterOption id="15938" count="3" label="Millennium Pharmaceuticals Ltd"/><FilterOption id="29741" count="3" label="Morphotek Inc"/><FilterOption id="1064629" count="3" label="Prothena Corp plc"/><FilterOption id="26327" count="3" label="Roche Diagnostics GmbH"/><FilterOption id="1109598" count="3" label="Roche Products India Pvt Ltd"/><FilterOption id="25554" count="3" label="Seattle Genetics Inc"/><FilterOption id="1020514" count="2" label="Abraxis BioScience Inc"/><FilterOption id="13979" count="2" label="Alexion Pharmaceuticals Inc"/><FilterOption id="14042" count="2" label="Allergan Inc"/><FilterOption id="29179" count="2" label="Ambit Biosciences Corp"/><FilterOption id="21737" count="2" label="Amgen Research (Munich) GmbH"/><FilterOption id="25902" count="2" label="Array BioPharma Inc"/><FilterOption id="20972" count="2" label="Astellas Pharma Europe Ltd"/><FilterOption id="30062" count="2" label="AstraZeneca AB"/><FilterOption id="1109159" count="2" label="Axovant Gene Therapies Ltd"/><FilterOption id="14438" count="2" label="Baxter Healthcare Corp"/><FilterOption id="1003983" count="2" label="Bayer HealthCare AG"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="7"><FilterOption id="4" count="548" label="Completed"/><FilterOption id="2" count="299" label="Recruiting"/><FilterOption id="3" count="196" label="No longer recruiting"/><FilterOption id="6" count="118" label="Terminated"/><FilterOption id="1" count="22" label="Not yet recruiting"/><FilterOption id="5" count="4" label="Suspended"/><FilterOption id="12" count="1" label="Status not specified"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="652" label="Yes"/><FilterOption id="NO" count="536" label="No"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="100"><FilterOption id="2399" count="12" label="Adenocarcinoma"/><FilterOption id="1069" count="10" label="Metastasis"/><FilterOption id="3713" count="8" label="Advanced solid tumor"/><FilterOption id="3657" count="8" label="Metastatic breast cancer"/><FilterOption id="3665" count="8" label="Metastatic non small cell lung cancer"/><FilterOption id="159" count="7" label="HIV-1 infection"/><FilterOption id="307" count="7" label="Squamous cell carcinoma"/><FilterOption id="3658" count="6" label="Metastatic colorectal cancer"/><FilterOption id="3669" count="6" label="Metastatic pancreas cancer"/><FilterOption id="1771" count="6" label="Transitional cell carcinoma"/><FilterOption id="1767" count="5" label="Hepatocellular carcinoma"/><FilterOption id="3673" count="5" label="Metastatic head and neck cancer"/><FilterOption id="3510" count="5" label="Pulmonary artery hypertension"/><FilterOption id="1731" count="4" label="Acute myelogenous leukemia"/><FilterOption id="84" count="4" label="Crohns disease"/><FilterOption id="158" count="4" label="HIV infection"/><FilterOption id="3246" count="4" label="Hormone refractory prostate cancer"/><FilterOption id="3676" count="4" label="Ischemic stroke"/><FilterOption id="70" count="4" label="Liver cirrhosis"/><FilterOption id="3866" count="4" label="Metastatic ovary cancer"/><FilterOption id="1272" count="4" label="Myelodysplastic syndrome"/><FilterOption id="1867" count="4" label="Pulmonary hypertension"/><FilterOption id="3395" count="3" label="Acute liver failure"/><FilterOption id="14" count="3" label="Alzheimers disease"/><FilterOption id="2193" count="3" label="Anal tumor"/><FilterOption id="1815" count="3" label="Bacterial pneumonia"/><FilterOption id="1765" count="3" label="Cholangiocarcinoma"/><FilterOption id="3919" count="3" label="Chronic liver failure"/><FilterOption id="3689" count="3" label="Compensated liver cirrhosis"/><FilterOption id="1705" count="3" label="Endometrioid carcinoma"/><FilterOption id="2454" count="3" label="Glioblastoma"/><FilterOption id="2212" count="3" label="Hepatorenal syndrome"/><FilterOption id="3771" count="3" label="Idiopathic pulmonary fibrosis"/><FilterOption id="3235" count="3" label="Merkel cell carcinoma"/><FilterOption id="1240" count="3" label="Mesothelioma"/><FilterOption id="3466" count="3" label="Metastatic bladder cancer"/><FilterOption id="3667" count="3" label="Metastatic esophageal cancer"/><FilterOption id="4250" count="3" label="Metastatic renal cell carcinoma"/><FilterOption id="3666" count="3" label="Metastatic stomach cancer"/><FilterOption id="793" count="3" label="Mouth tumor"/><FilterOption id="319" count="3" label="Non-Hodgkin lymphoma"/><FilterOption id="794" count="3" label="Pharynx tumor"/><FilterOption id="3239" count="3" label="Portal hypertension"/><FilterOption id="1995" count="3" label="Primary biliary cholangitis"/><FilterOption id="286" count="3" label="Renal disease"/><FilterOption id="1261" count="3" label="Small-cell lung cancer"/><FilterOption id="3256" count="3" label="Stage III melanoma"/><FilterOption id="3257" count="3" label="Stage IV melanoma"/><FilterOption id="427" count="3" label="Uterine cervix tumor"/><FilterOption id="2567" count="2" label="Anaplastic astrocytoma"/><FilterOption id="316" count="2" label="B-cell lymphoma"/><FilterOption id="1516" count="2" label="Biliary cancer"/><FilterOption id="2380" count="2" label="Bladder cancer"/><FilterOption id="2432" count="2" label="Bronchiectasis"/><FilterOption id="651" count="2" label="Cancer"/><FilterOption id="2217" count="2" label="Cholestasis"/><FilterOption id="989" count="2" label="Colorectal tumor"/><FilterOption id="97" count="2" label="Diabetes mellitus"/><FilterOption id="100" count="2" label="Diabetic nephropathy"/><FilterOption id="1011" count="2" label="Esophagus tumor"/><FilterOption id="2243" count="2" label="Fallopian tube cancer"/><FilterOption id="1127" count="2" label="Fibrosis"/><FilterOption id="1745" count="2" label="Follicle center lymphoma"/><FilterOption id="152" count="2" label="Hepatitis B virus infection"/><FilterOption id="161" count="2" label="Hodgkins disease"/><FilterOption id="170" count="2" label="Huntingtons chorea"/><FilterOption id="3198" count="2" label="Larynx tumor"/><FilterOption id="2318" count="2" label="Liver fibrosis"/><FilterOption id="3240" count="2" label="Medullary thyroid cancer"/><FilterOption id="3668" count="2" label="Metastatic lung cancer"/><FilterOption id="3664" count="2" label="Metastatic prostate cancer"/><FilterOption id="3467" count="2" label="Metastatic renal cancer"/><FilterOption id="3465" count="2" label="Metastatic urinary tract cancer"/><FilterOption id="1828" count="2" label="Multiple myeloma"/><FilterOption id="213" count="2" label="Multiple sclerosis"/><FilterOption id="273" count="2" label="Myeloproliferative disorder"/><FilterOption id="230" count="2" label="Neoplasm"/><FilterOption id="2273" count="2" label="Oligodendroglioma"/><FilterOption id="799" count="2" label="Ovary tumor"/><FilterOption id="3351" count="2" label="Papillary thyroid tumor"/><FilterOption id="396" count="2" label="Papillomavirus infection"/><FilterOption id="3083" count="2" label="Peritoneal tumor"/><FilterOption id="279" count="2" label="Pruritus"/><FilterOption id="337" count="2" label="Ulcerative colitis"/><FilterOption id="3678" count="2" label="Urethral cancer"/><FilterOption id="738" count="2" label="Urinary tract tumor"/><FilterOption id="4" count="1" label="Acquired immune deficiency syndrome"/><FilterOption id="1728" count="1" label="Acute lymphoblastic leukemia"/><FilterOption id="2562" count="1" label="Adult respiratory distress syndrome"/><FilterOption id="3492" count="1" label="AL amyloidosis"/><FilterOption id="1143" count="1" label="Amyloidosis"/><FilterOption id="17" count="1" label="Anemia"/><FilterOption id="29" count="1" label="Aspergillus infection"/><FilterOption id="2300" count="1" label="Autosomal dominant polycystic kidney disease"/><FilterOption id="1729" count="1" label="B-cell acute lymphoblastic leukemia"/><FilterOption id="1764" count="1" label="Basal cell carcinoma"/><FilterOption id="1515" count="1" label="Biliary tumor"/><FilterOption id="552" count="1" label="Bleeding"/><FilterOption id="554" count="1" label="Bone and joint infection"/><FilterOption id="3443" count="1" label="Bone resorption"/></Filter><Filter label="Registry Id" name="trialRegistries" total="24"><FilterOption id="1000" count="1175" label="CT.gov"/><FilterOption id="1001" count="795" label="EudraCT"/><FilterOption id="1030" count="130" label="RSRM CTR"/><FilterOption id="1006" count="94" label="JapicCTI"/><FilterOption id="1019" count="70" label="DRKS"/><FilterOption id="1023" count="63" label="UKCRN"/><FilterOption id="1035" count="39" label="Singapore HSA CTR"/><FilterOption id="1012" count="31" label="CTRI"/><FilterOption id="1039" count="29" label="CDE"/><FilterOption id="1021" count="24" label="NMRR"/><FilterOption id="1004" count="22" label="WHO ICTRP"/><FilterOption id="1002" count="20" label="ISRCTN"/><FilterOption id="1033" count="19" label="Mexico CTR"/><FilterOption id="1009" count="14" label="HKClinicalTrials.com"/><FilterOption id="1011" count="9" label="ANZCTR"/><FilterOption id="1038" count="6" label="PHRR"/><FilterOption id="1010" count="5" label="CRiS"/><FilterOption id="1008" count="3" label="Hong Kong CCTCTR"/><FilterOption id="1015" count="3" label="NTR"/><FilterOption id="1003" count="3" label="UMIN"/><FilterOption id="1040" count="2" label="REec"/><FilterOption id="1016" count="1" label="PACTR"/><FilterOption id="1020" count="1" label="ReBec"/><FilterOption id="1018" count="1" label="SLCTR"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="7"><FilterOption id="5" count="31" label="Patient Enrollment Issues"/><FilterOption id="1" count="28" label="Lack of Efficacy"/><FilterOption id="2" count="24" label="Not Reported"/><FilterOption id="4" count="16" label="Other"/><FilterOption id="8" count="16" label="Sponsor/Business Decision"/><FilterOption id="7" count="6" label="Safety Issues"/><FilterOption id="3" count="3" label="Operational Issues"/></Filter><Filter label="Active Controls" name="trialActiveControls" total="100"><FilterOption id="3803" count="21" label="paclitaxel"/><FilterOption id="44383" count="20" label="carboplatin"/><FilterOption id="3199" count="20" label="gemcitabine"/><FilterOption id="2953" count="18" label="docetaxel"/><FilterOption id="6736" count="12" label="rituximab"/><FilterOption id="12205" count="11" label="capecitabine"/><FilterOption id="7310" count="10" label="ritonavir"/><FilterOption id="49219" count="10" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="6386" count="10" label="trastuzumab"/><FilterOption id="14681" count="8" label="lopinavir + ritonavir"/><FilterOption id="8047" count="7" label="bevacizumab"/><FilterOption id="15954" count="7" label="bortezomib"/><FilterOption id="37370" count="6" label="azacitidine"/><FilterOption id="32981" count="6" label="darunavir"/><FilterOption id="10309" count="5" label="abiraterone"/><FilterOption id="47000" count="5" label="bendamustine"/><FilterOption id="7934" count="5" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="3072" count="5" label="etoposide phosphate"/><FilterOption id="27572" count="5" label="lenalidomide"/><FilterOption id="3792" count="5" label="oxaliplatin"/><FilterOption id="12973" count="5" label="sunitinib"/><FilterOption id="14493" count="5" label="tenofovir disoproxil fumarate"/><FilterOption id="15254" count="4" label="atazanavir"/><FilterOption id="13239" count="4" label="decitabine"/><FilterOption id="10172" count="4" label="efavirenz"/><FilterOption id="3313" count="4" label="fulvestrant"/><FilterOption id="48181" count="4" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="3536" count="4" label="pemetrexed disodium"/><FilterOption id="12150" count="4" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="72699" count="3" label="atezolizumab"/><FilterOption id="2836" count="3" label="clopidogrel"/><FilterOption id="72148" count="3" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="53981" count="3" label="enzalutamide"/><FilterOption id="13340" count="3" label="everolimus"/><FilterOption id="3081" count="3" label="exemestane"/><FilterOption id="2871" count="3" label="irinotecan"/><FilterOption id="2784" count="3" label="letrozole"/><FilterOption id="53227" count="3" label="obinutuzumab"/><FilterOption id="29016" count="3" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="70667" count="3" label="pembrolizumab"/><FilterOption id="54488" count="3" label="raltegravir"/><FilterOption id="44313" count="3" label="simvastatin"/><FilterOption id="4529" count="3" label="temozolomide"/><FilterOption id="4577" count="3" label="topotecan"/><FilterOption id="15130" count="3" label="vinflunine"/><FilterOption id="6408" count="3" label="vinorelbine"/><FilterOption id="44375" count="3" label="warfarin"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="44388" count="2" label="carbidopa + levodopa"/><FilterOption id="54601" count="2" label="carfilzomib"/><FilterOption id="62275" count="2" label="cobicistat"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="53200" count="2" label="daratumumab"/><FilterOption id="59062" count="2" label="dolutegravir"/><FilterOption id="51371" count="2" label="elvitegravir"/><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="4728" count="2" label="emtricitabine"/><FilterOption id="13928" count="2" label="enoxaparin sodium"/><FilterOption id="13486" count="2" label="entecavir"/><FilterOption id="28773" count="2" label="eribulin mesylate"/><FilterOption id="30682" count="2" label="etravirine"/><FilterOption id="44292" count="2" label="fluconazole"/><FilterOption id="6156" count="2" label="fludarabine"/><FilterOption id="24471" count="2" label="fosamprenavir"/><FilterOption id="55237" count="2" label="ibrutinib"/><FilterOption id="36630" count="2" label="ipilimumab"/><FilterOption id="3474" count="2" label="lamivudine"/><FilterOption id="33591" count="2" label="lapatinib"/><FilterOption id="5267" count="2" label="leuprorelin acetate"/><FilterOption id="6050" count="2" label="metformin hydrochloride"/><FilterOption id="11519" count="2" label="mitoxantrone"/><FilterOption id="3669" count="2" label="mycophenolate mofetil"/><FilterOption id="3700" count="2" label="nevirapine"/><FilterOption id="61287" count="2" label="niraparib"/><FilterOption id="54804" count="2" label="nivolumab"/><FilterOption id="23625" count="2" label="peginterferon alfa-2a"/><FilterOption id="28532" count="2" label="pertuzumab"/><FilterOption id="4196" count="2" label="ramipril"/><FilterOption id="5369" count="2" label="ribavirin"/><FilterOption id="52857" count="2" label="rilpivirine hydrochloride"/><FilterOption id="4259" count="2" label="saquinavir"/><FilterOption id="29831" count="2" label="sorafenib"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="44401" count="2" label="vancomycin"/><FilterOption id="6242" count="1" label="abacavir"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="2503" count="1" label="amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative"/><FilterOption id="7867" count="1" label="amprenavir"/><FilterOption id="3321" count="1" label="anastrozole"/><FilterOption id="52967" count="1" label="apixaban"/><FilterOption id="50484" count="1" label="apomorphine hydrochloride (Parkinson's disease), Britannia"/><FilterOption id="74263" count="1" label="atazanavir sulfate + cobicistat (fixed-dose combination, HIV infection), Bristol-Myers Squibb"/><FilterOption id="16905" count="1" label="atomoxetine"/><FilterOption id="11141" count="1" label="basiliximab"/><FilterOption id="100071" count="1" label="BMS-986177"/><FilterOption id="50935" count="1" label="cabozantinib S-malate"/><FilterOption id="63194" count="1" label="carbidopa + levodopa (Parkinsons disease, immediate/extended release), Impax"/><FilterOption id="12544" count="1" label="caspofungin"/></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="6859" count="72" label="HIV infection - Pregnant or Breast Feeding Subjects"/><FilterOption id="6554" count="56" label="Leukemia - Subjects with Co-morbid Conditions"/><FilterOption id="6258" count="43" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="6845" count="43" label="HIV infection - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="4702" count="43" label="Lymphoma - Subjects with Co-morbid Conditions"/><FilterOption id="6820" count="41" label="HIV infection - Subjects with Opportunistic/Other Infections"/><FilterOption id="6892" count="39" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="6294" count="38" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6534" count="37" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6065" count="35" label="Multiple myeloma - Subjects with Co-morbid Conditions"/><FilterOption id="4692" count="33" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6331" count="32" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6272" count="31" label="Breast tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6941" count="31" label="HIV infection - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Hypersensitivity/Contraindications to study medications or its excipients"/><FilterOption id="5132" count="31" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5193" count="31" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6247" count="30" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"/><FilterOption id="6843" count="29" label="HIV infection - Subjects with Co-morbid Conditions"/><FilterOption id="6660" count="29" label="Leukemia - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="5365" count="29" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="20282" count="29" label="Lung tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6393" count="28" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="6377" count="28" label="Breast tumor - Subjects with history of/planned radiotherapy"/><FilterOption id="4769" count="27" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6259" count="26" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="6082" count="26" label="Multiple myeloma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="24372" count="25" label="Other gastrointestinal disease - Subjects with Protocol Specified Reproductive Status - Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception"/><FilterOption id="4730" count="24" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable liver function"/><FilterOption id="6951" count="23" label="HIV infection - Subjects with AIDS/AIDS Defining Events"/><FilterOption id="6850" count="23" label="HIV infection - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5345" count="23" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="6767" count="23" label="Lymphoma - Lymphoma Subjects with Advanced Disease - Subjects with central nervous system involvement of lymphoma"/><FilterOption id="6474" count="22" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="6530" count="22" label="Leukemia - Leukemia Subjects with Advanced Disease - Subjects with central nervous system involvement of leukemia"/><FilterOption id="6504" count="22" label="Leukemia - Subjects with Acute Myeloid Leukemia - Subjects with promyelocytic leukemia (M3)"/><FilterOption id="6618" count="22" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="5125" count="22" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"/><FilterOption id="5291" count="22" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="5270" count="22" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="4718" count="22" label="Lymphoma - Subjects co-morbid with infections - Subjects co-morbid with HIV infection"/><FilterOption id="10704" count="22" label="Solid tumor - Subjects with Co-morbid Conditions"/><FilterOption id="9003" count="21" label="Bladder cancer - Subjects with Co-morbid Conditions"/><FilterOption id="6302" count="21" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"/><FilterOption id="5139" count="21" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="5282" count="21" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"/><FilterOption id="4739" count="21" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"/><FilterOption id="5414" count="21" label="Melanoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="17557" count="20" label="Breast tumor - Subjects with Abnormal Laboratory Findings"/><FilterOption id="20290" count="20" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="5128" count="20" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"/><FilterOption id="4810" count="20" label="Lymphoma - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="5405" count="20" label="Melanoma - Subjects with Evidence of Metastasis - Subjects with central nervous system metastasis"/><FilterOption id="25158" count="20" label="Other gastrointestinal disease - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4909" count="20" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6260" count="19" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="6253" count="19" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"/><FilterOption id="17531" count="19" label="End stage renal disease - Subjects co-morbid with infections"/><FilterOption id="7555" count="19" label="HIV infection - Subjects with Progressive/Treatment Refractory Disease - Subjects with resistant mutations"/><FilterOption id="6963" count="19" label="HIV infection - Subjects with history of/scheduled to receive therapy for other indication - Subjects with history/scheduled to receive immunomodulators for other indication"/><FilterOption id="5349" count="19" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"/><FilterOption id="4831" count="19" label="Lymphoma - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="5430" count="19" label="Melanoma - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="24468" count="19" label="Other gastrointestinal disease - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="25164" count="19" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"/><FilterOption id="6361" count="18" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled for targeted therapy"/><FilterOption id="20292" count="18" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="6659" count="18" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of stem cell therapy"/><FilterOption id="4731" count="18" label="Lymphoma - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable renal function"/><FilterOption id="5547" count="18" label="Melanoma - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="4847" count="18" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer - Subjects with brain metastasis"/><FilterOption id="6246" count="17" label="Breast tumor - Subjects by disease severity - Metastatic/TNM Stage IV Breast Cancer"/><FilterOption id="6328" count="17" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"/><FilterOption id="5149" count="17" label="Lung tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="4762" count="17" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subject with history of radiotherapy"/><FilterOption id="6091" count="17" label="Multiple myeloma - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="25163" count="17" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal hematological tests"/><FilterOption id="20114" count="17" label="Pain - Subjects with Co-morbid Conditions - Subjects co-morbid with CNS disorders/diseases"/><FilterOption id="7923" count="17" label="Renal cell carcinoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5841" count="16" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6862" count="16" label="HIV infection - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"/><FilterOption id="5163" count="16" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6756" count="16" label="Lung tumor - Subjects with History of/Scheduled for Other Cancer Therapies"/><FilterOption id="4733" count="16" label="Lymphoma - Subjects with Abnormal Laboratory Findings - Subjects with abnormal hematological tests"/><FilterOption id="5470" count="16" label="Melanoma - Subjects co-morbid with inflammatory disorders"/><FilterOption id="6133" count="16" label="Multiple myeloma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="6124" count="16" label="Multiple myeloma - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="25162" count="16" label="Other gastrointestinal disease - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"/><FilterOption id="11871" count="15" label="Anemia - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="6834" count="15" label="HIV infection - Subjects co-morbid with Psychiatric Disease/Disorder"/><FilterOption id="6874" count="15" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Drugs"/><FilterOption id="24596" count="15" label="Other gastrointestinal disease - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/><FilterOption id="24465" count="15" label="Other gastrointestinal disease - Subjects with history of psychiatric disease/disorder - Subjects with history of/current alcohol/drug/substance abuse"/><FilterOption id="9002" count="14" label="Bladder cancer - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6252" count="14" label="Breast tumor - Subjects with Co-morbid Conditions"/><FilterOption id="20289" count="14" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"/><FilterOption id="17519" count="14" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="17541" count="14" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"/><FilterOption id="6863" count="14" label="HIV infection - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"/><FilterOption id="6645" count="14" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="5285" count="14" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="13" label="201509"/><FilterOption count="11" label="201705"/><FilterOption count="11" label="201712"/><FilterOption count="11" label="201905"/><FilterOption count="10" label="201904"/><FilterOption count="9" label="201902"/><FilterOption count="8" label="201605"/><FilterOption count="8" label="201812"/><FilterOption count="7" label="201210"/><FilterOption count="7" label="201310"/><FilterOption count="7" label="201402"/><FilterOption count="7" label="201411"/><FilterOption count="7" label="201506"/><FilterOption count="7" label="201601"/><FilterOption count="7" label="201603"/><FilterOption count="7" label="201612"/><FilterOption count="7" label="201708"/><FilterOption count="7" label="201803"/><FilterOption count="7" label="201810"/><FilterOption count="6" label="201110"/><FilterOption count="6" label="201504"/><FilterOption count="6" label="201512"/><FilterOption count="6" label="201702"/><FilterOption count="6" label="201709"/><FilterOption count="6" label="201710"/><FilterOption count="6" label="201802"/><FilterOption count="6" label="201804"/><FilterOption count="6" label="201807"/><FilterOption count="6" label="201811"/><FilterOption count="6" label="201906"/><FilterOption count="5" label="200905"/><FilterOption count="5" label="201003"/><FilterOption count="5" label="201108"/><FilterOption count="5" label="201202"/><FilterOption count="5" label="201306"/><FilterOption count="5" label="201312"/><FilterOption count="5" label="201401"/><FilterOption count="5" label="201409"/><FilterOption count="5" label="201502"/><FilterOption count="5" label="201503"/><FilterOption count="5" label="201505"/><FilterOption count="5" label="201510"/><FilterOption count="5" label="201608"/><FilterOption count="5" label="201609"/><FilterOption count="5" label="201701"/><FilterOption count="5" label="201703"/><FilterOption count="5" label="201706"/><FilterOption count="5" label="201711"/><FilterOption count="5" label="201805"/><FilterOption count="5" label="201808"/><FilterOption count="5" label="201809"/><FilterOption count="5" label="201901"/><FilterOption count="5" label="201903"/><FilterOption count="4" label="200706"/><FilterOption count="4" label="200810"/><FilterOption count="4" label="200906"/><FilterOption count="4" label="200910"/><FilterOption count="4" label="201106"/><FilterOption count="4" label="201203"/><FilterOption count="4" label="201301"/><FilterOption count="4" label="201302"/><FilterOption count="4" label="201307"/><FilterOption count="4" label="201404"/><FilterOption count="4" label="201405"/><FilterOption count="4" label="201408"/><FilterOption count="4" label="201410"/><FilterOption count="4" label="201412"/><FilterOption count="4" label="201511"/><FilterOption count="4" label="201602"/><FilterOption count="4" label="201610"/><FilterOption count="4" label="201801"/><FilterOption count="4" label="201806"/><FilterOption count="3" label="200703"/><FilterOption count="3" label="200901"/><FilterOption count="3" label="200902"/><FilterOption count="3" label="200903"/><FilterOption count="3" label="200908"/><FilterOption count="3" label="201001"/><FilterOption count="3" label="201103"/><FilterOption count="3" label="201104"/><FilterOption count="3" label="201105"/><FilterOption count="3" label="201107"/><FilterOption count="3" label="201112"/><FilterOption count="3" label="201204"/><FilterOption count="3" label="201209"/><FilterOption count="3" label="201305"/><FilterOption count="3" label="201309"/><FilterOption count="3" label="201311"/><FilterOption count="3" label="201507"/><FilterOption count="3" label="201508"/><FilterOption count="3" label="201704"/><FilterOption count="3" label="201707"/><FilterOption count="2" label="200601"/><FilterOption count="2" label="200612"/><FilterOption count="2" label="200712"/><FilterOption count="2" label="200801"/><FilterOption count="2" label="200803"/><FilterOption count="2" label="200804"/><FilterOption count="2" label="200809"/><FilterOption count="2" label="200909"/></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="879" label="Company"/><FilterOption id="ACA" count="447" label="Academic"/><FilterOption id="GOV" count="16" label="Government"/><FilterOption id="OTH" count="13" label="Others"/><FilterOption id="NGO" count="4" label="Non-Government"/></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="1188" label="Northern, Southern &amp; Western Europe"/><FilterOption id="USCA" count="573" label="US &amp; Canada"/><FilterOption id="EEUR" count="497" label="Eastern Europe"/><FilterOption id="AUNZ" count="328" label="Australia &amp; New Zealand"/><FilterOption id="EAPO" count="286" label="East Asia &amp; Pacific Ocean"/><FilterOption id="MENA" count="274" label="Middle East &amp; North Africa"/><FilterOption id="SOAM" count="217" label="South America"/><FilterOption id="CAAC" count="157" label="Central America &amp; Caribbean"/><FilterOption id="CSAF" count="89" label="Central &amp; Southern Africa"/><FilterOption id="SOCA" count="53" label="Southern &amp; Central Asia"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="7126" count="75" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"/><FilterOption id="3954" count="37" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"/><FilterOption id="3634" count="33" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"/><FilterOption id="3977" count="32" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="3937" count="29" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="3617" count="29" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3952" count="27" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"/><FilterOption id="10295" count="25" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"/><FilterOption id="3530" count="25" label="Lymphoma - Subjects with Treatment Resistant Disease"/><FilterOption id="3926" count="24" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"/><FilterOption id="3564" count="24" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"/><FilterOption id="3936" count="23" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="3472" count="23" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="3525" count="23" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"/><FilterOption id="3680" count="23" label="Melanoma - Subjects with Stage IV Melanoma"/><FilterOption id="3931" count="22" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="3667" count="22" label="Melanoma - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="7108" count="21" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"/><FilterOption id="3975" count="21" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="3923" count="21" label="Multiple myeloma - Subjects with Treatment Resistant Disease"/><FilterOption id="7810" count="19" label="Bladder cancer - Subjects with Metastatic Bladder Cancer"/><FilterOption id="3965" count="19" label="Breast tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3502" count="19" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"/><FilterOption id="3500" count="19" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"/><FilterOption id="3980" count="18" label="Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)"/><FilterOption id="3999" count="18" label="Leukemia - Subjects with Treatment Resistant Disease"/><FilterOption id="3473" count="18" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="3870" count="18" label="Multiple myeloma - Subjects with Symptomatic Disease"/><FilterOption id="7961" count="18" label="Solid tumor - Subjects with Advanced/Metastatic Solid Tumors"/><FilterOption id="3824" count="17" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"/><FilterOption id="7107" count="17" label="HIV infection - Treatment Naive Subjects"/><FilterOption id="4003" count="17" label="Leukemia - Subjects with Relapsed/Recurrent Leukemia"/><FilterOption id="3698" count="17" label="Melanoma - Subjects with Surgically Non-resectable Melanoma"/><FilterOption id="7415" count="17" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"/><FilterOption id="7809" count="16" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"/><FilterOption id="12053" count="16" label="Lung tumor - Treatment Naive Subjects"/><FilterOption id="3489" count="16" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"/><FilterOption id="3583" count="16" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"/><FilterOption id="7806" count="15" label="Bladder cancer - Subjects with Locally Advanced Bladder Cancer"/><FilterOption id="3950" count="15" label="Breast tumor - Subjects with Early Stage Breast Cancer"/><FilterOption id="3956" count="15" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"/><FilterOption id="461" count="15" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"/><FilterOption id="7109" count="15" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent nucleoside reverse transcriptase inhibitors"/><FilterOption id="3647" count="15" label="Lung tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3944" count="14" label="Breast tumor - Subjects with Stage II Breast Cancer"/><FilterOption id="12845" count="14" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"/><FilterOption id="3623" count="14" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"/><FilterOption id="15979" count="14" label="Other gastrointestinal disease - Subjects with specific disease - Subjects with Liver Cirrhosis"/><FilterOption id="12018" count="14" label="Prostate tumor - Subjects with adenocarcinoma of prostate"/><FilterOption id="7414" count="14" label="Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma"/><FilterOption id="7967" count="14" label="Solid tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3932" count="13" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="3938" count="13" label="Breast tumor - Subjects with Triple Negative Breast Cancer"/><FilterOption id="368" count="13" label="Coronary artery disease - Subjects with Myocardial Ischemia"/><FilterOption id="7112" count="13" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART"/><FilterOption id="3501" count="13" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"/><FilterOption id="7879" count="13" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"/><FilterOption id="3565" count="13" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"/><FilterOption id="11242" count="13" label="Pulmonary artery hypertension - Subjects with Idiopathic PAH (IPAH)"/><FilterOption id="11954" count="12" label="Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer"/><FilterOption id="3966" count="12" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"/><FilterOption id="201" count="12" label="Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)"/><FilterOption id="7111" count="12" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent protease inhibitors"/><FilterOption id="3681" count="12" label="Melanoma - Subjects with Evidence of Metastasis"/><FilterOption id="3814" count="11" label="Colorectal tumor - Subjects with Colon Cancer"/><FilterOption id="3813" count="11" label="Colorectal tumor - Subjects with Rectal Cancer"/><FilterOption id="3979" count="11" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"/><FilterOption id="3496" count="11" label="Lymphoma - Subjects with specific Ann Arbor stage - Subjects with Ann Arbor Stage II Lymphoma"/><FilterOption id="19047" count="11" label="Melanoma - Treatment Naive Subjects"/><FilterOption id="7377" count="11" label="Parkinsons disease - Parkinson's Subjects with ON-OFF Episodes"/><FilterOption id="7402" count="11" label="Renal cell carcinoma - Subjects with Clear Cell Renal Cell Carcinoma"/><FilterOption id="7814" count="10" label="Bladder cancer - Subjects with Unresectable Bladder Cancer"/><FilterOption id="3955" count="10" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"/><FilterOption id="3946" count="10" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer"/><FilterOption id="77" count="10" label="Cardiac failure - Subjects with NYHA Functional Class - Moderate/NYHA Functional Class III Heart Failure Subjects"/><FilterOption id="7700" count="10" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"/><FilterOption id="8010" count="10" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"/><FilterOption id="302" count="9" label="Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects"/><FilterOption id="7808" count="9" label="Bladder cancer - Subjects with Stage III Bladder Cancer"/><FilterOption id="3970" count="9" label="Breast tumor - Others - Subjects with node positive breast cancer"/><FilterOption id="12005" count="9" label="Breast tumor - Subjects with invasive breast cancer"/><FilterOption id="78" count="9" label="Cardiac failure - Subjects with NYHA Functional Class - Severe/NYHA Functional Class IV Heart Failure Subjects"/><FilterOption id="7877" count="9" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"/><FilterOption id="3650" count="9" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"/><FilterOption id="3710" count="9" label="Melanoma - Subjects with Treatment Resistant Disease"/><FilterOption id="18822" count="9" label="Other gastrointestinal disease - Subjects with specific disease - Nonalcoholic steatohepatitis (NASH) subjects"/><FilterOption id="3586" count="9" label="Prostate tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="11487" count="9" label="Stem cell transplantation - Subjects with H/O Hematological Malignancies Indicated for SCT"/><FilterOption id="7820" count="8" label="Bladder cancer - Subjects with Treatment Resistant Disease"/><FilterOption id="561" count="8" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD"/><FilterOption id="562" count="8" label="Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD"/><FilterOption id="178" count="8" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)"/><FilterOption id="3404" count="8" label="Crohns disease - Subjects with Active Crohns Disease"/><FilterOption id="3981" count="8" label="Leukemia - Subjects with B-Cell Leukemia"/><FilterOption id="3679" count="8" label="Melanoma - Subjects with Stage III Melanoma - Subjects with stage IIIC melanoma"/><FilterOption id="8073" count="8" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"/><FilterOption id="7367" count="8" label="Parkinsons disease - Subjects with Advanced/Late Stage Parkinson's Disease"/><FilterOption id="161" count="7" label="Alzheimers disease - Subjects with Mild Alzheimer's Disease"/><FilterOption id="152" count="7" label="Alzheimers disease - Subjects with Mild Cognitive Impairment(MCI)"/><FilterOption id="7200" count="7" label="Atrial fibrillation - Subjects with specific disease - Subjects with Persistent Atrial Fibrillation"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="33" label="201912"/><FilterOption count="19" label="202012"/><FilterOption count="15" label="201810"/><FilterOption count="15" label="202001"/><FilterOption count="14" label="201906"/><FilterOption count="14" label="201908"/><FilterOption count="13" label="201612"/><FilterOption count="13" label="201812"/><FilterOption count="13" label="201909"/><FilterOption count="13" label="202007"/><FilterOption count="13" label="202109"/><FilterOption count="12" label="201803"/><FilterOption count="12" label="201910"/><FilterOption count="12" label="202003"/><FilterOption count="12" label="202011"/><FilterOption count="12" label="202106"/><FilterOption count="11" label="201709"/><FilterOption count="11" label="201905"/><FilterOption count="11" label="202006"/><FilterOption count="11" label="202009"/><FilterOption count="11" label="202103"/><FilterOption count="10" label="201604"/><FilterOption count="10" label="201704"/><FilterOption count="10" label="201707"/><FilterOption count="10" label="201911"/><FilterOption count="10" label="202004"/><FilterOption count="9" label="201111"/><FilterOption count="9" label="201409"/><FilterOption count="9" label="201512"/><FilterOption count="9" label="201607"/><FilterOption count="9" label="201710"/><FilterOption count="9" label="201907"/><FilterOption count="9" label="202005"/><FilterOption count="8" label="201006"/><FilterOption count="8" label="201301"/><FilterOption count="8" label="201310"/><FilterOption count="8" label="201408"/><FilterOption count="8" label="201705"/><FilterOption count="8" label="201712"/><FilterOption count="8" label="201801"/><FilterOption count="8" label="201807"/><FilterOption count="8" label="201811"/><FilterOption count="7" label="201001"/><FilterOption count="7" label="201106"/><FilterOption count="7" label="201207"/><FilterOption count="7" label="201212"/><FilterOption count="7" label="201307"/><FilterOption count="7" label="201312"/><FilterOption count="7" label="201406"/><FilterOption count="7" label="201411"/><FilterOption count="7" label="201507"/><FilterOption count="7" label="201605"/><FilterOption count="7" label="201606"/><FilterOption count="7" label="201609"/><FilterOption count="7" label="201611"/><FilterOption count="7" label="201808"/><FilterOption count="7" label="201809"/><FilterOption count="6" label="200812"/><FilterOption count="6" label="201112"/><FilterOption count="6" label="201204"/><FilterOption count="6" label="201305"/><FilterOption count="6" label="201407"/><FilterOption count="6" label="201502"/><FilterOption count="6" label="201504"/><FilterOption count="6" label="201506"/><FilterOption count="6" label="201601"/><FilterOption count="6" label="201602"/><FilterOption count="6" label="201610"/><FilterOption count="6" label="201703"/><FilterOption count="6" label="201706"/><FilterOption count="6" label="201711"/><FilterOption count="6" label="201802"/><FilterOption count="6" label="201904"/><FilterOption count="6" label="202010"/><FilterOption count="6" label="202104"/><FilterOption count="6" label="202112"/><FilterOption count="5" label="200807"/><FilterOption count="5" label="200905"/><FilterOption count="5" label="201012"/><FilterOption count="5" label="201101"/><FilterOption count="5" label="201203"/><FilterOption count="5" label="201206"/><FilterOption count="5" label="201209"/><FilterOption count="5" label="201302"/><FilterOption count="5" label="201311"/><FilterOption count="5" label="201402"/><FilterOption count="5" label="201405"/><FilterOption count="5" label="201505"/><FilterOption count="5" label="201608"/><FilterOption count="5" label="201804"/><FilterOption count="5" label="201805"/><FilterOption count="5" label="201806"/><FilterOption count="5" label="201901"/><FilterOption count="5" label="201903"/><FilterOption count="5" label="202002"/><FilterOption count="5" label="202008"/><FilterOption count="5" label="202110"/><FilterOption count="4" label="200702"/><FilterOption count="4" label="200809"/><FilterOption count="4" label="200911"/></Filter><Filter label="Trial Country" name="trialCountries" total="100"><FilterOption id="ES" count="1188" label="Spain"/><FilterOption id="DE" count="587" label="Germany"/><FilterOption id="FR" count="584" label="France"/><FilterOption id="IT" count="563" label="Italy"/><FilterOption id="US" count="540" label="US"/><FilterOption id="GB" count="532" label="UK"/><FilterOption id="BE" count="435" label="Belgium"/><FilterOption id="CA" count="397" label="Canada"/><FilterOption id="PL" count="347" label="Poland"/><FilterOption id="NL" count="336" label="Netherlands"/><FilterOption id="AU" count="323" label="Australia"/><FilterOption id="AT" count="286" label="Austria"/><FilterOption id="CZ" count="260" label="Czech Republic"/><FilterOption id="IL" count="226" label="Israel"/><FilterOption id="HU" count="218" label="Hungary"/><FilterOption id="RU" count="209" label="Russian Federation"/><FilterOption id="KR" count="205" label="South Korea"/><FilterOption id="SE" count="204" label="Sweden"/><FilterOption id="CH" count="188" label="Switzerland"/><FilterOption id="DK" count="186" label="Denmark"/><FilterOption id="PT" count="173" label="Portugal"/><FilterOption id="BR" count="165" label="Brazil"/><FilterOption id="TW" count="142" label="Taiwan"/><FilterOption id="GR" count="138" label="Greece"/><FilterOption id="JP" count="136" label="Japan"/><FilterOption id="AR" count="133" label="Argentina"/><FilterOption id="MX" count="128" label="Mexico"/><FilterOption id="RO" count="116" label="Romania"/><FilterOption id="TR" count="106" label="Turkey"/><FilterOption id="FI" count="104" label="Finland"/><FilterOption id="NZ" count="104" label="New Zealand"/><FilterOption id="UA" count="103" label="Ukraine"/><FilterOption id="BG" count="99" label="Bulgaria"/><FilterOption id="SK" count="92" label="Slovakia"/><FilterOption id="IE" count="90" label="Ireland"/><FilterOption id="ZA" count="87" label="South Africa"/><FilterOption id="NO" count="85" label="Norway"/><FilterOption id="CN" count="84" label="China"/><FilterOption id="SG" count="80" label="Singapore"/><FilterOption id="CL" count="75" label="Chile"/><FilterOption id="RS" count="72" label="Serbia"/><FilterOption id="HK" count="69" label="Hong Kong"/><FilterOption id="HR" count="62" label="Croatia"/><FilterOption id="TH" count="59" label="Thailand"/><FilterOption id="PE" count="55" label="Peru"/><FilterOption id="IN" count="52" label="India"/><FilterOption id="CO" count="51" label="Colombia"/><FilterOption id="PR" count="51" label="Puerto Rico"/><FilterOption id="LV" count="49" label="Latvia"/><FilterOption id="LT" count="45" label="Lithuania"/><FilterOption id="MY" count="44" label="Malaysia"/><FilterOption id="EE" count="43" label="Estonia"/><FilterOption id="X5" count="42" label="Europe"/><FilterOption id="SI" count="25" label="Slovenia"/><FilterOption id="XD" count="19" label="North America"/><FilterOption id="PH" count="19" label="Philippines"/><FilterOption id="X2" count="16" label="Asia"/><FilterOption id="BA" count="14" label="Bosnia and Herzegovina"/><FilterOption id="GE" count="14" label="Georgia"/><FilterOption id="PA" count="14" label="Panama"/><FilterOption id="CR" count="13" label="Costa Rica"/><FilterOption id="EG" count="13" label="Egypt"/><FilterOption id="GT" count="11" label="Guatemala"/><FilterOption id="BY" count="10" label="Belarus"/><FilterOption id="LU" count="10" label="Luxembourg"/><FilterOption id="XE" count="10" label="South America"/><FilterOption id="SA" count="8" label="Saudi Arabia"/><FilterOption id="LB" count="7" label="Lebanon"/><FilterOption id="VN" count="7" label="Vietnam"/><FilterOption id="MA" count="6" label="Morocco"/><FilterOption id="DO" count="5" label="Dominican Republic"/><FilterOption id="EU" count="5" label="EU"/><FilterOption id="MK" count="5" label="Macedonia, The Former Yugoslav Republic of"/><FilterOption id="KP" count="5" label="North Korea"/><FilterOption id="DZ" count="4" label="Algeria"/><FilterOption id="EC" count="4" label="Ecuador"/><FilterOption id="VE" count="4" label="Venezuela"/><FilterOption id="AL" count="3" label="Albania"/><FilterOption id="IS" count="3" label="Iceland"/><FilterOption id="ID" count="3" label="Indonesia"/><FilterOption id="AE" count="3" label="United Arab Emirates"/><FilterOption id="UY" count="3" label="Uruguay"/><FilterOption id="BS" count="2" label="Bahamas"/><FilterOption id="SV" count="2" label="El Salvador"/><FilterOption id="JO" count="2" label="Jordan"/><FilterOption id="KW" count="2" label="Kuwait"/><FilterOption id="MT" count="2" label="Malta"/><FilterOption id="PK" count="2" label="Pakistan"/><FilterOption id="PW" count="2" label="Palau"/><FilterOption id="LK" count="2" label="Sri Lanka"/><FilterOption id="TN" count="2" label="Tunisia"/><FilterOption id="UG" count="2" label="Uganda"/><FilterOption id="XW" count="2" label="Western Europe"/><FilterOption id="X0" count="1" label="Africa"/><FilterOption id="X1" count="1" label="Americas"/><FilterOption id="BH" count="1" label="Bahrain"/><FilterOption id="BN" count="1" label="Brunei"/><FilterOption id="MM" count="1" label="Burma"/><FilterOption id="KH" count="1" label="Cambodia"/><FilterOption id="CF" count="1" label="Central African Republic"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="17"><FilterOption id="EAMAA" count="1123" label="Middle-aged Adults (45-64 yrs)"/><FilterOption id="EAAAD" count="1095" label="Aged Adults (65-79 yrs)"/><FilterOption id="EAYAD" count="1095" label="Young Adults (18-44 yrs)"/><FilterOption id="EAELD" count="920" label="Elderly Adults (80 and over)"/><FilterOption id="EGFEM" count="84" label="Female"/><FilterOption id="EAADL" count="61" label="Adolescents (13-17 yrs)"/><FilterOption id="EACHI" count="45" label="Children (6-12 yrs)"/><FilterOption id="EVHVA" count="41" label="Healthy volunteers accepted"/><FilterOption id="EGMAL" count="34" label="Male"/><FilterOption id="EAPRE" count="13" label="Preschool Children (2-5 yrs)"/><FilterOption id="ECASI" count="10" label="Asian Ancestry"/><FilterOption id="EAINF" count="8" label="Infants (6-23 months)"/><FilterOption id="EANEW" count="8" label="Newborn Infants (up to 5 months)"/><FilterOption id="ECJAP" count="6" label="Japanese Ancestry"/><FilterOption id="EVHVO" count="5" label="Healthy volunteers only"/><FilterOption id="ECAFR" count="4" label="African Ancestry"/><FilterOption id="ECEUR" count="1" label="European Ancestry"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="25"><FilterOption id="SSTINV" count="1098" label="Interventional"/><FilterOption id="SIPTRE" count="1013" label="Treatment"/><FilterOption id="SIARND" count="811" label="Randomized"/><FilterOption id="SISPRL" count="788" label="Parallel Assignment"/><FilterOption id="SIMOPN" count="614" label="Open Label"/><FilterOption id="SIMMBD" count="427" label="Multiple Blind"/><FilterOption id="SICPLC" count="403" label="Placebo Control"/><FilterOption id="SICACT" count="274" label="Active Control"/><FilterOption id="SISSNG" count="247" label="Single Group Assignment"/><FilterOption id="SIANON" count="191" label="Non-Randomized"/><FilterOption id="SICNOC" count="149" label="No Control"/><FilterOption id="SSTOBS" count="90" label="Observational"/><FilterOption id="SIPPRE" count="68" label="Prevention"/><FilterOption id="SOTPRO" count="68" label="Prospective"/><FilterOption id="SOSCOH" count="57" label="Cohort"/><FilterOption id="SIMSBD" count="49" label="Single Blind"/><FilterOption id="SISXOV" count="27" label="Crossover Assignment"/><FilterOption id="SOTRET" count="19" label="Retrospective"/><FilterOption id="SIPDIA" count="13" label="Diagnosis"/><FilterOption id="SOSCSC" count="10" label="Case Control"/><FilterOption id="SODXSC" count="7" label="Cross-sectional"/><FilterOption id="SODLNG" count="5" label="Longitudinal"/><FilterOption id="SICDSC" count="3" label="Dose Comparison"/><FilterOption id="SISFCT" count="2" label="Factorial Assignment"/><FilterOption id="SISEAA" count="1" label="Expanded Access Assignment"/></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOVOTHERS" count="683" label="ClinicalTrials.gov and others"/><FilterOption id="CTGOV" count="485" label="ClinicalTrials.gov only"/><FilterOption id="OTHERS" count="11" label="Others only"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="444" label="Anticancer"/><FilterOption id="2953" count="245" label="Anti-inflammatory"/><FilterOption id="55685" count="227" label="Anticancer monoclonal antibody"/><FilterOption id="991" count="182" label="Antiviral"/><FilterOption id="62255" count="174" label="Anticancer protein kinase inhibitor"/><FilterOption id="1589" count="158" label="Apoptosis stimulator"/><FilterOption id="767" count="130" label="Cell cycle inhibitor"/><FilterOption id="61" count="111" label="Angiogenesis inhibitor"/><FilterOption id="7293" count="108" label="Synergist"/><FilterOption id="393" count="107" label="Immunostimulant"/><FilterOption id="7761" count="101" label="T-lymphocyte stimulator"/><FilterOption id="50" count="72" label="Anticancer alkylating agent"/><FilterOption id="140" count="69" label="DNA synthesis inhibitor"/><FilterOption id="1569" count="61" label="Anticancer antimetabolite"/><FilterOption id="1596" count="61" label="Immunomodulator"/><FilterOption id="2657" count="52" label="Antihypertensive"/><FilterOption id="382" count="39" label="TNF alpha synthesis inhibitor"/><FilterOption id="2575" count="38" label="Microtubule inhibitor"/><FilterOption id="2576" count="37" label="Microtubule stabilizer"/><FilterOption id="747" count="35" label="HIV replication inhibitor"/><FilterOption id="396" count="35" label="Immunosuppressant"/><FilterOption id="2660" count="34" label="Vasoprotectant"/><FilterOption id="1615" count="33" label="Neuroprotectant"/><FilterOption id="2946" count="28" label="Analgesic"/><FilterOption id="12379" count="26" label="Therapeutic vaccine"/><FilterOption id="2947" count="23" label="Antiparkinsonian"/><FilterOption id="1594" count="22" label="Antibacterial"/><FilterOption id="750" count="21" label="DNA intercalator"/><FilterOption id="399" count="20" label="Hypoglycemic agent"/><FilterOption id="15184" count="20" label="Systemic antipsoriatic product"/><FilterOption id="664" count="19" label="Fibrosuppressant"/><FilterOption id="539" count="17" label="Immunotoxin"/><FilterOption id="284" count="17" label="Nootropic agent"/><FilterOption id="388" count="17" label="Vasodilator"/><FilterOption id="62254" count="14" label="Anticancer hormone antagonist"/><FilterOption id="70" count="14" label="Anticonvulsant agent"/><FilterOption id="2941" count="14" label="Antidepressant"/><FilterOption id="2943" count="14" label="Antipsychotic"/><FilterOption id="312" count="14" label="Platelet aggregation inhibitor"/><FilterOption id="71" count="13" label="Antihypercholesterolemic agent"/><FilterOption id="5580" count="12" label="Chemotaxis inhibitor"/><FilterOption id="12372" count="12" label="Protein subunit vaccine"/><FilterOption id="59620" count="12" label="Unspecified drug target"/><FilterOption id="55684" count="11" label="Anticancer antibody"/><FilterOption id="5704" count="11" label="B-lymphocyte adhesion inhibitor"/><FilterOption id="5710" count="11" label="B-lymphocyte migration inhibitor"/><FilterOption id="1332" count="11" label="Gastrointestinal system agent"/><FilterOption id="695" count="11" label="Metastasis inhibitor"/><FilterOption id="449" count="10" label="Antiarrhythmic agent"/><FilterOption id="646" count="10" label="Bronchodilator"/><FilterOption id="659" count="10" label="Coagulation inhibitor"/><FilterOption id="3980" count="10" label="HIV fusion inhibitor"/><FilterOption id="12378" count="10" label="Prophylactic vaccine"/><FilterOption id="439" count="10" label="RNA synthesis inhibitor"/><FilterOption id="2659" count="9" label="Cardioprotectant"/><FilterOption id="610" count="9" label="Hematopoietic stimulator"/><FilterOption id="32411" count="9" label="Hepatitis B virus replication inhibitor"/><FilterOption id="15187" count="9" label="Systemic dermatological antibacterial product"/><FilterOption id="104" count="8" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="285" count="8" label="Norepinephrine uptake inhibitor"/><FilterOption id="1532" count="8" label="Viral replication inhibitor"/><FilterOption id="1590" count="7" label="Apoptosis inhibitor"/><FilterOption id="3984" count="7" label="Bacterial nucleic acid synthesis inhibitor"/><FilterOption id="863" count="7" label="Bile acid modulator"/><FilterOption id="1748" count="7" label="Fungicide"/><FilterOption id="7292" count="7" label="Vulnerary agent"/><FilterOption id="937" count="6" label="Androgen synthesis inhibitor"/><FilterOption id="7294" count="6" label="Antisense oligonucleotide inhibitor"/><FilterOption id="137" count="6" label="Diuretic agent"/><FilterOption id="151" count="6" label="Dopamine uptake inhibitor"/><FilterOption id="805" count="6" label="Folate modulator"/><FilterOption id="7760" count="6" label="T-lymphocyte inhibitor"/><FilterOption id="524" count="5" label="Adjuvant"/><FilterOption id="74" count="5" label="Antioxidant agent"/><FilterOption id="89" count="5" label="Bone resorption inhibitor"/><FilterOption id="966" count="5" label="Cardiac agent"/><FilterOption id="7211" count="5" label="CNS diagnostic agent"/><FilterOption id="11593" count="5" label="DNA repair inhibitor"/><FilterOption id="15128" count="5" label="Ophthalmological agent"/><FilterOption id="26035" count="5" label="siRNA agent"/><FilterOption id="2970" count="4" label="Anti-emetic"/><FilterOption id="2667" count="4" label="Antiarteriosclerotic"/><FilterOption id="4007" count="4" label="Antidiarrhoeal"/><FilterOption id="7018" count="4" label="Antihypertriglyceridemic agent"/><FilterOption id="2638" count="4" label="Antiparasitic"/><FilterOption id="2942" count="4" label="Anxiolytic"/><FilterOption id="1538" count="4" label="Bacterial protein synthesis inhibitor"/><FilterOption id="65" count="4" label="Class I antiarrhythmic agent"/><FilterOption id="2939" count="4" label="CNS modulator"/><FilterOption id="161" count="4" label="Ergosterol synthesis inhibitor"/><FilterOption id="166" count="4" label="Fibrinolysis stimulator"/><FilterOption id="4790" count="4" label="Genetically engineered autologous cell therapy"/><FilterOption id="1129" count="4" label="Non-steroid hormone receptor antagonist"/><FilterOption id="12596" count="4" label="Osteoclast inhibitor"/><FilterOption id="5555" count="4" label="PET contrast agent"/><FilterOption id="339" count="4" label="Protein synthesis inhibitor"/><FilterOption id="5720" count="4" label="Radiodiagnostic"/><FilterOption id="12370" count="4" label="Recombinant viral vector vaccine"/><FilterOption id="53558" count="4" label="Stem cell modulator"/><FilterOption id="15178" count="4" label="Systemic dermatological antifungal product"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="274" label="Unspecified"/><FilterOption id="YES" count="171" label="Yes"/><FilterOption id="NO" count="92" label="No"/></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8712" count="39" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="9218" count="36" label="HIV infection - Assessment of Immune Response"/><FilterOption id="7538" count="35" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="9247" count="34" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8719" count="33" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7879" count="32" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="9215" count="30" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="8721" count="29" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7354" count="27" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="8078" count="26" label="Leukemia - Assessment of adverse events"/><FilterOption id="8720" count="25" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="9213" count="25" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="8481" count="25" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8738" count="24" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="7908" count="24" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8489" count="24" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7611" count="24" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="8998" count="23" label="Breast tumor - Assessment of adverse events"/><FilterOption id="7563" count="22" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8713" count="21" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7547" count="21" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7680" count="21" label="Lymphoma - Assessment of adverse events"/><FilterOption id="6919" count="21" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="8722" count="19" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"/><FilterOption id="9242" count="19" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="9153" count="19" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7679" count="19" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="7360" count="19" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7898" count="18" label="Leukemia - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="7569" count="18" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="6924" count="18" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="6940" count="18" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="7393" count="18" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="8725" count="17" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"/><FilterOption id="7027" count="17" label="Melanoma - Assessment of adverse events"/><FilterOption id="9212" count="16" label="HIV infection - Assessment of Viral Load"/><FilterOption id="7909" count="16" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8077" count="16" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="8505" count="16" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="7367" count="16" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8754" count="15" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="8522" count="15" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="7558" count="15" label="Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)"/><FilterOption id="11728" count="14" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)"/><FilterOption id="8744" count="14" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="8999" count="14" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8996" count="14" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="2622" count="14" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="9238" count="14" label="HIV infection - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8109" count="14" label="Leukemia - Assessment of Mortality/Death Rates"/><FilterOption id="7907" count="14" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="9300" count="14" label="Leukemia - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="7564" count="14" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7372" count="14" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8714" count="13" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="8430" count="13" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="2492" count="13" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="2703" count="13" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="8147" count="13" label="Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease"/><FilterOption id="7373" count="13" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="42921" count="13" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="43526" count="13" label="Other gastrointestinal disease - Clinical Assessments"/><FilterOption id="10828" count="13" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7190" count="13" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="11717" count="12" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="11735" count="12" label="Bladder cancer - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="6951" count="12" label="Melanoma - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="43393" count="12" label="Other gastrointestinal disease - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="10540" count="12" label="Renal cell carcinoma - Assessment of Overall Survival (OS)"/><FilterOption id="10545" count="12" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="11780" count="11" label="Bladder cancer - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="11722" count="11" label="Bladder cancer - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8151" count="11" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="2623" count="11" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"/><FilterOption id="2565" count="11" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis"/><FilterOption id="6863" count="11" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="9241" count="11" label="HIV infection - Assessment of Renal Function"/><FilterOption id="9255" count="11" label="HIV infection - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation"/><FilterOption id="7891" count="11" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8640" count="11" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="7489" count="11" label="Multiple myeloma - Assessment of Safety and Tolerability - Assessment of other adverse events"/><FilterOption id="43670" count="11" label="Other gastrointestinal disease - Assessment of adverse events"/><FilterOption id="10839" count="11" label="Ovary tumor - Assessment of Response Rates (RR) - Assessment of overall/objective response rate(ORR)"/><FilterOption id="15212" count="11" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="8759" count="10" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8187" count="10" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="2518" count="10" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis (Definite /Probable /Possible)"/><FilterOption id="7921" count="10" label="Leukemia - Assessment of Disease Relapse/Recurrence"/><FilterOption id="7916" count="10" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="6972" count="10" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="10187" count="10" label="Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part III scale/score"/><FilterOption id="11773" count="9" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="9415" count="9" label="Lymphoma - Assessment of Disease Progression"/><FilterOption id="2619" count="8" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"/><FilterOption id="2621" count="8" label="Coronary artery disease - Assessment of Mortality/Death Rates"/><FilterOption id="9217" count="8" label="HIV infection - Assessment of CD8 Cell Responses - Assessment of CD8 cell count/percentage"/><FilterOption id="9272" count="8" label="HIV infection - Assessment of Mortality/Death Rates"/><FilterOption id="8514" count="8" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7395" count="8" label="Multiple myeloma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="42861" count="8" label="Other cardiovascular disease - Assessment of Safety and Tolerability"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="1211" count="93" label="Alanine transaminase"/><FilterOption id="213" count="77" label="Creatinine"/><FilterOption id="2527" count="76" label="Aspartate aminotransferase"/><FilterOption id="1236" count="64" label="Hemoglobin"/><FilterOption id="2054" count="63" label="Blood platelets"/><FilterOption id="3" count="63" label="HER2"/><FilterOption id="1857" count="61" label="T-cell surface glycoprotein CD4"/><FilterOption id="12058" count="60" label="Total body mass"/><FilterOption id="1925" count="51" label="Neutrophils"/><FilterOption id="2387" count="49" label="Bilirubin"/><FilterOption id="46" count="49" label="C-reactive protein"/><FilterOption id="1880" count="45" label="T-Helper Lymphocytes"/><FilterOption id="1904" count="44" label="Heart rate"/><FilterOption id="824" count="44" label="Programmed cell death 1 ligand 1"/><FilterOption id="5" count="41" label="Estrogen receptor"/><FilterOption id="1735" count="40" label="Glucose"/><FilterOption id="2586" count="39" label="Blood pressure"/><FilterOption id="44218" count="38" label="Human immunodeficiency virus RNA"/><FilterOption id="176" count="38" label="Interleukin-6"/><FilterOption id="3447" count="38" label="T-cell surface glycoprotein CD8 alpha chain"/><FilterOption id="133" count="38" label="Total cholesterol"/><FilterOption id="125" count="36" label="Leukocyte count"/><FilterOption id="152" count="35" label="Low-density lipoprotein cholesterol"/><FilterOption id="217" count="35" label="Triglycerides"/><FilterOption id="118" count="34" label="Albumin"/><FilterOption id="28899" count="34" label="Alkaline phosphatase"/><FilterOption id="147" count="32" label="Six-minute walk distance"/><FilterOption id="153" count="30" label="High-density lipoprotein cholesterol"/><FilterOption id="6" count="30" label="Progesterone receptor"/><FilterOption id="46505" count="29" label="Cytotoxic T-Lymphocytes"/><FilterOption id="8" count="29" label="Epidermal growth factor receptor"/><FilterOption id="7895" count="29" label="Estimated glomerular filtration rate"/><FilterOption id="14767" count="28" label="Lipids"/><FilterOption id="36136" count="27" label="Cytokines"/><FilterOption id="4806" count="27" label="Lymphocytes"/><FilterOption id="82" count="26" label="B-Raf proto-oncogene serine/threonine-protein kinase"/><FilterOption id="330" count="26" label="Systolic blood pressure"/><FilterOption id="113" count="25" label="Body Mass Index"/><FilterOption id="38" count="25" label="Prostate-specific antigen"/><FilterOption id="8024" count="24" label="Creatine kinase"/><FilterOption id="8458" count="24" label="gamma-Glutamyltransferase"/><FilterOption id="106" count="24" label="N-terminal Pro Brain Natriuretic Peptide"/><FilterOption id="332" count="21" label="Diastolic blood pressure"/><FilterOption id="46506" count="21" label="T-Lymphocytes"/><FilterOption id="1945" count="20" label="Left ventricular ejection fraction"/><FilterOption id="2662" count="20" label="Sodium"/><FilterOption id="4522" count="19" label="Erythrocytes"/><FilterOption id="274" count="19" label="Tumor necrosis factor"/><FilterOption id="1731" count="18" label="B-lymphocyte antigen CD20"/><FilterOption id="3374" count="18" label="Bone mineral density"/><FilterOption id="2417" count="18" label="Calcium"/><FilterOption id="289" count="18" label="Hemoglobin A, glycosylated"/><FilterOption id="252" count="18" label="Interferon gamma"/><FilterOption id="165" count="17" label="Beta-2-microglobulin"/><FilterOption id="10684" count="17" label="Blood cells"/><FilterOption id="44216" count="17" label="Body temperature"/><FilterOption id="1912" count="17" label="Forced Vital Capacity"/><FilterOption id="2098" count="17" label="Potassium"/><FilterOption id="148" count="17" label="QT interval"/><FilterOption id="5700" count="16" label="ALK receptor"/><FilterOption id="6663" count="16" label="B-lymphocytes"/><FilterOption id="154" count="16" label="Lactate dehydrogenase"/><FilterOption id="2713" count="15" label="Forced expiratory volume"/><FilterOption id="749" count="15" label="Free light chains"/><FilterOption id="808" count="15" label="Insulin"/><FilterOption id="7" count="14" label="Antigen KI-67"/><FilterOption id="1289" count="14" label="Tumor mass"/><FilterOption id="175" count="13" label="Interleukin-10"/><FilterOption id="2412" count="12" label="Immunoglobulin M"/><FilterOption id="13158" count="12" label="Myeloma protein"/><FilterOption id="11117" count="12" label="Plasma cells"/><FilterOption id="2411" count="12" label="Pulmonary vascular resistance"/><FilterOption id="11857" count="12" label="Transaminases"/><FilterOption id="12516" count="12" label="Urinary protein"/><FilterOption id="126" count="11" label="BCR-ABL1 fusion protein"/><FilterOption id="17697" count="11" label="Body height"/><FilterOption id="22" count="11" label="Breast cancer type 1 susceptibility protein"/><FilterOption id="9" count="11" label="Cellular tumor antigen p53"/><FilterOption id="2254" count="11" label="HLA-DR Antigens"/><FilterOption id="3451" count="11" label="Immunoglobulin G"/><FilterOption id="7033" count="11" label="Lipase"/><FilterOption id="900" count="11" label="Microtubule associated protein tau"/><FilterOption id="2613" count="11" label="Norepinephrine"/><FilterOption id="122" count="11" label="Renin"/><FilterOption id="769" count="10" label="ADP-ribosyl cyclase 1"/><FilterOption id="41" count="10" label="Breast cancer type 2 susceptibility protein"/><FilterOption id="71" count="10" label="CA-125 antigen"/><FilterOption id="3098" count="10" label="Calprotectin"/><FilterOption id="64" count="10" label="Circulating Tumor Cells"/><FilterOption id="2139" count="10" label="Pulmonary arterial pressure"/><FilterOption id="11114" count="9" label="Brain"/><FilterOption id="52" count="9" label="GTPase KRas"/><FilterOption id="1221" count="9" label="Hematocrit"/><FilterOption id="2986" count="9" label="Hepatic venous pressure gradient"/><FilterOption id="10833" count="9" label="Myomesin-2"/><FilterOption id="105" count="9" label="Natriuretic peptides B"/><FilterOption id="2689" count="9" label="Partial pressure of oxygen"/><FilterOption id="92" count="9" label="Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform"/><FilterOption id="10260" count="9" label="Respiratory frequency"/><FilterOption id="1005" count="8" label="C-X-C motif chemokine 10"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="5"><FilterOption id="SIEEFC" count="1080" label="Efficacy"/><FilterOption id="SIESFT" count="1021" label="Safety"/><FilterOption id="SIEPCK" count="397" label="Pharmacokinetics"/><FilterOption id="SIEPCD" count="213" label="Pharmacodynamics"/><FilterOption id="SIEBAV" count="4" label="Bioavailability"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="3803" count="29" label="paclitaxel"/><FilterOption id="6736" count="29" label="rituximab"/><FilterOption id="3199" count="28" label="gemcitabine"/><FilterOption id="44383" count="26" label="carboplatin"/><FilterOption id="72699" count="25" label="atezolizumab"/><FilterOption id="8047" count="20" label="bevacizumab"/><FilterOption id="15954" count="18" label="bortezomib"/><FilterOption id="27572" count="18" label="lenalidomide"/><FilterOption id="7310" count="17" label="ritonavir"/><FilterOption id="2953" count="16" label="docetaxel"/><FilterOption id="6386" count="15" label="trastuzumab"/><FilterOption id="3792" count="13" label="oxaliplatin"/><FilterOption id="3072" count="12" label="etoposide phosphate"/><FilterOption id="70667" count="12" label="pembrolizumab"/><FilterOption id="47000" count="10" label="bendamustine"/><FilterOption id="14681" count="10" label="lopinavir + ritonavir"/><FilterOption id="54804" count="10" label="nivolumab"/><FilterOption id="12205" count="9" label="capecitabine"/><FilterOption id="6156" count="9" label="fludarabine"/><FilterOption id="55237" count="9" label="ibrutinib"/><FilterOption id="3474" count="9" label="lamivudine"/><FilterOption id="2784" count="9" label="letrozole"/><FilterOption id="54601" count="8" label="carfilzomib"/><FilterOption id="56544" count="8" label="cobimetinib"/><FilterOption id="32981" count="8" label="darunavir"/><FilterOption id="3313" count="8" label="fulvestrant"/><FilterOption id="29016" count="8" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="28532" count="8" label="pertuzumab"/><FilterOption id="54488" count="8" label="raltegravir"/><FilterOption id="5369" count="8" label="ribavirin"/><FilterOption id="15254" count="7" label="atazanavir"/><FilterOption id="53200" count="7" label="daratumumab"/><FilterOption id="3081" count="7" label="exemestane"/><FilterOption id="11519" count="7" label="mitoxantrone"/><FilterOption id="53227" count="7" label="obinutuzumab"/><FilterOption id="14493" count="7" label="tenofovir disoproxil fumarate"/><FilterOption id="10309" count="6" label="abiraterone"/><FilterOption id="4728" count="6" label="emtricitabine"/><FilterOption id="13022" count="6" label="epirubicin"/><FilterOption id="11961" count="6" label="erlotinib"/><FilterOption id="36630" count="6" label="ipilimumab"/><FilterOption id="45841" count="6" label="lenvatinib mesylate"/><FilterOption id="12646" count="6" label="panitumumab"/><FilterOption id="3536" count="6" label="pemetrexed disodium"/><FilterOption id="6242" count="5" label="abacavir"/><FilterOption id="83065" count="5" label="avelumab"/><FilterOption id="37370" count="5" label="azacitidine"/><FilterOption id="5999" count="5" label="ciclosporin, Novartis"/><FilterOption id="59062" count="5" label="dolutegravir"/><FilterOption id="81193" count="5" label="durvalumab"/><FilterOption id="10172" count="5" label="efavirenz"/><FilterOption id="2871" count="5" label="irinotecan"/><FilterOption id="37613" count="5" label="maraviroc"/><FilterOption id="23625" count="5" label="peginterferon alfa-2a"/><FilterOption id="27696" count="5" label="pomalidomide"/><FilterOption id="54469" count="5" label="vemurafenib"/><FilterOption id="12150" count="5" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="55305" count="4" label="binimetinib"/><FilterOption id="10388" count="4" label="cetuximab"/><FilterOption id="2836" count="4" label="clopidogrel"/><FilterOption id="73843" count="4" label="encorafenib"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="13340" count="4" label="everolimus"/><FilterOption id="61287" count="4" label="niraparib"/><FilterOption id="4510" count="4" label="tacrolimus"/><FilterOption id="44314" count="4" label="tamoxifen"/><FilterOption id="49219" count="4" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="70678" count="4" label="xentuzumab"/><FilterOption id="3321" count="3" label="anastrozole"/><FilterOption id="39172" count="3" label="brentuximab vedotin"/><FilterOption id="13239" count="3" label="decitabine"/><FilterOption id="4563" count="3" label="doxorubicin (liposome formulation), Cephalon"/><FilterOption id="48099" count="3" label="farletuzumab"/><FilterOption id="3130" count="3" label="filgrastim"/><FilterOption id="48319" count="3" label="idelalisib"/><FilterOption id="66051" count="3" label="ipatasertib dihydrochloride"/><FilterOption id="3669" count="3" label="mycophenolate mofetil"/><FilterOption id="4200" count="3" label="sirolimus"/><FilterOption id="45562" count="3" label="tremelimumab"/><FilterOption id="70895" count="3" label="venetoclax"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="72538" count="2" label="abemaciclib"/><FilterOption id="24885" count="2" label="albinterferon alfa-2b"/><FilterOption id="69066" count="2" label="alectinib"/><FilterOption id="2716" count="2" label="alemtuzumab"/><FilterOption id="7867" count="2" label="amprenavir"/><FilterOption id="66828" count="2" label="bemcentinib"/><FilterOption id="50935" count="2" label="cabozantinib S-malate"/><FilterOption id="44384" count="2" label="ceftriaxone"/><FilterOption id="64231" count="2" label="copanlisib hydrochloride"/><FilterOption id="9049" count="2" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="7934" count="2" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="13486" count="2" label="entecavir"/><FilterOption id="55085" count="2" label="filanesib"/><FilterOption id="5202" count="2" label="gemtuzumab ozogamicin"/><FilterOption id="11460" count="2" label="imatinib"/><FilterOption id="7067" count="2" label="imiquimod"/><FilterOption id="2714" count="2" label="inotuzumab ozogamicin"/><FilterOption id="72635" count="2" label="ivosidenib"/><FilterOption id="64947" count="2" label="ixazomib citrate (oral, multiple myeloma/amyloidosis), Takeda"/></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="OTHER" count="394" label="Other Publications"/><FilterOption id="PR" count="393" label="Press Releases"/><FilterOption id="SERIAL" count="355" label="Serial Publications"/><FilterOption id="CORPORATE" count="103" label="Corporate Publications"/><FilterOption id="CONFERENCE" count="76" label="Conference Reports"/></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="27572" count="12" label="lenalidomide"/><FilterOption id="72699" count="11" label="atezolizumab"/><FilterOption id="14681" count="7" label="lopinavir + ritonavir"/><FilterOption id="52854" count="7" label="macitentan"/><FilterOption id="70667" count="7" label="pembrolizumab"/><FilterOption id="45499" count="7" label="tofacitinib citrate (oral, inflammation), Pfizer"/><FilterOption id="8047" count="6" label="bevacizumab"/><FilterOption id="57369" count="6" label="etrolizumab"/><FilterOption id="55237" count="6" label="ibrutinib"/><FilterOption id="83065" count="5" label="avelumab"/><FilterOption id="5871" count="5" label="bosentan"/><FilterOption id="3700" count="5" label="nevirapine"/><FilterOption id="50963" count="5" label="obeticholic acid (primary biliary cholangitis), Intercept/AOP Orphan"/><FilterOption id="30379" count="4" label="bosutinib"/><FilterOption id="53981" count="4" label="enzalutamide"/><FilterOption id="11961" count="4" label="erlotinib"/><FilterOption id="37613" count="4" label="maraviroc"/><FilterOption id="54488" count="4" label="raltegravir"/><FilterOption id="6736" count="4" label="rituximab"/><FilterOption id="88619" count="4" label="sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead"/><FilterOption id="75324" count="4" label="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"/><FilterOption id="14163" count="3" label="adalimumab"/><FilterOption id="69066" count="3" label="alectinib"/><FilterOption id="7781" count="3" label="aripiprazole"/><FilterOption id="100097" count="3" label="bictegravir + emtricitabine + tenofovir alafenamide (HIV-1 infection), Gilead"/><FilterOption id="72743" count="3" label="birtamimab"/><FilterOption id="15954" count="3" label="bortezomib"/><FilterOption id="24343" count="3" label="dabigatran etexilate"/><FilterOption id="62277" count="3" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="89500" count="3" label="esketamine (intranasal), Janssen Research &amp; Development"/><FilterOption id="4567" count="3" label="etanercept"/><FilterOption id="13340" count="3" label="everolimus"/><FilterOption id="53840" count="3" label="gantenerumab"/><FilterOption id="3199" count="3" label="gemcitabine"/><FilterOption id="6850" count="3" label="infliximab"/><FilterOption id="54804" count="3" label="nivolumab"/><FilterOption id="56776" count="3" label="SHP-647"/><FilterOption id="4529" count="3" label="temozolomide"/><FilterOption id="50038" count="3" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"/><FilterOption id="7982" count="2" label="abetimus"/><FilterOption id="50961" count="2" label="abobotulinumtoxinA"/><FilterOption id="84728" count="2" label="abrocitinib"/><FilterOption id="64893" count="2" label="acetylsalicylic acid + simvastatin + ramipril (oral, cardiovascular disease), Ferrer Internacional"/><FilterOption id="6306" count="2" label="aldesleukin"/><FilterOption id="6893" count="2" label="alteplase"/><FilterOption id="44374" count="2" label="amiodarone"/><FilterOption id="15254" count="2" label="atazanavir"/><FilterOption id="39209" count="2" label="axitinib"/><FilterOption id="37370" count="2" label="azacitidine"/><FilterOption id="31831" count="2" label="belimumab"/><FilterOption id="34140" count="2" label="blinatumomab"/><FilterOption id="105633" count="2" label="bumetanide (autism), Servier/ Neurochlore"/><FilterOption id="5929" count="2" label="bupropion (oral sustained release), GlaxoSmithKline"/><FilterOption id="8955" count="2" label="carvedilol"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="63587" count="2" label="Cx-611"/><FilterOption id="9049" count="2" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="63586" count="2" label="darvadstrocel"/><FilterOption id="54116" count="2" label="disitertide"/><FilterOption id="81193" count="2" label="durvalumab"/><FilterOption id="15593" count="2" label="eculizumab"/><FilterOption id="51255" count="2" label="edoxaban"/><FilterOption id="10172" count="2" label="efavirenz"/><FilterOption id="55066" count="2" label="elafibranor"/><FilterOption id="58762" count="2" label="empagliflozin"/><FilterOption id="16156" count="2" label="emricasan (oral, islet transplant rejection/liver disease), Novartis"/><FilterOption id="13486" count="2" label="entecavir"/><FilterOption id="25912" count="2" label="eprodisate"/><FilterOption id="60512" count="2" label="erdafitinib"/><FilterOption id="87805" count="2" label="faricimab"/><FilterOption id="67653" count="2" label="inotersen"/><FilterOption id="36630" count="2" label="ipilimumab"/><FilterOption id="16696" count="2" label="lamivudine + zidovudine, GlaxoSmithKline"/><FilterOption id="3474" count="2" label="lamivudine"/><FilterOption id="55488" count="2" label="lanabecestat"/><FilterOption id="52798" count="2" label="lebrikizumab"/><FilterOption id="19462" count="2" label="micafungin"/><FilterOption id="62073" count="2" label="mongersen"/><FilterOption id="60575" count="2" label="murepavadin"/><FilterOption id="18097" count="2" label="neramexane"/><FilterOption id="3705" count="2" label="nicotine"/><FilterOption id="51160" count="2" label="nintedanib"/><FilterOption id="3738" count="2" label="olanzapine"/><FilterOption id="2534" count="2" label="omalizumab"/><FilterOption id="43738" count="2" label="pazopanib"/><FilterOption id="54422" count="2" label="QPI-1002"/><FilterOption id="63895" count="2" label="ralinepag"/><FilterOption id="4199" count="2" label="ranolazine"/><FilterOption id="32677" count="2" label="rivaroxaban"/><FilterOption id="81852" count="2" label="selonsertib"/><FilterOption id="7707" count="2" label="seocalcitol"/><FilterOption id="67205" count="2" label="simtuzumab"/><FilterOption id="79811" count="2" label="sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead"/><FilterOption id="65416" count="2" label="sofosbuvir"/><FilterOption id="54730" count="2" label="sotatercept"/><FilterOption id="12973" count="2" label="sunitinib"/><FilterOption id="63988" count="2" label="tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride (HIV-1 infection, fixed dose), Gilead Sciences"/><FilterOption id="14493" count="2" label="tenofovir disoproxil fumarate"/><FilterOption id="8165" count="2" label="tiotropium bromide"/><FilterOption id="46613" count="2" label="tralokinumab"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="99"><FilterOption id="44383" count="19" label="carboplatin"/><FilterOption id="3199" count="16" label="gemcitabine"/><FilterOption id="3803" count="16" label="paclitaxel"/><FilterOption id="6736" count="12" label="rituximab"/><FilterOption id="2953" count="11" label="docetaxel"/><FilterOption id="7310" count="9" label="ritonavir"/><FilterOption id="49219" count="9" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="6386" count="9" label="trastuzumab"/><FilterOption id="8047" count="7" label="bevacizumab"/><FilterOption id="15954" count="7" label="bortezomib"/><FilterOption id="12205" count="7" label="capecitabine"/><FilterOption id="32981" count="6" label="darunavir"/><FilterOption id="14681" count="6" label="lopinavir + ritonavir"/><FilterOption id="10309" count="5" label="abiraterone"/><FilterOption id="47000" count="5" label="bendamustine"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="3072" count="5" label="etoposide phosphate"/><FilterOption id="27572" count="5" label="lenalidomide"/><FilterOption id="3792" count="5" label="oxaliplatin"/><FilterOption id="15254" count="4" label="atazanavir"/><FilterOption id="48181" count="4" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="3536" count="4" label="pemetrexed disodium"/><FilterOption id="12150" count="4" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="7934" count="3" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="10172" count="3" label="efavirenz"/><FilterOption id="53227" count="3" label="obinutuzumab"/><FilterOption id="29016" count="3" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="54488" count="3" label="raltegravir"/><FilterOption id="14493" count="3" label="tenofovir disoproxil fumarate"/><FilterOption id="72699" count="2" label="atezolizumab"/><FilterOption id="37370" count="2" label="azacitidine"/><FilterOption id="54601" count="2" label="carfilzomib"/><FilterOption id="2836" count="2" label="clopidogrel"/><FilterOption id="62275" count="2" label="cobicistat"/><FilterOption id="72148" count="2" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="59062" count="2" label="dolutegravir"/><FilterOption id="51371" count="2" label="elvitegravir"/><FilterOption id="4728" count="2" label="emtricitabine"/><FilterOption id="30682" count="2" label="etravirine"/><FilterOption id="13340" count="2" label="everolimus"/><FilterOption id="3081" count="2" label="exemestane"/><FilterOption id="6156" count="2" label="fludarabine"/><FilterOption id="24471" count="2" label="fosamprenavir"/><FilterOption id="3474" count="2" label="lamivudine"/><FilterOption id="33591" count="2" label="lapatinib"/><FilterOption id="11519" count="2" label="mitoxantrone"/><FilterOption id="3700" count="2" label="nevirapine"/><FilterOption id="23625" count="2" label="peginterferon alfa-2a"/><FilterOption id="28532" count="2" label="pertuzumab"/><FilterOption id="4196" count="2" label="ramipril"/><FilterOption id="5369" count="2" label="ribavirin"/><FilterOption id="52857" count="2" label="rilpivirine hydrochloride"/><FilterOption id="4259" count="2" label="saquinavir"/><FilterOption id="44313" count="2" label="simvastatin"/><FilterOption id="8050" count="2" label="thalidomide, Celgene"/><FilterOption id="15130" count="2" label="vinflunine"/><FilterOption id="44375" count="2" label="warfarin"/><FilterOption id="6242" count="1" label="abacavir"/><FilterOption id="14163" count="1" label="adalimumab"/><FilterOption id="7867" count="1" label="amprenavir"/><FilterOption id="74263" count="1" label="atazanavir sulfate + cobicistat (fixed-dose combination, HIV infection), Bristol-Myers Squibb"/><FilterOption id="12544" count="1" label="caspofungin"/><FilterOption id="44384" count="1" label="ceftriaxone"/><FilterOption id="5999" count="1" label="ciclosporin, Novartis"/><FilterOption id="44370" count="1" label="clindamycin"/><FilterOption id="9049" count="1" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="13239" count="1" label="decitabine"/><FilterOption id="2935" count="1" label="didanosine"/><FilterOption id="4563" count="1" label="doxorubicin (liposome formulation), Cephalon"/><FilterOption id="13486" count="1" label="entecavir"/><FilterOption id="53981" count="1" label="enzalutamide"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="3130" count="1" label="filgrastim"/><FilterOption id="44292" count="1" label="fluconazole"/><FilterOption id="3195" count="1" label="ganciclovir (oral), Roche Bioscience"/><FilterOption id="36630" count="1" label="ipilimumab"/><FilterOption id="2871" count="1" label="irinotecan"/><FilterOption id="65757" count="1" label="JNJ-3989"/><FilterOption id="100866" count="1" label="JNJ-56136379"/><FilterOption id="26574" count="1" label="lamivudine + abacavir + zidovudine, GSK"/><FilterOption id="16696" count="1" label="lamivudine + zidovudine, GlaxoSmithKline"/><FilterOption id="3488" count="1" label="leflunomide"/><FilterOption id="37613" count="1" label="maraviroc"/><FilterOption id="6050" count="1" label="metformin hydrochloride"/><FilterOption id="61287" count="1" label="niraparib"/><FilterOption id="54804" count="1" label="nivolumab"/><FilterOption id="52139" count="1" label="ofloxacin"/><FilterOption id="21374" count="1" label="pegfilgrastim"/><FilterOption id="44499" count="1" label="sitagliptin"/><FilterOption id="4481" count="1" label="stavudine"/><FilterOption id="12973" count="1" label="sunitinib"/><FilterOption id="4529" count="1" label="temozolomide"/><FilterOption id="40532" count="1" label="tenofovir alafenamide fumarate"/><FilterOption id="36332" count="1" label="ticagrelor"/><FilterOption id="4577" count="1" label="topotecan"/><FilterOption id="25182" count="1" label="valganciclovir"/><FilterOption id="44401" count="1" label="vancomycin"/><FilterOption id="6408" count="1" label="vinorelbine"/><FilterOption id="44316" count="1" label="zidovudine"/></Filter><Filter label="Trial Category" name="trialCategory" total="16"><FilterOption id="4" count="807" label="Small molecule"/><FilterOption id="3" count="409" label="Biological"/><FilterOption id="8" count="112" label="Medical device"/><FilterOption id="9" count="59" label="Medical procedure"/><FilterOption id="5" count="35" label="Vaccine"/><FilterOption id="16" count="32" label="Behavioral intervention"/><FilterOption id="15" count="26" label="Radiation therapy"/><FilterOption id="6" count="20" label="Cell therapy"/><FilterOption id="11" count="20" label="Dietary supplement"/><FilterOption id="7" count="20" label="Gene therapy"/><FilterOption id="18" count="11" label="Pathophysiology"/><FilterOption id="14" count="10" label="Diagnostic"/><FilterOption id="17" count="9" label="Biomarker identification"/><FilterOption id="19" count="2" label="Surgical procedure"/><FilterOption id="10" count="1" label="Borderline product"/><FilterOption id="13" count="1" label="Hospital solutions"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="NO" count="651" label="No"/><FilterOption id="YES" count="537" label="Yes"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="14007" count="51" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="5085" count="43" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="67136" count="40" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="1832" count="39" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="1016" count="33" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="740" count="32" label="Epidermal growth factor receptor antagonist"/><FilterOption id="204" count="31" label="HIV protease inhibitor"/><FilterOption id="3808" count="31" label="Kit tyrosine kinase inhibitor"/><FilterOption id="4917" count="31" label="Proteasome inhibitor"/><FilterOption id="138" count="30" label="DNA polymerase inhibitor"/><FilterOption id="3848" count="29" label="VEGF-2 receptor antagonist"/><FilterOption id="7588" count="28" label="HIV-1 integrase inhibitor"/><FilterOption id="768" count="28" label="HIV-1 protease inhibitor"/><FilterOption id="3846" count="28" label="VEGF-1 receptor antagonist"/><FilterOption id="3756" count="27" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="3850" count="27" label="VEGF-3 receptor antagonist"/><FilterOption id="142" count="25" label="Topoisomerase II inhibitor"/><FilterOption id="12521" count="22" label="VEGF ligand inhibitor"/><FilterOption id="76469" count="21" label="26S proteasome complex inhibitor"/><FilterOption id="3806" count="21" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="48492" count="21" label="PDGF receptor beta antagonist"/><FilterOption id="948" count="19" label="PDGF receptor antagonist"/><FilterOption id="7424" count="18" label="Cytochrome P450 3A4 inhibitor"/><FilterOption id="3682" count="18" label="FGF1 receptor antagonist"/><FilterOption id="3688" count="18" label="FGF3 receptor antagonist"/><FilterOption id="48489" count="18" label="PDGF receptor alpha antagonist"/><FilterOption id="76" count="17" label="Aromatase inhibitor"/><FilterOption id="10240" count="17" label="mTOR inhibitor"/><FilterOption id="1833" count="17" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="3754" count="16" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="4548" count="16" label="Raf B protein kinase inhibitor"/><FilterOption id="372" count="16" label="Thymidylate synthase inhibitor"/><FilterOption id="770" count="15" label="Endothelin ET-A receptor antagonist"/><FilterOption id="1722" count="15" label="VEGF receptor antagonist"/><FilterOption id="3685" count="14" label="FGF2 receptor antagonist"/><FilterOption id="4762" count="14" label="MEK-1 protein kinase inhibitor"/><FilterOption id="4764" count="14" label="MEK-2 protein kinase inhibitor"/><FilterOption id="3816" count="14" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="3592" count="13" label="Btk tyrosine kinase inhibitor"/><FilterOption id="286" count="13" label="Estrogen receptor antagonist"/><FilterOption id="4760" count="13" label="MEK protein kinase inhibitor"/><FilterOption id="5482" count="12" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="771" count="12" label="Endothelin ET-B receptor antagonist"/><FilterOption id="38283" count="12" label="Poly ADP ribose polymerase 1 inhibitor"/><FilterOption id="38286" count="12" label="Poly ADP ribose polymerase 2 inhibitor"/><FilterOption id="3576" count="12" label="Src tyrosine kinase inhibitor"/><FilterOption id="4010" count="11" label="Calcineurin inhibitor"/><FilterOption id="3154" count="11" label="CSF-1 antagonist"/><FilterOption id="3562" count="11" label="Jak1 tyrosine kinase inhibitor"/><FilterOption id="4314" count="10" label="Cyclin-dependent kinase-4 inhibitor"/><FilterOption id="4318" count="10" label="Cyclin-dependent kinase-6 inhibitor"/><FilterOption id="675" count="10" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="214" count="10" label="Interferon alpha 2 ligand"/><FilterOption id="2506" count="10" label="PARP modulator"/><FilterOption id="3818" count="10" label="Ret tyrosine kinase receptor inhibitor"/><FilterOption id="5136" count="9" label="ADP ribosyl cyclase-1 inhibitor"/><FilterOption id="621" count="9" label="Amyloid protein deposition inhibitor"/><FilterOption id="60" count="9" label="Androgen receptor antagonist"/><FilterOption id="13571" count="9" label="Bcr protein inhibitor"/><FilterOption id="3107" count="9" label="CCR5 chemokine antagonist"/><FilterOption id="5027" count="9" label="CD4 agonist"/><FilterOption id="51708" count="9" label="DNA polymerase alpha inhibitor"/><FilterOption id="6830" count="9" label="DNA primase inhibitor"/><FilterOption id="144" count="9" label="Dopamine receptor agonist"/><FilterOption id="120" count="9" label="Factor Xa antagonist"/><FilterOption id="168" count="9" label="FGF receptor antagonist"/><FilterOption id="71851" count="9" label="HIV GAG POL polyprotein inhibitor"/><FilterOption id="12395" count="9" label="HIV GAG protein inhibitor"/><FilterOption id="11219" count="9" label="HIV-1 gp120 protein inhibitor"/><FilterOption id="205" count="9" label="HMG CoA reductase inhibitor"/><FilterOption id="3560" count="9" label="JAK tyrosine kinase inhibitor"/><FilterOption id="3566" count="9" label="Jak3 tyrosine kinase inhibitor"/><FilterOption id="3584" count="9" label="Lck tyrosine kinase inhibitor"/><FilterOption id="76090" count="9" label="mTOR complex 1 inhibitor"/><FilterOption id="385" count="9" label="Protein tyrosine kinase inhibitor"/><FilterOption id="551" count="9" label="RNA DNA polymerase inhibitor"/><FilterOption id="347" count="9" label="RNA polymerase inhibitor"/><FilterOption id="3524" count="8" label="Abl tyrosine kinase inhibitor"/><FilterOption id="3736" count="8" label="Anaplastic lymphoma kinase receptor inhibitor"/><FilterOption id="7418" count="8" label="Cytochrome P450 3 inhibitor"/><FilterOption id="431" count="8" label="DNA gyrase inhibitor"/><FilterOption id="6512" count="8" label="DNA methyltransferase inhibitor"/><FilterOption id="3691" count="8" label="FGF4 receptor antagonist"/><FilterOption id="327" count="8" label="PGI2 agonist"/><FilterOption id="141" count="8" label="Topoisomerase I inhibitor"/><FilterOption id="58716" count="8" label="Ubiquitin inhibitor"/><FilterOption id="3851" count="7" label="ALK tyrosine kinase receptor family inhibitor"/><FilterOption id="7343" count="7" label="Beta amyloid antagonist"/><FilterOption id="7423" count="7" label="Cytochrome P450 3A4 stimulator"/><FilterOption id="135" count="7" label="DHFR inhibitor"/><FilterOption id="18889" count="7" label="DNA binding protein inhibitor"/><FilterOption id="12358" count="7" label="Hepatitis C virus NS5B polymerase inhibitor"/><FilterOption id="1671" count="7" label="HIV integrase inhibitor"/><FilterOption id="2950" count="7" label="Integrin alpha-4/beta-7 antagonist"/><FilterOption id="346" count="7" label="Ribonucleotide reductase inhibitor"/><FilterOption id="541" count="7" label="Tubulin receptor antagonist"/><FilterOption id="7472" count="6" label="Cytochrome P450 17 inhibitor"/><FilterOption id="150" count="6" label="Dopamine D2 receptor antagonist"/><FilterOption id="4039" count="6" label="Farnesoid X receptor agonist"/><FilterOption id="181" count="6" label="GAR transformylase inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="1017818" count="20" label="Instituto de Salud Carlos III"/><FilterOption id="19446" count="18" label="Roche Holding AG"/><FilterOption id="1039423" count="17" label="Hospital Clinic of Barcelona"/><FilterOption id="18767" count="17" label="Pfizer Inc"/><FilterOption id="15331" count="16" label="Celgene Corp"/><FilterOption id="20300" count="15" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="28355" count="12" label="GlaxoSmithKline plc"/><FilterOption id="14109" count="11" label="Amgen Inc"/><FilterOption id="15065" count="11" label="Bristol-Myers Squibb Co"/><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."/><FilterOption id="14190" count="10" label="AstraZeneca plc"/><FilterOption id="23137" count="10" label="Novartis AG"/><FilterOption id="1039086" count="9" label="Germans Trias i Pujol Hospital"/><FilterOption id="1017771" count="9" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="1013295" count="8" label="Astellas Pharma Inc"/><FilterOption id="17810" count="8" label="Eli Lilly &amp; Co"/><FilterOption id="19453" count="8" label="Genentech Inc"/><FilterOption id="1067538" count="8" label="Janssen Research &amp; Development LLC"/><FilterOption id="1059823" count="8" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="13601" count="7" label="Abbott Laboratories"/><FilterOption id="26178" count="7" label="F Hoffmann-La Roche AG"/><FilterOption id="1059977" count="6" label="European Commission"/><FilterOption id="1053612" count="6" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="18077" count="6" label="Merck &amp; Co Inc"/><FilterOption id="1097931" count="5" label="Andalusian Initiative for Advanced Therapies"/><FilterOption id="25902" count="5" label="Array BioPharma Inc"/><FilterOption id="14455" count="5" label="Bayer AG"/><FilterOption id="19620" count="5" label="Eisai Inc"/><FilterOption id="22676" count="5" label="Exelixis Inc"/><FilterOption id="1045910" count="5" label="Hospital Clinico San Carlos"/><FilterOption id="17416" count="5" label="Janssen LP"/><FilterOption id="17401" count="5" label="Janssen-Cilag SA"/><FilterOption id="1067340" count="5" label="Pivotal SL"/><FilterOption id="25554" count="5" label="Seattle Genetics Inc"/><FilterOption id="1061163" count="4" label="Abbott Vascular"/><FilterOption id="1072507" count="4" label="AbbVie Inc"/><FilterOption id="1041980" count="4" label="Charite University"/><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"/><FilterOption id="1073758" count="4" label="Fondo de Investigacion Sanitaria"/><FilterOption id="28959" count="4" label="Hannover Medical School"/><FilterOption id="1040862" count="4" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="1003065" count="4" label="Hospital Vall D'Hebron"/><FilterOption id="18438" count="4" label="Medical Research Council"/><FilterOption id="18101" count="4" label="Merck KGaA"/><FilterOption id="1074428" count="4" label="Ministerio de Economia y Competitividad"/><FilterOption id="20519" count="4" label="National Cancer Institute"/><FilterOption id="1053488" count="4" label="NCIC Clinical Trials Group"/><FilterOption id="1116693" count="4" label="Productos Roche, S.A. de C.V."/><FilterOption id="1009547" count="4" label="Sanofi SA"/><FilterOption id="21279" count="4" label="Universite Catholique de Louvain"/><FilterOption id="1038808" count="3" label="Azienda Ospedaliera di Padova"/><FilterOption id="1052569" count="3" label="B Braun Surgical Sa"/><FilterOption id="1103224" count="3" label="Centro Hospitalar do Porto"/><FilterOption id="15414" count="3" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1091345" count="3" label="Complejo Hospitalario de Navarra"/><FilterOption id="1062976" count="3" label="Europath Biosciences Sl"/><FilterOption id="1063203" count="3" label="Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico"/><FilterOption id="1039087" count="3" label="Fundacio Lluita Contra La Sida"/><FilterOption id="1045896" count="3" label="Fundacion Para La Investigacion Hospital La Fe"/><FilterOption id="1017513" count="3" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="1033112" count="3" label="Hospital Universitario 12 de Octubre"/><FilterOption id="1006639" count="3" label="Hospital Universitario Ramon y Cajal"/><FilterOption id="1072647" count="3" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1056690" count="3" label="Institut Investigació Biomèdica Bellvitge"/><FilterOption id="1101929" count="3" label="IQVIA Holdings Inc"/><FilterOption id="17392" count="3" label="Janssen-Cilag Ltd"/><FilterOption id="21110" count="3" label="Karolinska Institutet"/><FilterOption id="1075878" count="3" label="Klinikum der Universität Köln"/><FilterOption id="22137" count="3" label="Ludwig-Maximilians University of Munich"/><FilterOption id="1175391" count="3" label="Medivation LLC"/><FilterOption id="21404" count="3" label="MorphoSys AG"/><FilterOption id="19087" count="3" label="Pierre Fabre SA"/><FilterOption id="1114888" count="3" label="Quartz Bio SA"/><FilterOption id="1119200" count="3" label="Sanofi-Aventis Research and Development"/><FilterOption id="1058089" count="3" label="Servicio Andaluz De Salud"/><FilterOption id="1096345" count="3" label="Servicio Cántabro De Salud"/><FilterOption id="21991" count="3" label="Takeda Oncology"/><FilterOption id="1054559" count="3" label="TESARO Inc"/><FilterOption id="1114403" count="3" label="TFS Trial Form Support"/><FilterOption id="1119462" count="3" label="The Cyprus Foundation For Muscular Dystrophy Research"/><FilterOption id="1104050" count="3" label="UCB Biopharma SPRL"/><FilterOption id="20625" count="3" label="Universita degli Studi di Milano"/><FilterOption id="1003992" count="3" label="Universitat de Barcelona"/><FilterOption id="1042041" count="3" label="University Hospital, Brest"/><FilterOption id="24222" count="3" label="University of Geneva"/><FilterOption id="25460" count="3" label="University of Granada"/><FilterOption id="DOL1000156" count="3" label="University of Szeged"/><FilterOption id="21082" count="3" label="Walter and Eliza Hall Institute of Medical Research"/><FilterOption id="1150199" count="2" label="A2F-Associates Limited"/><FilterOption id="1012474" count="2" label="AC Immune SA"/><FilterOption id="19864" count="2" label="Adir &amp; Co"/><FilterOption id="1117605" count="2" label="Adknoma Health Research"/><FilterOption id="1150200" count="2" label="alphabioresearch"/><FilterOption id="23948" count="2" label="Assistance Publique Hopitaux de Paris"/><FilterOption id="1037956" count="2" label="Astellas Pharma Global Development Inc"/><FilterOption id="1045129" count="2" label="Australasian Leukaemia and Lymphoma Group"/><FilterOption id="1061993" count="2" label="Azienda Ospedaliera Universitaria di Bologna Policlinico"/><FilterOption id="27847" count="2" label="Boston Scientific Corp"/><FilterOption id="1042255" count="2" label="Breast International Group"/><FilterOption id="1056053" count="2" label="Celgene International Sarl"/></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="96"><FilterOption id="1545" count="147" label="Anticancer"/><FilterOption id="767" count="61" label="Cell cycle inhibitor"/><FilterOption id="55685" count="46" label="Anticancer monoclonal antibody"/><FilterOption id="991" count="45" label="Antiviral"/><FilterOption id="1569" count="43" label="Anticancer antimetabolite"/><FilterOption id="2953" count="42" label="Anti-inflammatory"/><FilterOption id="140" count="39" label="DNA synthesis inhibitor"/><FilterOption id="50" count="35" label="Anticancer alkylating agent"/><FilterOption id="1589" count="35" label="Apoptosis stimulator"/><FilterOption id="62255" count="30" label="Anticancer protein kinase inhibitor"/><FilterOption id="2575" count="26" label="Microtubule inhibitor"/><FilterOption id="61" count="25" label="Angiogenesis inhibitor"/><FilterOption id="2576" count="24" label="Microtubule stabilizer"/><FilterOption id="2660" count="21" label="Vasoprotectant"/><FilterOption id="7293" count="17" label="Synergist"/><FilterOption id="750" count="12" label="DNA intercalator"/><FilterOption id="747" count="12" label="HIV replication inhibitor"/><FilterOption id="1596" count="12" label="Immunomodulator"/><FilterOption id="393" count="10" label="Immunostimulant"/><FilterOption id="7761" count="10" label="T-lymphocyte stimulator"/><FilterOption id="396" count="9" label="Immunosuppressant"/><FilterOption id="2657" count="7" label="Antihypertensive"/><FilterOption id="382" count="7" label="TNF alpha synthesis inhibitor"/><FilterOption id="1594" count="6" label="Antibacterial"/><FilterOption id="937" count="5" label="Androgen synthesis inhibitor"/><FilterOption id="62254" count="5" label="Anticancer hormone antagonist"/><FilterOption id="659" count="5" label="Coagulation inhibitor"/><FilterOption id="32411" count="5" label="Hepatitis B virus replication inhibitor"/><FilterOption id="2947" count="4" label="Antiparkinsonian"/><FilterOption id="805" count="4" label="Folate modulator"/><FilterOption id="1748" count="4" label="Fungicide"/><FilterOption id="399" count="4" label="Hypoglycemic agent"/><FilterOption id="312" count="4" label="Platelet aggregation inhibitor"/><FilterOption id="1532" count="4" label="Viral replication inhibitor"/><FilterOption id="2946" count="3" label="Analgesic"/><FilterOption id="70" count="3" label="Anticonvulsant agent"/><FilterOption id="71" count="3" label="Antihypercholesterolemic agent"/><FilterOption id="1538" count="3" label="Bacterial protein synthesis inhibitor"/><FilterOption id="563" count="3" label="Microtubule modulator"/><FilterOption id="15148" count="3" label="Ocular antineovascularisation agent"/><FilterOption id="439" count="3" label="RNA synthesis inhibitor"/><FilterOption id="15184" count="3" label="Systemic antipsoriatic product"/><FilterOption id="15187" count="3" label="Systemic dermatological antibacterial product"/><FilterOption id="5704" count="2" label="B-lymphocyte adhesion inhibitor"/><FilterOption id="5710" count="2" label="B-lymphocyte migration inhibitor"/><FilterOption id="104" count="2" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="38206" count="2" label="Biguanide antidiabetic product"/><FilterOption id="2659" count="2" label="Cardioprotectant"/><FilterOption id="5580" count="2" label="Chemotaxis inhibitor"/><FilterOption id="7211" count="2" label="CNS diagnostic agent"/><FilterOption id="11593" count="2" label="DNA repair inhibitor"/><FilterOption id="664" count="2" label="Fibrosuppressant"/><FilterOption id="38211" count="2" label="Human insulin fast acting product"/><FilterOption id="1615" count="2" label="Neuroprotectant"/><FilterOption id="5555" count="2" label="PET contrast agent"/><FilterOption id="5720" count="2" label="Radiodiagnostic"/><FilterOption id="463" count="2" label="Ribosome binding agent"/><FilterOption id="1479" count="2" label="RNA synthesis modulator"/><FilterOption id="26035" count="2" label="siRNA agent"/><FilterOption id="15178" count="2" label="Systemic dermatological antifungal product"/><FilterOption id="388" count="2" label="Vasodilator"/><FilterOption id="882" count="1" label="5-HETE modulator"/><FilterOption id="449" count="1" label="Antiarrhythmic agent"/><FilterOption id="2941" count="1" label="Antidepressant"/><FilterOption id="15135" count="1" label="Antiglaucoma agent"/><FilterOption id="955" count="1" label="Antimicrobial permeability enhancer"/><FilterOption id="2638" count="1" label="Antiparasitic"/><FilterOption id="2942" count="1" label="Anxiolytic"/><FilterOption id="863" count="1" label="Bile acid modulator"/><FilterOption id="743" count="1" label="Bile acid transport inhibitor"/><FilterOption id="646" count="1" label="Bronchodilator"/><FilterOption id="1260" count="1" label="Calcium metabolism modulator"/><FilterOption id="1537" count="1" label="Cephalosporin"/><FilterOption id="2833" count="1" label="CMV replication inhibitor"/><FilterOption id="2939" count="1" label="CNS modulator"/><FilterOption id="124" count="1" label="Collagen synthesis inhibitor"/><FilterOption id="137" count="1" label="Diuretic agent"/><FilterOption id="38439" count="1" label="DPP IV inhibitor antidiabetic product"/><FilterOption id="839" count="1" label="Ergosterol modulator"/><FilterOption id="7251" count="1" label="Female contraceptive"/><FilterOption id="1668" count="1" label="General anesthetic"/><FilterOption id="3313" count="1" label="Glucagon-like peptide 1 metabolism modulator"/><FilterOption id="610" count="1" label="Hematopoietic stimulator"/><FilterOption id="3980" count="1" label="HIV fusion inhibitor"/><FilterOption id="539" count="1" label="Immunotoxin"/><FilterOption id="211" count="1" label="Inotropic agent"/><FilterOption id="1379" count="1" label="Interferon modulator"/><FilterOption id="1540" count="1" label="Macrolide antibiotic"/><FilterOption id="695" count="1" label="Metastasis inhibitor"/><FilterOption id="1129" count="1" label="Non-steroid hormone receptor antagonist"/><FilterOption id="284" count="1" label="Nootropic agent"/><FilterOption id="285" count="1" label="Norepinephrine uptake inhibitor"/><FilterOption id="15128" count="1" label="Ophthalmological agent"/><FilterOption id="472" count="1" label="Phosphate lowering agent"/><FilterOption id="5717" count="1" label="Sensitizer"/><FilterOption id="15189" count="1" label="Topical dermatological antiviral product"/></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="596" label="Proteomic"/><FilterOption id="38" count="582" label="Genomic"/><FilterOption id="31" count="251" label="Physiological"/><FilterOption id="32" count="247" label="Biochemical"/><FilterOption id="75" count="215" label="Cellular"/><FilterOption id="40" count="90" label="Structural (imaging)"/><FilterOption id="39" count="82" label="Anthropomorphic"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="607" label="Therapeutic effect marker"/><FilterOption id="1571666123" count="301" label="Disease marker"/><FilterOption id="730490367" count="158" label="Toxic effect marker"/><FilterOption id="3242045531" count="5" label="Not determined"/></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="72699" count="33" label="atezolizumab"/><FilterOption id="6736" count="32" label="rituximab"/><FilterOption id="3803" count="29" label="paclitaxel"/><FilterOption id="3199" count="28" label="gemcitabine"/><FilterOption id="27572" count="28" label="lenalidomide"/><FilterOption id="44383" count="26" label="carboplatin"/><FilterOption id="8047" count="22" label="bevacizumab"/><FilterOption id="15954" count="21" label="bortezomib"/><FilterOption id="70667" count="18" label="pembrolizumab"/><FilterOption id="7310" count="18" label="ritonavir"/><FilterOption id="6386" count="17" label="trastuzumab"/><FilterOption id="2953" count="16" label="docetaxel"/><FilterOption id="14681" count="16" label="lopinavir + ritonavir"/><FilterOption id="3072" count="13" label="etoposide phosphate"/><FilterOption id="3792" count="13" label="oxaliplatin"/><FilterOption id="54488" count="13" label="raltegravir"/><FilterOption id="54804" count="12" label="nivolumab"/><FilterOption id="55237" count="11" label="ibrutinib"/><FilterOption id="3474" count="11" label="lamivudine"/><FilterOption id="83065" count="10" label="avelumab"/><FilterOption id="47000" count="10" label="bendamustine"/><FilterOption id="12205" count="10" label="capecitabine"/><FilterOption id="11961" count="10" label="erlotinib"/><FilterOption id="2784" count="10" label="letrozole"/><FilterOption id="29016" count="10" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="15254" count="9" label="atazanavir"/><FilterOption id="32981" count="9" label="darunavir"/><FilterOption id="6156" count="9" label="fludarabine"/><FilterOption id="37613" count="9" label="maraviroc"/><FilterOption id="5369" count="9" label="ribavirin"/><FilterOption id="14493" count="9" label="tenofovir disoproxil fumarate"/><FilterOption id="54601" count="8" label="carfilzomib"/><FilterOption id="56544" count="8" label="cobimetinib"/><FilterOption id="3081" count="8" label="exemestane"/><FilterOption id="36630" count="8" label="ipilimumab"/><FilterOption id="11519" count="8" label="mitoxantrone"/><FilterOption id="28532" count="8" label="pertuzumab"/><FilterOption id="45499" count="8" label="tofacitinib citrate (oral, inflammation), Pfizer"/><FilterOption id="37370" count="7" label="azacitidine"/><FilterOption id="53200" count="7" label="daratumumab"/><FilterOption id="10172" count="7" label="efavirenz"/><FilterOption id="4728" count="7" label="emtricitabine"/><FilterOption id="53981" count="7" label="enzalutamide"/><FilterOption id="13340" count="7" label="everolimus"/><FilterOption id="3313" count="7" label="fulvestrant"/><FilterOption id="52854" count="7" label="macitentan"/><FilterOption id="53227" count="7" label="obinutuzumab"/><FilterOption id="27696" count="7" label="pomalidomide"/><FilterOption id="4529" count="7" label="temozolomide"/><FilterOption id="49219" count="7" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="54469" count="7" label="vemurafenib"/><FilterOption id="6242" count="6" label="abacavir"/><FilterOption id="10309" count="6" label="abiraterone"/><FilterOption id="59062" count="6" label="dolutegravir"/><FilterOption id="57369" count="6" label="etrolizumab"/><FilterOption id="45841" count="6" label="lenvatinib mesylate"/><FilterOption id="50963" count="6" label="obeticholic acid (primary biliary cholangitis), Intercept/AOP Orphan"/><FilterOption id="12646" count="6" label="panitumumab"/><FilterOption id="23625" count="6" label="peginterferon alfa-2a"/><FilterOption id="3536" count="6" label="pemetrexed disodium"/><FilterOption id="55305" count="5" label="binimetinib"/><FilterOption id="5871" count="5" label="bosentan"/><FilterOption id="5999" count="5" label="ciclosporin, Novartis"/><FilterOption id="81193" count="5" label="durvalumab"/><FilterOption id="13022" count="5" label="epirubicin"/><FilterOption id="3700" count="5" label="nevirapine"/><FilterOption id="61287" count="5" label="niraparib"/><FilterOption id="44314" count="5" label="tamoxifen"/><FilterOption id="12150" count="5" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="69066" count="4" label="alectinib"/><FilterOption id="3321" count="4" label="anastrozole"/><FilterOption id="30379" count="4" label="bosutinib"/><FilterOption id="2836" count="4" label="clopidogrel"/><FilterOption id="9049" count="4" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="73843" count="4" label="encorafenib"/><FilterOption id="13486" count="4" label="entecavir"/><FilterOption id="48319" count="4" label="idelalisib"/><FilterOption id="2871" count="4" label="irinotecan"/><FilterOption id="16696" count="4" label="lamivudine + zidovudine, GlaxoSmithKline"/><FilterOption id="10271" count="4" label="palbociclib"/><FilterOption id="4200" count="4" label="sirolimus"/><FilterOption id="88619" count="4" label="sofosbuvir + velpatasvir (fixed dose combination, HCV), Gilead"/><FilterOption id="12973" count="4" label="sunitinib"/><FilterOption id="4510" count="4" label="tacrolimus"/><FilterOption id="75324" count="4" label="tenofovir alafenamide + emtricitabine + cobicistat + elvitegravir (FDC, HIV), Gilead/ Japan Tobacco"/><FilterOption id="70678" count="4" label="xentuzumab"/><FilterOption id="72538" count="3" label="abemaciclib"/><FilterOption id="14163" count="3" label="adalimumab"/><FilterOption id="6306" count="3" label="aldesleukin"/><FilterOption id="7781" count="3" label="aripiprazole"/><FilterOption id="72743" count="3" label="birtamimab"/><FilterOption id="39172" count="3" label="brentuximab vedotin"/><FilterOption id="10388" count="3" label="cetuximab"/><FilterOption id="24343" count="3" label="dabigatran etexilate"/><FilterOption id="13239" count="3" label="decitabine"/><FilterOption id="4567" count="3" label="etanercept"/><FilterOption id="3130" count="3" label="filgrastim"/><FilterOption id="53840" count="3" label="gantenerumab"/><FilterOption id="6850" count="3" label="infliximab"/><FilterOption id="2714" count="3" label="inotuzumab ozogamicin"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="9213" count="23" label="HIV infection - Assessment of Viral Load - Assessment of HIV RNA levels"/><FilterOption id="8489" count="21" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8713" count="20" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9247" count="19" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7908" count="19" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7547" count="19" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8140" count="15" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="9153" count="15" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="7563" count="15" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9218" count="14" label="HIV infection - Assessment of Immune Response"/><FilterOption id="7360" count="14" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7367" count="14" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="9215" count="13" label="HIV infection - Assessment of CD4 Cell Responses - Assessment of CD4 cell count/percentage"/><FilterOption id="9212" count="13" label="HIV infection - Assessment of Viral Load"/><FilterOption id="8721" count="12" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7909" count="12" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8714" count="11" label="Breast tumor - Assessment of Disease Free Survival (DFS)"/><FilterOption id="2622" count="11" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="3736" count="11" label="Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)"/><FilterOption id="8078" count="11" label="Leukemia - Assessment of adverse events"/><FilterOption id="42921" count="11" label="Other gastrointestinal disease - Assessment of Safety and Tolerability"/><FilterOption id="8719" count="10" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8523" count="10" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="8505" count="10" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="6924" count="10" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="10830" count="10" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7049" count="10" label="Prostate tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="10545" count="10" label="Renal cell carcinoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="2492" count="9" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"/><FilterOption id="9272" count="9" label="HIV infection - Assessment of Mortality/Death Rates"/><FilterOption id="9242" count="9" label="HIV infection - Assessment of lipid profiles"/><FilterOption id="7879" count="9" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="7372" count="9" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="25660" count="9" label="Pulmonary artery hypertension - Assessment of Six Minute Walk Test"/><FilterOption id="15293" count="9" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="15287" count="9" label="Solid tumor - Assessment of adverse events"/><FilterOption id="8720" count="8" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8759" count="8" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="7916" count="8" label="Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response"/><FilterOption id="6940" count="8" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="6972" count="8" label="Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="10224" count="8" label="Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States - Assessment of OFF state of Parkinson's disease"/><FilterOption id="15285" count="8" label="Solid tumor - Assessment of Safety and Tolerability"/><FilterOption id="15907" count="8" label="Ulcerative colitis - Ulcerative Colitis Assessed by Activity Indices - Assessment by Mayo clinic score (MCS)/ disease activity index (DAI)"/><FilterOption id="17356" count="7" label="Anemia - Assessment of adverse events"/><FilterOption id="9510" count="7" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"/><FilterOption id="11773" count="7" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8744" count="7" label="Breast tumor - Assessment of Disease Progression"/><FilterOption id="8163" count="7" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9246" count="7" label="HIV infection - Assessment of Safety and Tolerability"/><FilterOption id="9195" count="7" label="HIV infection - Assessment of virological response"/><FilterOption id="7907" count="7" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7906" count="7" label="Leukemia - Assessment of Response Rates (RR)"/><FilterOption id="9155" count="7" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="9415" count="7" label="Lymphoma - Assessment of Disease Progression"/><FilterOption id="7680" count="7" label="Lymphoma - Assessment of adverse events"/><FilterOption id="7374" count="7" label="Multiple myeloma - Assessment of Therapy Related Outcomes"/><FilterOption id="43670" count="7" label="Other gastrointestinal disease - Assessment of adverse events"/><FilterOption id="15212" count="7" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="26827" count="7" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="2332" count="6" label="Alzheimers disease - Assessment of Dementia - Clinical dementia rating sum of boxes (CDR-SOB)"/><FilterOption id="11778" count="6" label="Bladder cancer - Assessment of Mortality/Death Rates"/><FilterOption id="11949" count="6" label="Bladder cancer - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="11786" count="6" label="Bladder cancer - Assessment of Therapy Related Outcomes - Assessment of imaging/diagnostic tests"/><FilterOption id="2619" count="6" label="Coronary artery disease - Assessment of Cardiovascular Events - Assessment of major adverse cardiac events (MACEs)"/><FilterOption id="9174" count="6" label="HIV infection - Assessment of AIDS Defining Events(CDC Criteria)"/><FilterOption id="9197" count="6" label="HIV infection - Assessment of virological response - Assessment of virological failure"/><FilterOption id="7891" count="6" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7914" count="6" label="Leukemia - Assessment of Response Rates (RR) - Assessment of cytogenetic response"/><FilterOption id="7569" count="6" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="7373" count="6" label="Multiple myeloma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7045" count="6" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="2981" count="5" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"/><FilterOption id="9504" count="5" label="Atrial fibrillation - Assessment of Cerebrovascular Events - Assessment of ischemic stroke"/><FilterOption id="9519" count="5" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"/><FilterOption id="11793" count="5" label="Bladder cancer - Assessment of Disease Progression"/><FilterOption id="11717" count="5" label="Bladder cancer - Assessment of Overall Survival (OS)"/><FilterOption id="8754" count="5" label="Breast tumor - Assessment of Mortality/Death Rates"/><FilterOption id="2703" count="5" label="Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)"/><FilterOption id="6863" count="5" label="Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics"/><FilterOption id="12048" count="5" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8077" count="5" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="8481" count="5" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8514" count="5" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8513" count="5" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8640" count="5" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="6952" count="5" label="Melanoma - Assessment of Disease Progression"/><FilterOption id="43393" count="5" label="Other gastrointestinal disease - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="46305" count="5" label="Other gastrointestinal disease - Assessment of Liver Functions - Alkaline phosphatase levels"/><FilterOption id="43526" count="5" label="Other gastrointestinal disease - Clinical Assessments"/><FilterOption id="10895" count="5" label="Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="25647" count="5" label="Pulmonary artery hypertension - Assessment of Pulmonary Vascular Resistance"/><FilterOption id="15302" count="5" label="Solid tumor - Assessment of Mortality/Death Rates"/><FilterOption id="15936" count="5" label="Ulcerative colitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="2980" count="4" label="Acute coronary syndrome - Assessment of Mortality/Death Rates"/><FilterOption id="17220" count="4" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"/><FilterOption id="9438" count="4" label="Atrial fibrillation - Assessment of Mortality/Death Rates - Assessment of all cause death"/><FilterOption id="2184" count="4" label="Cardiac failure - Assessment of Device Related Endpoints - Device complication free rate"/><FilterOption id="2621" count="4" label="Coronary artery disease - Assessment of Mortality/Death Rates"/><FilterOption id="22506" count="4" label="End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="1039423" count="126" label="Hospital Clinic of Barcelona"/><FilterOption id="19446" count="100" label="Roche Holding AG"/><FilterOption id="18767" count="75" label="Pfizer Inc"/><FilterOption id="26178" count="74" label="F Hoffmann-La Roche AG"/><FilterOption id="15331" count="47" label="Celgene Corp"/><FilterOption id="1038736" count="42" label="PETHEMA Foundation"/><FilterOption id="16450" count="36" label="Gilead Sciences Inc"/><FilterOption id="14881" count="29" label="Boehringer Ingelheim International GmbH"/><FilterOption id="1067538" count="26" label="Janssen Research &amp; Development LLC"/><FilterOption id="19453" count="24" label="Genentech Inc"/><FilterOption id="1059823" count="24" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="15414" count="23" label="Chugai Pharmaceutical Co Ltd"/><FilterOption id="1017818" count="22" label="Instituto de Salud Carlos III"/><FilterOption id="1053612" count="21" label="Fundacion Clinic per a la Recerca Biomédica"/><FilterOption id="15065" count="20" label="Bristol-Myers Squibb Co"/><FilterOption id="20300" count="18" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="27847" count="16" label="Boston Scientific Corp"/><FilterOption id="1039086" count="16" label="Germans Trias i Pujol Hospital"/><FilterOption id="14455" count="15" label="Bayer AG"/><FilterOption id="17810" count="15" label="Eli Lilly &amp; Co"/><FilterOption id="1091809" count="15" label="Janssen-Cilag International NV (BE)"/><FilterOption id="1042061" count="15" label="Spanish Breast Cancer Research Group"/><FilterOption id="23780" count="14" label="Actelion Ltd"/><FilterOption id="14109" count="14" label="Amgen Inc"/><FilterOption id="28355" count="14" label="GlaxoSmithKline plc"/><FilterOption id="1013295" count="13" label="Astellas Pharma Inc"/><FilterOption id="1017513" count="13" label="Fundació Clínic Per A La Recerca Biomèdica"/><FilterOption id="1017771" count="13" label="Institut d'Investigacions Biomediques August Pi I Sunyer"/><FilterOption id="23137" count="13" label="Novartis AG"/><FilterOption id="1042371" count="13" label="Spanish Oncology Genito-Urinary Group"/><FilterOption id="22546" count="12" label="Boehringer Ingelheim GmbH"/><FilterOption id="1043659" count="12" label="Grupo Espanol Multidisciplinario del Cancer Digestivo"/><FilterOption id="21991" count="12" label="Takeda Oncology"/><FilterOption id="13601" count="11" label="Abbott Laboratories"/><FilterOption id="14190" count="11" label="AstraZeneca plc"/><FilterOption id="1065900" count="10" label="Apices Soluciones, S.L."/><FilterOption id="28611" count="9" label="Actelion Pharmaceuticals Ltd"/><FilterOption id="1020322" count="9" label="Daiichi Sankyo Inc"/><FilterOption id="19620" count="9" label="Eisai Inc"/><FilterOption id="23119" count="9" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="1051470" count="9" label="Fundacio Clinic Per A La Recerca Biomedica"/><FilterOption id="1052299" count="9" label="Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla"/><FilterOption id="1003065" count="9" label="Hospital Vall D'Hebron"/><FilterOption id="1042252" count="8" label="Grupo Espanol de Linfomas y Transplante Autologo de Medula Osea"/><FilterOption id="18077" count="8" label="Merck &amp; Co Inc"/><FilterOption id="18101" count="8" label="Merck KGaA"/><FilterOption id="25554" count="8" label="Seattle Genetics Inc"/><FilterOption id="25902" count="7" label="Array BioPharma Inc"/><FilterOption id="22554" count="7" label="Boehringer Ingelheim BV"/><FilterOption id="22586" count="7" label="Boehringer Ingelheim Corp"/><FilterOption id="1103352" count="7" label="Boehringer Ingelheim Espana Sa"/><FilterOption id="22563" count="7" label="Boehringer Ingelheim Ltd"/><FilterOption id="1040940" count="7" label="Hospital Universitari de Bellvitge"/><FilterOption id="17259" count="7" label="Ipsen"/><FilterOption id="1059977" count="6" label="European Commission"/><FilterOption id="1045910" count="6" label="Hospital Clinico San Carlos"/><FilterOption id="1072647" count="6" label="Institut de Recherches Internationales Servier (France)"/><FilterOption id="1009440" count="6" label="Intercept Pharmaceuticals Inc"/><FilterOption id="1097361" count="6" label="Medtronic plc"/><FilterOption id="15938" count="6" label="Millennium Pharmaceuticals Ltd"/><FilterOption id="20519" count="6" label="National Cancer Institute"/><FilterOption id="1097931" count="5" label="Andalusian Initiative for Advanced Therapies"/><FilterOption id="1005244" count="5" label="Biogen Inc"/><FilterOption id="22549" count="5" label="Boehringer Ingelheim Austria GmbH"/><FilterOption id="1035512" count="5" label="EMD Serono Inc"/><FilterOption id="1073758" count="5" label="Fondo de Investigacion Sanitaria"/><FilterOption id="1040862" count="5" label="Hospital General Universitario Gregorio Marañon"/><FilterOption id="17416" count="5" label="Janssen LP"/><FilterOption id="17401" count="5" label="Janssen-Cilag SA"/><FilterOption id="19063" count="5" label="Pharmacyclics Inc"/><FilterOption id="1067340" count="5" label="Pivotal SL"/><FilterOption id="1009547" count="5" label="Sanofi SA"/><FilterOption id="1122528" count="5" label="SCS Boehringer Ingelheim Comm.V"/><FilterOption id="1045513" count="5" label="Spanish Lung Cancer Group"/><FilterOption id="1073757" count="5" label="Spanish Society of Cardiology"/><FilterOption id="1122527" count="4" label="Boehringer Ingelheim Finland Ky"/><FilterOption id="22556" count="4" label="Boehringer Ingelheim France SARL"/><FilterOption id="22560" count="4" label="Boehringer Ingelheim Italia SpA"/><FilterOption id="1056053" count="4" label="Celgene International Sarl"/><FilterOption id="1056497" count="4" label="CETLAM Group"/><FilterOption id="1067616" count="4" label="Clinica Universidad de Navarra"/><FilterOption id="1017506" count="4" label="Daiichi Sankyo Co Ltd"/><FilterOption id="22676" count="4" label="Exelixis Inc"/><FilterOption id="16118" count="4" label="Ferrer Internacional SA"/><FilterOption id="1046331" count="4" label="Fundacion SEIMC-GESIDA"/><FilterOption id="1079783" count="4" label="FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU"/><FilterOption id="28959" count="4" label="Hannover Medical School"/><FilterOption id="1056690" count="4" label="Institut Investigació Biomèdica Bellvitge"/><FilterOption id="17392" count="4" label="Janssen-Cilag Ltd"/><FilterOption id="17437" count="4" label="Johnson &amp; Johnson Sdn Bhd"/><FilterOption id="18438" count="4" label="Medical Research Council"/><FilterOption id="1014884" count="4" label="Medivation Inc"/><FilterOption id="1074428" count="4" label="Ministerio de Economia y Competitividad"/><FilterOption id="19087" count="4" label="Pierre Fabre SA"/><FilterOption id="1116693" count="4" label="Productos Roche, S.A. de C.V."/><FilterOption id="1064629" count="4" label="Prothena Corp plc"/><FilterOption id="1091820" count="4" label="Roche China Co Ltd"/><FilterOption id="24652" count="4" label="Shire plc"/><FilterOption id="1054559" count="4" label="TESARO Inc"/><FilterOption id="22598" count="4" label="Unilfarma Lda"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="35" label="2019-01-24"/><FilterOption count="26" label="2018-10-14"/><FilterOption count="26" label="2019-01-26"/><FilterOption count="23" label="2019-01-25"/><FilterOption count="23" label="2019-07-02"/><FilterOption count="18" label="2018-10-13"/><FilterOption count="18" label="2018-10-15"/><FilterOption count="18" label="2019-06-27"/><FilterOption count="18" label="2019-07-03"/><FilterOption count="17" label="2019-06-19"/><FilterOption count="17" label="2019-06-20"/><FilterOption count="16" label="2019-06-21"/><FilterOption count="16" label="2019-06-28"/><FilterOption count="15" label="2019-03-07"/><FilterOption count="14" label="2019-06-07"/><FilterOption count="14" label="2019-06-14"/><FilterOption count="14" label="2019-06-26"/><FilterOption count="13" label="2018-10-12"/><FilterOption count="13" label="2019-07-01"/><FilterOption count="12" label="2019-06-25"/><FilterOption count="11" label="2013-12-02"/><FilterOption count="10" label="2019-05-17"/><FilterOption count="10" label="2019-05-23"/><FilterOption count="9" label="2019-06-06"/><FilterOption count="9" label="2019-06-13"/><FilterOption count="8" label="2019-04-22"/><FilterOption count="8" label="2019-05-07"/><FilterOption count="8" label="2019-05-27"/><FilterOption count="8" label="2019-06-10"/><FilterOption count="8" label="2019-06-11"/><FilterOption count="8" label="2019-06-22"/><FilterOption count="7" label="2018-07-07"/><FilterOption count="7" label="2018-10-16"/><FilterOption count="7" label="2018-12-12"/><FilterOption count="7" label="2019-05-24"/><FilterOption count="7" label="2019-06-12"/><FilterOption count="7" label="2019-06-24"/><FilterOption count="6" label="2013-09-13"/><FilterOption count="6" label="2018-06-23"/><FilterOption count="6" label="2018-07-14"/><FilterOption count="6" label="2018-12-14"/><FilterOption count="6" label="2019-02-08"/><FilterOption count="6" label="2019-04-15"/><FilterOption count="6" label="2019-04-23"/><FilterOption count="5" label="2018-01-24"/><FilterOption count="5" label="2018-05-26"/><FilterOption count="5" label="2018-12-13"/><FilterOption count="5" label="2019-01-09"/><FilterOption count="5" label="2019-02-20"/><FilterOption count="5" label="2019-03-20"/><FilterOption count="5" label="2019-03-21"/><FilterOption count="5" label="2019-04-05"/><FilterOption count="5" label="2019-05-10"/><FilterOption count="5" label="2019-05-31"/><FilterOption count="5" label="2019-06-04"/><FilterOption count="5" label="2019-06-08"/><FilterOption count="4" label="2018-12-05"/><FilterOption count="4" label="2018-12-18"/><FilterOption count="4" label="2019-01-28"/><FilterOption count="4" label="2019-02-04"/><FilterOption count="4" label="2019-04-12"/><FilterOption count="4" label="2019-04-25"/><FilterOption count="4" label="2019-06-05"/><FilterOption count="4" label="2019-06-18"/><FilterOption count="4" label="2019-06-29"/><FilterOption count="3" label="2013-09-14"/><FilterOption count="3" label="2018-05-19"/><FilterOption count="3" label="2018-06-02"/><FilterOption count="3" label="2018-11-19"/><FilterOption count="3" label="2018-11-20"/><FilterOption count="3" label="2018-11-21"/><FilterOption count="3" label="2018-12-03"/><FilterOption count="3" label="2019-01-04"/><FilterOption count="3" label="2019-02-06"/><FilterOption count="3" label="2019-02-07"/><FilterOption count="3" label="2019-02-11"/><FilterOption count="3" label="2019-02-22"/><FilterOption count="3" label="2019-03-05"/><FilterOption count="3" label="2019-03-15"/><FilterOption count="3" label="2019-03-18"/><FilterOption count="3" label="2019-03-19"/><FilterOption count="3" label="2019-03-22"/><FilterOption count="3" label="2019-04-01"/><FilterOption count="3" label="2019-04-02"/><FilterOption count="3" label="2019-04-10"/><FilterOption count="3" label="2019-04-24"/><FilterOption count="3" label="2019-05-30"/><FilterOption count="3" label="2019-06-15"/><FilterOption count="3" label="2019-06-17"/><FilterOption count="2" label="2013-02-12"/><FilterOption count="2" label="2014-03-25"/><FilterOption count="2" label="2014-07-31"/><FilterOption count="2" label="2015-09-21"/><FilterOption count="2" label="2016-12-06"/><FilterOption count="2" label="2017-03-30"/><FilterOption count="2" label="2017-04-17"/><FilterOption count="2" label="2017-06-17"/><FilterOption count="2" label="2017-07-10"/><FilterOption count="2" label="2017-07-15"/><FilterOption count="2" label="2017-07-18"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="22" label="201912"/><FilterOption count="19" label="202012"/><FilterOption count="16" label="202112"/><FilterOption count="14" label="202007"/><FilterOption count="13" label="201612"/><FilterOption count="13" label="201712"/><FilterOption count="12" label="201901"/><FilterOption count="12" label="201909"/><FilterOption count="12" label="202006"/><FilterOption count="12" label="202103"/><FilterOption count="12" label="202106"/><FilterOption count="11" label="201112"/><FilterOption count="11" label="201409"/><FilterOption count="11" label="201801"/><FilterOption count="11" label="201810"/><FilterOption count="11" label="201812"/><FilterOption count="11" label="201910"/><FilterOption count="11" label="202003"/><FilterOption count="10" label="201312"/><FilterOption count="10" label="201710"/><FilterOption count="10" label="202005"/><FilterOption count="10" label="202109"/><FilterOption count="9" label="201704"/><FilterOption count="9" label="201805"/><FilterOption count="9" label="201806"/><FilterOption count="9" label="201903"/><FilterOption count="9" label="201908"/><FilterOption count="9" label="201911"/><FilterOption count="8" label="201401"/><FilterOption count="8" label="201405"/><FilterOption count="8" label="201604"/><FilterOption count="8" label="201709"/><FilterOption count="8" label="201803"/><FilterOption count="8" label="201807"/><FilterOption count="8" label="201811"/><FilterOption count="8" label="202001"/><FilterOption count="8" label="202009"/><FilterOption count="8" label="202107"/><FilterOption count="8" label="202206"/><FilterOption count="8" label="202209"/><FilterOption count="7" label="201012"/><FilterOption count="7" label="201106"/><FilterOption count="7" label="201212"/><FilterOption count="7" label="201307"/><FilterOption count="7" label="201412"/><FilterOption count="7" label="201508"/><FilterOption count="7" label="201601"/><FilterOption count="7" label="201605"/><FilterOption count="7" label="201808"/><FilterOption count="7" label="201905"/><FilterOption count="7" label="201906"/><FilterOption count="7" label="201907"/><FilterOption count="7" label="202011"/><FilterOption count="7" label="202202"/><FilterOption count="7" label="202204"/><FilterOption count="7" label="202205"/><FilterOption count="6" label="201203"/><FilterOption count="6" label="201302"/><FilterOption count="6" label="201411"/><FilterOption count="6" label="201504"/><FilterOption count="6" label="201505"/><FilterOption count="6" label="201512"/><FilterOption count="6" label="201610"/><FilterOption count="6" label="201702"/><FilterOption count="6" label="201706"/><FilterOption count="6" label="201804"/><FilterOption count="6" label="201809"/><FilterOption count="6" label="201904"/><FilterOption count="6" label="202008"/><FilterOption count="6" label="202010"/><FilterOption count="6" label="202102"/><FilterOption count="6" label="202212"/><FilterOption count="6" label="202303"/><FilterOption count="6" label="202307"/><FilterOption count="5" label="200812"/><FilterOption count="5" label="201006"/><FilterOption count="5" label="201205"/><FilterOption count="5" label="201207"/><FilterOption count="5" label="201306"/><FilterOption count="5" label="201310"/><FilterOption count="5" label="201410"/><FilterOption count="5" label="201506"/><FilterOption count="5" label="201603"/><FilterOption count="5" label="201607"/><FilterOption count="5" label="201609"/><FilterOption count="5" label="201611"/><FilterOption count="5" label="201705"/><FilterOption count="5" label="201707"/><FilterOption count="5" label="201711"/><FilterOption count="5" label="202105"/><FilterOption count="5" label="202201"/><FilterOption count="5" label="202203"/><FilterOption count="5" label="202304"/><FilterOption count="4" label="200702"/><FilterOption count="4" label="200712"/><FilterOption count="4" label="200807"/><FilterOption count="4" label="200810"/><FilterOption count="4" label="200902"/><FilterOption count="4" label="200904"/><FilterOption count="4" label="200905"/></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="15" label="201606"/><FilterOption count="15" label="201706"/><FilterOption count="15" label="201707"/><FilterOption count="14" label="201701"/><FilterOption count="14" label="201711"/><FilterOption count="13" label="201001"/><FilterOption count="13" label="201805"/><FilterOption count="13" label="201806"/><FilterOption count="12" label="201212"/><FilterOption count="12" label="201411"/><FilterOption count="12" label="201512"/><FilterOption count="12" label="201604"/><FilterOption count="12" label="201710"/><FilterOption count="12" label="201811"/><FilterOption count="11" label="201110"/><FilterOption count="11" label="201407"/><FilterOption count="11" label="201506"/><FilterOption count="11" label="201704"/><FilterOption count="11" label="201801"/><FilterOption count="11" label="201803"/><FilterOption count="11" label="201810"/><FilterOption count="11" label="201812"/><FilterOption count="10" label="200610"/><FilterOption count="10" label="200711"/><FilterOption count="10" label="201103"/><FilterOption count="10" label="201204"/><FilterOption count="10" label="201210"/><FilterOption count="10" label="201301"/><FilterOption count="10" label="201402"/><FilterOption count="10" label="201501"/><FilterOption count="10" label="201503"/><FilterOption count="10" label="201504"/><FilterOption count="10" label="201807"/><FilterOption count="9" label="201009"/><FilterOption count="9" label="201111"/><FilterOption count="9" label="201303"/><FilterOption count="9" label="201412"/><FilterOption count="9" label="201603"/><FilterOption count="9" label="201703"/><FilterOption count="9" label="201705"/><FilterOption count="9" label="201709"/><FilterOption count="9" label="201804"/><FilterOption count="9" label="201902"/><FilterOption count="8" label="201006"/><FilterOption count="8" label="201011"/><FilterOption count="8" label="201101"/><FilterOption count="8" label="201107"/><FilterOption count="8" label="201309"/><FilterOption count="8" label="201310"/><FilterOption count="8" label="201404"/><FilterOption count="8" label="201405"/><FilterOption count="8" label="201509"/><FilterOption count="8" label="201607"/><FilterOption count="8" label="201611"/><FilterOption count="8" label="201901"/><FilterOption count="8" label="201905"/><FilterOption count="7" label="200808"/><FilterOption count="7" label="200904"/><FilterOption count="7" label="200911"/><FilterOption count="7" label="201201"/><FilterOption count="7" label="201306"/><FilterOption count="7" label="201307"/><FilterOption count="7" label="201312"/><FilterOption count="7" label="201605"/><FilterOption count="7" label="201612"/><FilterOption count="7" label="201809"/><FilterOption count="7" label="201903"/><FilterOption count="6" label="200601"/><FilterOption count="6" label="200603"/><FilterOption count="6" label="200804"/><FilterOption count="6" label="200807"/><FilterOption count="6" label="200812"/><FilterOption count="6" label="200907"/><FilterOption count="6" label="201003"/><FilterOption count="6" label="201007"/><FilterOption count="6" label="201102"/><FilterOption count="6" label="201105"/><FilterOption count="6" label="201109"/><FilterOption count="6" label="201202"/><FilterOption count="6" label="201206"/><FilterOption count="6" label="201207"/><FilterOption count="6" label="201305"/><FilterOption count="6" label="201401"/><FilterOption count="6" label="201609"/><FilterOption count="6" label="201712"/><FilterOption count="6" label="201808"/><FilterOption count="6" label="201904"/><FilterOption count="6" label="201906"/><FilterOption count="5" label="200509"/><FilterOption count="5" label="200712"/><FilterOption count="5" label="200809"/><FilterOption count="5" label="200811"/><FilterOption count="5" label="200901"/><FilterOption count="5" label="200902"/><FilterOption count="5" label="201108"/><FilterOption count="5" label="201203"/><FilterOption count="5" label="201211"/><FilterOption count="5" label="201311"/><FilterOption count="5" label="201403"/><FilterOption count="5" label="201408"/></Filter><Filter label="Trial Phase" name="trialPhase" total="13"><FilterOption id="C3" count="402" label="Phase 3 Clinical"/><FilterOption id="C2" count="285" label="Phase 2 Clinical"/><FilterOption id="C4" count="162" label="Phase 4 Clinical"/><FilterOption id="PNA" count="108" label="Phase Not Applicable"/><FilterOption id="C12" count="55" label="Phase 1/Phase 2 Clinical"/><FilterOption id="C1" count="35" label="Phase 1 Clinical"/><FilterOption id="C23" count="29" label="Phase 2/Phase 3 Clinical"/><FilterOption id="C2B" count="28" label="Phase 2b Clinical"/><FilterOption id="NS" count="27" label="Phase not specified"/><FilterOption id="C3B" count="23" label="Phase 3b Clinical"/><FilterOption id="C2A" count="16" label="Phase 2a Clinical"/><FilterOption id="C1B" count="14" label="Phase 1b Clinical"/><FilterOption id="C0" count="4" label="Phase 0 Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="5418" count="57" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 infection"/><FilterOption id="5317" count="53" label="HIV infection - Subjects with Protocol Specified HIV Viral Load"/><FilterOption id="4879" count="50" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4880" count="50" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3537" count="45" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3538" count="45" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5086" count="43" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="5087" count="42" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3976" count="40" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3977" count="40" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5088" count="38" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="3539" count="38" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4691" count="36" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4692" count="36" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4840" count="34" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3957" count="34" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"/><FilterOption id="5322" count="33" label="HIV infection - Subjects with Protocol Specified CD4+ T Cell Counts"/><FilterOption id="3900" count="33" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3548" count="33" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"/><FilterOption id="4981" count="32" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="4814" count="29" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="3936" count="29" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"/><FilterOption id="22417" count="27" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"/><FilterOption id="22381" count="27" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"/><FilterOption id="4693" count="27" label="Multiple myeloma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="5074" count="26" label="Leukemia - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3940" count="26" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="5073" count="25" label="Leukemia - Subjects with Normal/Acceptable Organ Function - Subjects with normal/adequate liver function"/><FilterOption id="3642" count="25" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4169" count="25" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4170" count="25" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4628" count="25" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum M-protein"/><FilterOption id="32953" count="25" label="Other gastrointestinal disease - Protocol Specified Other Inclusion Criteria"/><FilterOption id="4928" count="24" label="Breast tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4024" count="24" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4672" count="24" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological status"/><FilterOption id="4675" count="24" label="Multiple myeloma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="7091" count="24" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4813" count="23" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="4808" count="23" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="5344" count="23" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy"/><FilterOption id="3447" count="23" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="4162" count="23" label="Melanoma - Subjects with Diagnosis of Melanoma - Subjects with histological diagnosis of melanoma"/><FilterOption id="4139" count="23" label="Melanoma - Subjects with Stage IV Melanoma"/><FilterOption id="4973" count="22" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="22405" count="22" label="Leukemia - Treatment Naive Subjects"/><FilterOption id="4074" count="22" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="4032" count="22" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4676" count="22" label="Multiple myeloma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4767" count="22" label="Multiple myeloma - Subjects with Relapsed/Recurrent Disease"/><FilterOption id="4106" count="21" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"/><FilterOption id="3622" count="21" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4630" count="21" label="Multiple myeloma - Subjects with Measurable Disease - Subjects with measurable serum/urine light chain"/><FilterOption id="7465" count="20" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4857" count="20" label="Breast tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4955" count="20" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="3914" count="20" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4041" count="20" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="3448" count="20" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="4198" count="20" label="Melanoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="7441" count="19" label="Bladder cancer - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="7464" count="19" label="Bladder cancer - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="5164" count="19" label="Leukemia - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="4756" count="19" label="Multiple myeloma - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="13096" count="19" label="Solid tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4864" count="18" label="Breast tumor - Subjects with Normal/Acceptable Organ Function - Subjects with acceptable hematological test values"/><FilterOption id="3475" count="18" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with indolent (slow-growing, low grade) lymphoma"/><FilterOption id="32955" count="18" label="Other gastrointestinal disease - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="13110" count="18" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="13111" count="18" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="7485" count="17" label="Bladder cancer - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4483" count="17" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4527" count="17" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4528" count="17" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5331" count="17" label="HIV infection - Subjects with Normal/Acceptable Laboratory Criteria - Subjects with normal/acceptable liver function tests"/><FilterOption id="3935" count="17" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"/><FilterOption id="4208" count="17" label="Melanoma - Subjects with Feasibility for Specific Treatment Modalities - Subjects with surgically non-resectable melanoma"/><FilterOption id="35070" count="17" label="Other gastrointestinal disease - Subjects with specific disease"/><FilterOption id="7445" count="16" label="Bladder cancer - Subjects with Stage IV Bladder Cancer"/><FilterOption id="4817" count="16" label="Breast tumor - Postmenopausal Breast Cancer Women"/><FilterOption id="4922" count="16" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="4877" count="16" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"/><FilterOption id="3477" count="16" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with aggressive (high grade) lymphoma"/><FilterOption id="7440" count="15" label="Bladder cancer - Subjects with Locally Advanced Cancer/Tumor"/><FilterOption id="22418" count="15" label="Breast tumor - Subjects with Early Breast Cancer"/><FilterOption id="22416" count="15" label="Breast tumor - Subjects with Unresectable Breast Cancer"/><FilterOption id="4569" count="15" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematopoetic/marrow function"/><FilterOption id="1751" count="15" label="Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection"/><FilterOption id="5348" count="15" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent HAART (Highly Active Anti Retroviral Therapy)"/><FilterOption id="5345" count="15" label="HIV infection - Subjects on Prior/Concurrent Antiretroviral Therapy - Subjects on prior/concurrent nucleoside reverse transcriptase inhibitors"/><FilterOption id="5278" count="15" label="HIV infection - Subjects with HIV Infection"/><FilterOption id="5332" count="15" label="HIV infection - Subjects with Normal/Acceptable Laboratory Criteria - Subjects with normal/acceptable renal function tests"/><FilterOption id="5329" count="15" label="HIV infection - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="3971" count="15" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"/><FilterOption id="32043" count="15" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="13129" count="15" label="Solid tumor - Subjects with Treatment Refractory Disease"/><FilterOption id="22362" count="14" label="Bladder cancer - Subjects with Urothelial Cell/Transitional Cell Bladder Cancer"/><FilterOption id="4894" count="14" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="4809" count="14" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="4509" count="14" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="97"><FilterOption id="2953" count="7" label="docetaxel"/><FilterOption id="3803" count="5" label="paclitaxel"/><FilterOption id="37370" count="4" label="azacitidine"/><FilterOption id="12205" count="4" label="capecitabine"/><FilterOption id="3313" count="4" label="fulvestrant"/><FilterOption id="3199" count="4" label="gemcitabine"/><FilterOption id="12973" count="4" label="sunitinib"/><FilterOption id="13239" count="3" label="decitabine"/><FilterOption id="2784" count="3" label="letrozole"/><FilterOption id="70667" count="3" label="pembrolizumab"/><FilterOption id="14493" count="3" label="tenofovir disoproxil fumarate"/><FilterOption id="99926" count="2" label="18F-GTP1"/><FilterOption id="53547" count="2" label="aflibercept (intravitreal, wet AMD, macular edema, diabetic retinopathy), Regeneron/Bayer"/><FilterOption id="44388" count="2" label="carbidopa + levodopa"/><FilterOption id="55798" count="2" label="crizotinib"/><FilterOption id="53200" count="2" label="daratumumab"/><FilterOption id="7934" count="2" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="62277" count="2" label="emtricitabine + tenofovir disoproxil fumarate + elvitegravir + cobicistat (single tablet regimen, HIV/AIDS), Gilead Sciences"/><FilterOption id="13928" count="2" label="enoxaparin sodium"/><FilterOption id="53981" count="2" label="enzalutamide"/><FilterOption id="55237" count="2" label="ibrutinib"/><FilterOption id="2871" count="2" label="irinotecan"/><FilterOption id="5267" count="2" label="leuprorelin acetate"/><FilterOption id="14681" count="2" label="lopinavir + ritonavir"/><FilterOption id="3669" count="2" label="mycophenolate mofetil"/><FilterOption id="54804" count="2" label="nivolumab"/><FilterOption id="29831" count="2" label="sorafenib"/><FilterOption id="4529" count="2" label="temozolomide"/><FilterOption id="4577" count="2" label="topotecan"/><FilterOption id="6408" count="2" label="vinorelbine"/><FilterOption id="2503" count="1" label="amphotericin B (liposomal iv, visceral leishmaniasis), Drugs for Neglected Diseases initiative"/><FilterOption id="3321" count="1" label="anastrozole"/><FilterOption id="52967" count="1" label="apixaban"/><FilterOption id="50484" count="1" label="apomorphine hydrochloride (Parkinson's disease), Britannia"/><FilterOption id="72699" count="1" label="atezolizumab"/><FilterOption id="16905" count="1" label="atomoxetine"/><FilterOption id="11141" count="1" label="basiliximab"/><FilterOption id="8047" count="1" label="bevacizumab"/><FilterOption id="100071" count="1" label="BMS-986177"/><FilterOption id="50935" count="1" label="cabozantinib S-malate"/><FilterOption id="63194" count="1" label="carbidopa + levodopa (Parkinsons disease, immediate/extended release), Impax"/><FilterOption id="44383" count="1" label="carboplatin"/><FilterOption id="95204" count="1" label="cemiplimab"/><FilterOption id="2836" count="1" label="clopidogrel"/><FilterOption id="2911" count="1" label="daptomycin"/><FilterOption id="72148" count="1" label="darunavir + cobicistat (fixed dose, HIV infection), Janssen R&amp;D/ Gilead"/><FilterOption id="72153" count="1" label="darunavir + tenofovir alafenamide + emtricitabine + cobicistat (single tablet regimen, HIV-1),Janssen R&amp;D"/><FilterOption id="2992" count="1" label="donepezil hydrochloride"/><FilterOption id="10172" count="1" label="efavirenz"/><FilterOption id="4728" count="1" label="emtricitabine"/><FilterOption id="13486" count="1" label="entecavir"/><FilterOption id="14603" count="1" label="eplerenone"/><FilterOption id="28773" count="1" label="eribulin mesylate"/><FilterOption id="13340" count="1" label="everolimus"/><FilterOption id="3081" count="1" label="exemestane"/><FilterOption id="44292" count="1" label="fluconazole"/><FilterOption id="8888" count="1" label="hydroxycarbamide (sickle cell anemia, thrombocythemia, polycythemia), BMS"/><FilterOption id="44397" count="1" label="hylan G-F 20"/><FilterOption id="62922" count="1" label="IFX-1"/><FilterOption id="11460" count="1" label="imatinib"/><FilterOption id="7067" count="1" label="imiquimod"/><FilterOption id="6850" count="1" label="infliximab"/><FilterOption id="10411" count="1" label="insulin aspart"/><FilterOption id="3353" count="1" label="insulin lispro"/><FilterOption id="3360" count="1" label="interferon beta-1a, Biogen"/><FilterOption id="36630" count="1" label="ipilimumab"/><FilterOption id="9819" count="1" label="lanthanum carbonate"/><FilterOption id="9443" count="1" label="levosimendan"/><FilterOption id="11036" count="1" label="linezolid"/><FilterOption id="6050" count="1" label="metformin hydrochloride"/><FilterOption id="44303" count="1" label="midazolam hydrochloride"/><FilterOption id="61287" count="1" label="niraparib"/><FilterOption id="13460" count="1" label="oseltamivir"/><FilterOption id="8747" count="1" label="palivizumab"/><FilterOption id="67037" count="1" label="patisiran"/><FilterOption id="7871" count="1" label="pirfenidone"/><FilterOption id="22395" count="1" label="ranibizumab"/><FilterOption id="7310" count="1" label="ritonavir"/><FilterOption id="54662" count="1" label="ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis"/><FilterOption id="44312" count="1" label="salmeterol"/><FilterOption id="8713" count="1" label="sildenafil citrate"/><FilterOption id="44313" count="1" label="simvastatin"/><FilterOption id="44314" count="1" label="tamoxifen"/><FilterOption id="49219" count="1" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="50038" count="1" label="tenofovir disoproxil fumarate + emtricitabine + efavirenz, Gilead/BMS/Merck &amp; Co"/><FilterOption id="8050" count="1" label="thalidomide, Celgene"/><FilterOption id="44315" count="1" label="timolol"/><FilterOption id="6386" count="1" label="trastuzumab"/><FilterOption id="36669" count="1" label="trastuzumab emtansine"/><FilterOption id="23239" count="1" label="ulipristal"/><FilterOption id="61574" count="1" label="umirolimus stent (BioMatrix, restenosis), Biosensors"/><FilterOption id="13338" count="1" label="ursodeoxycholic acid"/><FilterOption id="2773" count="1" label="valsartan"/><FilterOption id="44401" count="1" label="vancomycin"/><FilterOption id="54469" count="1" label="vemurafenib"/><FilterOption id="15130" count="1" label="vinflunine"/><FilterOption id="44375" count="1" label="warfarin"/></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="1016" count="18" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="1832" count="16" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="5085" count="15" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="204" count="15" label="HIV protease inhibitor"/><FilterOption id="372" count="15" label="Thymidylate synthase inhibitor"/><FilterOption id="142" count="15" label="Topoisomerase II inhibitor"/><FilterOption id="138" count="13" label="DNA polymerase inhibitor"/><FilterOption id="768" count="12" label="HIV-1 protease inhibitor"/><FilterOption id="7424" count="10" label="Cytochrome P450 3A4 inhibitor"/><FilterOption id="3756" count="10" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="3808" count="9" label="Kit tyrosine kinase inhibitor"/><FilterOption id="4917" count="9" label="Proteasome inhibitor"/><FilterOption id="3846" count="9" label="VEGF-1 receptor antagonist"/><FilterOption id="3848" count="9" label="VEGF-2 receptor antagonist"/><FilterOption id="3806" count="8" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="3816" count="8" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="3850" count="8" label="VEGF-3 receptor antagonist"/><FilterOption id="76469" count="7" label="26S proteasome complex inhibitor"/><FilterOption id="76" count="7" label="Aromatase inhibitor"/><FilterOption id="48492" count="7" label="PDGF receptor beta antagonist"/><FilterOption id="814" count="7" label="Tubulin modulator"/><FilterOption id="12521" count="7" label="VEGF ligand inhibitor"/><FilterOption id="7418" count="6" label="Cytochrome P450 3 inhibitor"/><FilterOption id="6512" count="6" label="DNA methyltransferase inhibitor"/><FilterOption id="7588" count="6" label="HIV-1 integrase inhibitor"/><FilterOption id="67136" count="6" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="141" count="6" label="Topoisomerase I inhibitor"/><FilterOption id="3154" count="5" label="CSF-1 antagonist"/><FilterOption id="7472" count="5" label="Cytochrome P450 17 inhibitor"/><FilterOption id="82444" count="5" label="DNA helicase inhibitor"/><FilterOption id="286" count="5" label="Estrogen receptor antagonist"/><FilterOption id="1833" count="5" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="2506" count="5" label="PARP modulator"/><FilterOption id="48489" count="5" label="PDGF receptor alpha antagonist"/><FilterOption id="374" count="5" label="Transferase inhibitor"/><FilterOption id="6515" count="4" label="Cytosine DNA methyltransferase inhibitor"/><FilterOption id="135" count="4" label="DHFR inhibitor"/><FilterOption id="740" count="4" label="Epidermal growth factor receptor antagonist"/><FilterOption id="181" count="4" label="GAR transformylase inhibitor"/><FilterOption id="71851" count="4" label="HIV GAG POL polyprotein inhibitor"/><FilterOption id="12395" count="4" label="HIV GAG protein inhibitor"/><FilterOption id="1671" count="4" label="HIV integrase inhibitor"/><FilterOption id="10240" count="4" label="mTOR inhibitor"/><FilterOption id="948" count="4" label="PDGF receptor antagonist"/><FilterOption id="1722" count="4" label="VEGF receptor antagonist"/><FilterOption id="60" count="3" label="Androgen receptor antagonist"/><FilterOption id="7423" count="3" label="Cytochrome P450 3A4 stimulator"/><FilterOption id="18889" count="3" label="DNA binding protein inhibitor"/><FilterOption id="5554" count="3" label="Dopa decarboxylase inhibitor"/><FilterOption id="144" count="3" label="Dopamine receptor agonist"/><FilterOption id="111" count="3" label="Factor IIa antagonist"/><FilterOption id="113" count="3" label="Factor IX antagonist"/><FilterOption id="114" count="3" label="Factor VII antagonist"/><FilterOption id="119" count="3" label="Factor X antagonist"/><FilterOption id="675" count="3" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="205" count="3" label="HMG CoA reductase inhibitor"/><FilterOption id="3796" count="3" label="MET tyrosine kinase receptor family inhibitor"/><FilterOption id="76090" count="3" label="mTOR complex 1 inhibitor"/><FilterOption id="4913" count="3" label="P2Y12 purinoceptor antagonist"/><FilterOption id="14007" count="3" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="35354" count="3" label="Prostate specific antigen modulator"/><FilterOption id="4548" count="3" label="Raf B protein kinase inhibitor"/><FilterOption id="346" count="3" label="Ribonucleotide reductase inhibitor"/><FilterOption id="78089" count="3" label="Translocation associated protein inhibitor"/><FilterOption id="10583" count="3" label="Vitamin K epoxide reductase inhibitor"/><FilterOption id="18" count="2" label="ACE inhibitor"/><FilterOption id="5136" count="2" label="ADP ribosyl cyclase-1 inhibitor"/><FilterOption id="3851" count="2" label="ALK tyrosine kinase receptor family inhibitor"/><FilterOption id="8805" count="2" label="AMP activated protein kinase stimulator"/><FilterOption id="3736" count="2" label="Anaplastic lymphoma kinase receptor inhibitor"/><FilterOption id="77" count="2" label="Aspartic protease inhibitor"/><FilterOption id="3592" count="2" label="Btk tyrosine kinase inhibitor"/><FilterOption id="5482" count="2" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="51708" count="2" label="DNA polymerase alpha inhibitor"/><FilterOption id="6830" count="2" label="DNA primase inhibitor"/><FilterOption id="48389" count="2" label="Echinoderm microtubule like protein 4 inhibitor"/><FilterOption id="1092" count="2" label="GNRH receptor agonist"/><FilterOption id="629" count="2" label="Inosine monophosphate dehydrogenase inhibitor"/><FilterOption id="23014" count="2" label="Insulin ligand"/><FilterOption id="400" count="2" label="Insulin receptor agonist"/><FilterOption id="214" count="2" label="Interferon alpha 2 ligand"/><FilterOption id="777" count="2" label="Lanosterol-14 demethylase inhibitor"/><FilterOption id="1741" count="2" label="Low molecular weight heparin"/><FilterOption id="57003" count="2" label="Peptidoglycan recognition protein inhibitor"/><FilterOption id="15904" count="2" label="Placenta growth factor ligand inhibitor"/><FilterOption id="38283" count="2" label="Poly ADP ribose polymerase 1 inhibitor"/><FilterOption id="38286" count="2" label="Poly ADP ribose polymerase 2 inhibitor"/><FilterOption id="11778" count="2" label="PurH purine biosynthesis protein inhibitor"/><FilterOption id="4550" count="2" label="Raf 1 protein kinase inhibitor"/><FilterOption id="4542" count="2" label="Raf protein kinase inhibitor"/><FilterOption id="345" count="2" label="Reverse transcriptase inhibitor"/><FilterOption id="551" count="2" label="RNA DNA polymerase inhibitor"/><FilterOption id="3826" count="2" label="Ros1 tyrosine kinase receptor inhibitor"/><FilterOption id="2422" count="2" label="Tau protein modulator"/><FilterOption id="381" count="2" label="TNF alpha ligand inhibitor"/><FilterOption id="721" count="2" label="TNF binding agent"/><FilterOption id="1513" count="2" label="Topoisomerase II modulator"/><FilterOption id="58716" count="2" label="Ubiquitin inhibitor"/><FilterOption id="1689" count="2" label="VEGF-A ligand inhibitor"/><FilterOption id="61991" count="1" label="1,3 beta glucan synthase inhibitor"/></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="102" count="129" label="Diarrhea"/><FilterOption id="226" count="121" label="Nausea"/><FilterOption id="1991" count="112" label="Neutropenia"/><FilterOption id="829" count="111" label="Fatigue"/><FilterOption id="17" count="97" label="Anemia"/><FilterOption id="324" count="88" label="Thrombocytopenia"/><FilterOption id="110" count="65" label="Emesis"/><FilterOption id="148" count="58" label="Headache"/><FilterOption id="404" count="51" label="Constipation"/><FilterOption id="3020" count="50" label="Skin rash"/><FilterOption id="1833" count="46" label="Fever"/><FilterOption id="3038" count="44" label="Appetite loss"/><FilterOption id="360" count="44" label="Pneumonia"/><FilterOption id="746" count="43" label="Infectious disease"/><FilterOption id="3062" count="39" label="Death"/><FilterOption id="3795" count="37" label="Febrile neutropenia"/><FilterOption id="178" count="35" label="Hypertension"/><FilterOption id="680" count="35" label="Leukopenia"/><FilterOption id="259" count="32" label="Peripheral neuropathy"/><FilterOption id="82" count="31" label="Cough"/><FilterOption id="2439" count="28" label="Arthralgia"/><FilterOption id="402" count="28" label="Edema"/><FilterOption id="2274" count="27" label="Rhinopharyngitis"/><FilterOption id="516" count="26" label="Upper respiratory tract infection"/><FilterOption id="2400" count="25" label="Dyspnea"/><FilterOption id="3472" count="24" label="Abdominal pain"/><FilterOption id="3221" count="22" label="Back pain"/><FilterOption id="13" count="19" label="Alopecia"/><FilterOption id="3454" count="19" label="Dizziness"/><FilterOption id="279" count="19" label="Pruritus"/><FilterOption id="1821" count="18" label="Hyperglycemia"/><FilterOption id="750" count="18" label="Insomnia"/><FilterOption id="20" count="18" label="Pain"/><FilterOption id="552" count="17" label="Bleeding"/><FilterOption id="181" count="17" label="Hypokalemia"/><FilterOption id="1078" count="17" label="Lung embolism"/><FilterOption id="1039" count="17" label="Myalgia"/><FilterOption id="1992" count="16" label="Lymphocytopenia"/><FilterOption id="1009" count="15" label="Urinary tract infection"/><FilterOption id="574" count="14" label="Deep vein thrombosis"/><FilterOption id="129" count="14" label="Gastrointestinal disease"/><FilterOption id="50" count="11" label="Bronchitis"/><FilterOption id="1016" count="11" label="Stomatitis"/><FilterOption id="3050" count="10" label="Chill"/><FilterOption id="2576" count="10" label="Dysgeusia"/><FilterOption id="224" count="10" label="Myocardial infarction"/><FilterOption id="2955" count="10" label="Weight loss"/><FilterOption id="408" count="9" label="Hypotension"/><FilterOption id="114" count="9" label="Sepsis"/><FilterOption id="1072" count="8" label="Colitis"/><FilterOption id="1280" count="8" label="Hypophosphatemia"/><FilterOption id="1263" count="8" label="Mucositis"/><FilterOption id="93" count="7" label="Depression"/><FilterOption id="182" count="7" label="Hypothyroidism"/><FilterOption id="358" count="7" label="Muscle spasm"/><FilterOption id="2440" count="7" label="Musculoskeletal pain"/><FilterOption id="69" count="7" label="Renal failure"/><FilterOption id="325" count="7" label="Thromboembolism"/><FilterOption id="55" count="6" label="Cardiac failure"/><FilterOption id="2024" count="6" label="Erythema"/><FilterOption id="154" count="6" label="Hepatitis"/><FilterOption id="2529" count="6" label="Hot flashes"/><FilterOption id="201" count="6" label="Liver disease"/><FilterOption id="307" count="6" label="Squamous cell carcinoma"/><FilterOption id="2948" count="6" label="Tumor lysis syndrome"/><FilterOption id="25" count="5" label="Anxiety disorder"/><FilterOption id="3073" count="5" label="Drowsiness"/><FilterOption id="2184" count="5" label="Gastrointestinal bleeding"/><FilterOption id="172" count="5" label="Hyperbilirubinemia"/><FilterOption id="505" count="5" label="Hypersensitivity"/><FilterOption id="191" count="5" label="Influenza virus infection"/><FilterOption id="277" count="5" label="Proteinuria"/><FilterOption id="286" count="5" label="Renal disease"/><FilterOption id="2434" count="5" label="Vertigo"/><FilterOption id="1063" count="5" label="Xerostomia"/><FilterOption id="6832" count="4" label="Acral erythema"/><FilterOption id="57" count="4" label="Cardiovascular disease"/><FilterOption id="2525" count="4" label="Cellulitis"/><FilterOption id="95" count="4" label="Dermatological disease"/><FilterOption id="1835" count="4" label="Epistaxis"/><FilterOption id="626" count="4" label="Heart disease"/><FilterOption id="444" count="4" label="Hypocalcemia"/><FilterOption id="668" count="4" label="Muscle weakness"/><FilterOption id="678" count="4" label="Neuropathy"/><FilterOption id="2469" count="4" label="Paresthesia"/><FilterOption id="509" count="4" label="Respiratory tract infection"/><FilterOption id="1076" count="4" label="Thrombosis"/><FilterOption id="1542" count="3" label="Atrial fibrillation"/><FilterOption id="412" count="3" label="Bradycardia"/><FilterOption id="1559" count="3" label="Congestive heart failure"/><FilterOption id="89" count="3" label="Cytomegalovirus infection"/><FilterOption id="3063" count="3" label="Delirium"/><FilterOption id="432" count="3" label="Dyspepsia"/><FilterOption id="2749" count="3" label="Hematoma"/><FilterOption id="2738" count="3" label="Hyperkalemia"/><FilterOption id="2112" count="3" label="Hyperkeratosis"/><FilterOption id="179" count="3" label="Hyperthyroidism"/><FilterOption id="1053" count="3" label="Hypoxia"/><FilterOption id="250" count="3" label="Pancreatitis"/><FilterOption id="717" count="3" label="Seizure disorder"/></Filter></Filters><SearchResults><Trial Id="371661"><Indications><Indication>Arterial thrombosis</Indication><Indication>Metastasis</Indication><Indication>Phlebothrombosis</Indication></Indications><CompaniesSponsor><Company>Fundación Sociedad Española de Oncologia Médica</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-03-05T00:00:00Z</DateChangeLast><DateEnd>2019-07-31T00:00:00Z</DateEnd><DateStart>2018-07-04T00:00:00Z</DateStart><Identifiers><Identifier>NCT03855592</Identifier><Identifier>SEOM-TESEO-2017-01</Identifier><Identifier>TESEO</Identifier></Identifiers><PatientCountEnrollment>700</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is an epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis or at anytime after such diagnosis.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cancer supportive care - Clinical Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Solid tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Solid tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Solid tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Solid tumor - Protocol Specified Other Endpoints - Assessment of hematological status</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Morbidity</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of symptomatic thrombotic/thromboembolic events</EndpointIndex><EndpointIndex>Thrombosis - Clinical Assessments</EndpointIndex><EndpointIndex>Thrombosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Thrombosis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TESEO: Registry of Thrombosis And Neoplasia of 'Sociedad Española de Oncología Médica'</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Cancer-Hematological Complications</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Thrombosis - Subjects with comorbid conditions - Subjects co-morbid with active malignancy/tumors</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with thromboembolic manifestations</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>35</NumberOfSites><ContactNames><Name>Alberto Carmona Bayonas, M.D.</Name><Name>Andres Muñoz, M.D.</Name><Name>Eva Martínez de Castro, M.D.</Name><Name>Federico Nepote</Name><Name>José Muñoz Langa, M.D.</Name><Name>Paula Jiménez Fonseca, M.D.</Name><Name>Pedro Pérez Segura, M.D.</Name></ContactNames></Trial><Trial Id="137593"><Indications><Indication>Coronary artery disease</Indication></Indications><CompaniesSponsor><Company>BIOTRONIK SE &amp; Co</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Germany</Country><Country>Latvia</Country><Country>Spain</Country><Country>Hungary</Country><Country>France</Country><Country>Austria</Country><Country>Netherlands</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>BIOFLOW-II</Identifier><Identifier>C1004</Identifier><Identifier>NCT01356888</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Orsiro drug eluting stent system alone</Intervention><Intervention>Xience Prime drug eluting stent system alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>452</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Subject has provided a written informed consent Single &lt;b&gt;de&lt;/b&gt; novo lesion with &amp;gt;/= 50 and&amp;lt; 100% stenosis in up to two coronary arteries The target lesion length is&amp;lt;/= 26 mm The target reference vessel diameter is &amp;gt;/= 2.25 and&amp;lt;/= 4.0 mm...purpose of this study was to compare the Biotronik-Orsiro drug eluting stent system with the Abbott-Xience Prime drug eluting stent system with respect to in-stent late lumen loss in a non-inferiority study in &lt;b&gt;de&lt;/b&gt;-novo coronary lesions at 9 months.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Stenosis/Restenosis - Minimal luminal diameter</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BIOFLOW-II: Study of the Orsiro Drug Eluting Stent System</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - De novo lesion/lesions</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - Stenosis/Narrowing of vessel</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - Target lesion measurements by visual estimation in coronary angiogram</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Multiple Vessel CAD</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Stable Coronary Artery Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Q-wave</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>91 Months</TrialDuration><NumberOfSites>24</NumberOfSites><ContactNames><Name>Stephan Windecker</Name><Name>Thierry Lefèvre</Name></ContactNames></Trial><Trial Id="267627"><Indications><Indication>Acute liver failure</Indication><Indication>Chronic liver failure</Indication><Indication>Liver cirrhosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Stem cell therapy</Technology></Technologies><CompaniesCollaborator><Company>Clinica Universidad de Navarra</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Clinic of Barcelona</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-25T00:00:00Z</DateChangeLast><DateEnd>2020-02-29T00:00:00Z</DateEnd><DateStart>2016-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2012-003900-11</Identifier><Identifier>Liveradvance</Identifier><Identifier>NCT02857010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mesenchymal stem cell therapy (liver failure), Hospital Clinic of Barcelona/Clinica Universidad de Navarra alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this double-blind, placebo randomized, controlled trial is to investigate the effects of allogenic bone marrow derived mesenchymal stem cells (MSCs) transplantation on liver and other organ functions and systemic inflammation in patients with acute-on-chronic liver failure (ACLF). Expected results: therapy with MSCs could have beneficial effects on the evolution of patients with ACLF (modulation of inflammatory response and improvement of liver and extra-hepatic organ function) what</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Liveradvance: Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure</TitleDisplay><BiomarkerNames><BiomarkerName>Ammonia </BiomarkerName><BiomarkerName> Bile acids and salts </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Hepatic venous pressure gradient </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Nitric oxide </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Renin </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> von Willebrand factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Javier Fernandez, MD PhD</Name><Name>Javier Fernandez, MD, PhD</Name><Name>PERE GINES, MD PhD</Name><Name>Pere Ginès, MD, PhD</Name></ContactNames></Trial><Trial Id="215055"><Indications><Indication>Glioblastoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ALK tyrosine kinase receptor family inhibitor</Action><Action>Anaplastic lymphoma kinase receptor inhibitor</Action><Action>Echinoderm microtubule like protein 4 inhibitor</Action><Action>Hepatocyte growth factor receptor antagonist</Action><Action>MET tyrosine kinase receptor family inhibitor</Action><Action>Ros1 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Intravenous formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Grupo Español de Investigación en Neurooncología</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-07-11T00:00:00Z</DateChangeLast><DateEnd>2019-02-28T00:00:00Z</DateEnd><DateStart>2014-08-13T00:00:00Z</DateStart><Identifiers><Identifier>GEINO 1402</Identifier><Identifier>NCT02270034</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Hypophosphatemia</Indication><Indication>Lymphocytopenia</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>radiotherapy (60 Gy) alone</Intervention><Intervention>Variable regimens including concurrent phase , crizotinib , sequential adjuvant phase , temozolomide</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 1b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> angina within 6 months Congestive heart failure within 6 months Diagnosed or suspected congenital long QT syndrome Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades &lt;b&gt;de&lt;/b&gt; pointes) Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (&gt; 470 ms) Any history of second or third degree heart block (may be eligible if currently have a pacemaker) Heart rate&amp;lt;/= 50/min on pre-entry electrocardiogram Uncontrolled</Teaser><TrialCategories><Category>Radiation therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Glioblastoma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Glioblastoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Glioblastoma - Assessment of adverse events</EndpointIndex><EndpointIndex>Glioblastoma - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Glioblastoma - Subjects with De Novo Glioblastoma Multiforme</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2016-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Ana Márquez, Graduate</Name><Name>Ana Márquez, Pharmacist</Name><Name>Estela Pineda, MD</Name><Name>Juan Manuel Sepúlveda, MD</Name><Name>Juan Sepulveda, MD</Name><Name>María Martínez, MD</Name><Name>Miguel Gil, MD</Name></ContactNames></Trial><Trial Id="10603"><Indications><Indication>Aspergillus infection</Indication><Indication>Candida infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>1,3 beta glucan synthase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Fungicide</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Spanish Society of Critical Care Medicine, and Critical Coronay Units</Company></CompaniesCollaborator><CompaniesSponsor><Company>PETHEMA Foundation</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-12-20T00:00:00Z</DateChangeLast><DateEnd>2008-02-01T00:00:00Z</DateEnd><DateStart>2004-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00388167</Identifier><Identifier>PET-CAS-2003-01</Identifier><Identifier>PET-CAS-2004-01</Identifier><Identifier>PROCAS</Identifier></Identifiers><IndicationsAdverse><Indication>Dermatological disease</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>caspofungin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>320</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>A phase IV study was designed to assess the efficacy and the safety of caspofungin (Cancidas) in the treatment of invader fungal infection (IFI) specifically, invasive candidiasis (IC) in adults patients without neutropenia and invasive aspergillosis (IA) in adults patients who were refractory to or intolerant of other therapies (ie, amphotericin B, lipid formulations of amphotericin B, and/or itraconazole).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Candida infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Candida infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PROCAS: Acetato de Caspofungin (Cancidas) in the Treatment of Fungal Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Candida infection - Subjects with Invasive Candidiasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Creatinine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>46 Months</TrialDuration><NumberOfSites>27</NumberOfSites><ContactNames><Name>Miguel Angel Sanz, Dr</Name></ContactNames></Trial><Trial Id="97331"><Indications><Indication>Atherosclerosis</Indication><Indication>Coronary artery disease</Indication></Indications><CompaniesSponsor><Company>Boston Scientific Corp</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>Australia</Country><Country>New Zealand</Country><Country>Sweden</Country><Country>Poland</Country><Country>Spain</Country><Country>UK</Country><Country>Denmark</Country><Country>France</Country></Countries><DateChangeLast>2018-12-03T00:00:00Z</DateChangeLast><DateEnd>2016-04-30T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>EVOLVE</Identifier><Identifier>NCT01135225</Identifier><Identifier>S2060</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Promus Element Stent System alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Evolution Stent System alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>291</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>lesion that will be treated during the index procedure Angiographic Inclusion criteria (Visual Estimate): Target lesion must be a &lt;b&gt;de&lt;/b&gt; novo lesion located in a native coronary artery with a visually estimated reference vessel diameter (RVD) &amp;gt;/= 2.25...of the EVOLVE trial was to assess the safety and performance of the everolimus -eluting evolution stent for the treatment of a &lt;b&gt;de&lt;/b&gt; novo atherosclerotic lesion of up to 28 mm in length in a native coronary artery 2.25 to 3.5 mm in diameter. The</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Therapy Related Outcomes - Assessment of target vessel revascularization (TVR)</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)</EndpointIndex><EndpointIndex>Atherosclerosis - Protocol Specified Other Endpoints - Assessment of stent related events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Target lesion failure (TLF)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization - Target vessel failure after stent placement</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Stenosis/Restenosis - In-segment late loss/In-lesion late loss</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Stenosis/Restenosis - Minimal luminal diameter</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis (Definite /Probable /Possible)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EVOLVE: Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent</TitleDisplay><PatientSegmentTerms><PatientSegment>Atherosclerosis - Subjects with History of/Undergoing Specified Procedures - Subjects with history of/undergoing coronary artery bypass graft surgery (CABG)</PatientSegment><PatientSegment>Atherosclerosis - Subjects with History of/Undergoing Specified Procedures - Subjects with history of/undergoing percutaneous intervention</PatientSegment><PatientSegment>Atherosclerosis - Subjects with comorbid conditions - Subjects with cardiovascular diseases/disorders</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - De novo lesion/lesions</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Echo/ECG findings - Abnormal left ventricular ejection fraction</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Myocardial Ischemia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>69 Months</TrialDuration><NumberOfSites>29</NumberOfSites><ContactNames><Name>Ian Meredith, Prof</Name><Name>Stefan Verheye, Dr</Name></ContactNames></Trial><Trial Id="154454"><Indications><Indication>Coronary artery disease</Indication></Indications><CompaniesSponsor><Company>Biotronik VI Patent AG</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Spain</Country><Country>Netherlands</Country><Country>Japan</Country><Country>Germany</Country><Country>Australia</Country><Country>New Zealand</Country><Country>Israel</Country><Country>Denmark</Country><Country>Poland</Country><Country>Belgium</Country><Country>Sweden</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2020-01-31T00:00:00Z</DateEnd><DateStart>2013-09-30T00:00:00Z</DateStart><Identifiers><Identifier>BIOFLOW-IV</Identifier><Identifier>C1204</Identifier><Identifier>NCT01939249</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Xience Prime/Xience Xpedition drug eluting stent alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Biotronik Orsiro drug eluting stent system alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>585</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>either visually or by online QCA Target lesion length is&amp;lt;/= 26 mm (assessed either visual estimate or by online QCA) and can be covered by one study stent Single &lt;b&gt;de&lt;/b&gt; novo lesion with &amp;gt;/= 50 and&amp;lt; 100% stenosis in up to two coronary arteries...the Biotronik Orsiro drug eluting stent system with the Xience Prime/Xience Xpedition (Xience) drug eluting stent system in &lt;b&gt;de&lt;/b&gt; novo coronary lesions. The study is powered for non-inferiority with respect to Target Vessel Failure (TVF) at 12 months</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Target lesion failure (TLF)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization - Target vessel failure after stent placement</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BIOFLOW-IV: Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - De novo lesion/lesions</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - Target lesion measurements by visual estimation in coronary angiogram</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-03-23T00:00:00Z</PrimaryCompletionDate><TrialDuration>76 Months</TrialDuration><NumberOfSites>45</NumberOfSites><ContactNames><Name>Shigeru Saito, MD</Name><Name>Ton Slagboom, MD</Name></ContactNames></Trial><Trial Id="234304"><Indications><Indication>Lung disease</Indication></Indications><CompaniesCollaborator><Company>Baxter Healthcare Corp</Company><Company>Instituto de Investigación Biomédica de Salamanca</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundación Instituto De Estudios De Ciencias De La Salud De Castilla Y León</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2018-10-30T00:00:00Z</DateChangeLast><DateEnd>2019-05-31T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>HEMOPATCH/FAP/2014</Identifier><Identifier>NCT02491671</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard preventive measures alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Hemopatch alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>276</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this research is to investigate the effect of routine application of a novel tissue sealant in patients selected on the basis of a high risk of PAL estimated before surgery. The investigators hypothesize that one of the main reasons for tissue sealants to prevent Prolonged Air Leak (PAL) after lung resection procedures is the heterogeneity of previously studied populations.</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection</TitleDisplay><PrimaryCompletionDate type="Anticipated">2019-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Ana-Isabel Blanco</Name><Name>Ana-Isabel Blanco, M.D.</Name><Name>Ana-Isabel Blanco, MD</Name><Name>David Sánchez</Name><Name>David Sánchez, Ph.D.</Name><Name>Florentino Hernand</Name><Name>Florentino Hernando, Ph.D.</Name><Name>Gonzalo Varela, MD PhD FETCS</Name><Name>Laura Sánchez</Name><Name>Laura Sánchez, Ph.D.</Name><Name>Marcelo F. Jimenez, MD PhD FETCS</Name><Name>Marcelo F. Jiménez</Name><Name>Marcelo F. Jiménez, MD PhD FECTS</Name><Name>Nicolás Moreno</Name><Name>Nicolás Moreno, Ph.D.</Name></ContactNames></Trial><Trial Id="92063"><Indications><Indication>Stage III melanoma</Indication><Indication>Stage IV melanoma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Raf B protein kinase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>MEK protein kinase inhibitor</Action><Action>MEK-1 protein kinase inhibitor</Action><Action>MEK-2 protein kinase inhibitor</Action><Action>Raf B protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company><Company>Genentech Inc</Company><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Turkey</Country><Country>US</Country><Country>Australia</Country><Country>Sweden</Country><Country>Finland</Country><Country>Austria</Country><Country>Brazil</Country><Country>Liechtenstein</Country><Country>Iceland</Country><Country>Hungary</Country><Country>Italy</Country><Country>Norway</Country><Country>Croatia</Country><Country>Belgium</Country><Country>Argentina</Country><Country>Czech Republic</Country><Country>New Zealand</Country><Country>Germany</Country><Country>Israel</Country><Country>UK</Country><Country>Switzerland</Country><Country>Canada</Country><Country>Russian Federation</Country><Country>Denmark</Country><Country>Netherlands</Country><Country>France</Country><Country>Spain</Country></Countries><DateChangeLast>2019-07-03T00:00:00Z</DateChangeLast><DateEnd>2019-12-28T00:00:00Z</DateEnd><DateStart>2013-01-09T00:00:00Z</DateStart><Identifiers><Identifier>2012-003008-11</Identifier><Identifier>AT::GO28141</Identifier><Identifier>CZ::GO28141</Identifier><Identifier>DE::GO28141</Identifier><Identifier>DRKS00004509</Identifier><Identifier>ES::GO28141</Identifier><Identifier>GB::GO28141</Identifier><Identifier>GO28141</Identifier><Identifier>HU::GO28141</Identifier><Identifier>NCT01689519</Identifier><Identifier>SE::GO28141</Identifier><Identifier>UKCRN 13621</Identifier><Identifier>coBRIM</Identifier></Identifiers><IndicationsAdverse><Indication>Alopecia</Indication><Indication>Arthralgia</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Hyperkeratosis</Indication><Indication>Nausea</Indication><Indication>Neoplasm</Indication><Indication>Retinopathy</Indication><Indication>Skin photosensitivity disorder</Indication><Indication>Squamous cell carcinoma</Indication><Indication>Sunburn</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>vemurafenib alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including cobimetinib , vemurafenib , vemurafenib + cobimetinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>495</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This multicenter, randomized, double-blind, placebo-controlled, phase III study was to evaluate the safety and efficacy of vemurafenib alone and vemurafenib in combination with cobimetinib in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma [ 1697857 ], [ 1700698 ], [ 1712146 ], [ 1712333 ], [ 1598501 ], [ 1744784 ], [ 1769157 ], [ 1766169 ]. The primary objective of the trial was to evaluate the efficacy of vemurafenib in combination</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Melanoma - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Melanoma - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Melanoma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Melanoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Melanoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Melanoma - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Melanoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Melanoma - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate</EndpointIndex><EndpointIndex>Melanoma - Assessment of adverse events</EndpointIndex><EndpointIndex>Melanoma - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Melanoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Melanoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EuroQol (EQ-5D)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>coBRIM: A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma</TitleDisplay><PatientSegmentTerms><PatientSegment>Melanoma - Subjects with Advanced/Metastatic Cancer</PatientSegment><PatientSegment>Melanoma - Subjects with Stage III Melanoma - Subjects with stage IIIC melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with Stage IV Melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with Surgically Non-resectable Melanoma</PatientSegment><PatientSegment>Melanoma - Subjects with gene variants - BRAF_HUMAN_Mutation(codon600)</PatientSegment><PatientSegment>Melanoma - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> B-Raf proto-oncogene serine/threonine-protein kinase </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Skin </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-05-09T00:00:00Z</PrimaryCompletionDate><TrialDuration>83 Months</TrialDuration><NumberOfSites>474</NumberOfSites><ContactNames><Name>Clinical Trials</Name><Name>Country Head Clin Ops Italy</Name><Name>James Larkin</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="177158"><Indications><Indication>Coronary atherosclerosis</Indication></Indications><CompaniesSponsor><Company>Boston Scientific Corp</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>US</Country><Country>France</Country><Country>Netherlands</Country><Country>Latvia</Country><Country>Belgium</Country><Country>Spain</Country></Countries><DateChangeLast>2018-05-20T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01419171</Identifier><Identifier>OMEGA</Identifier><Identifier>S2215</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Omega Monorail Coronary Stent System alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>328</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Subject is willing to comply with all protocol-required follow-up evaluations Angiographic Inclusion Criteria: Target lesion must be a &lt;b&gt;de&lt;/b&gt; novo lesion located in a native coronary artery with a visually estimated reference vessel diameter (RVD) &amp;gt;/= 2.25... The purpose of this study was to evaluate the safety and effectiveness of the Omega coronary stent system for the treatment of subjects with a &lt;b&gt;de&lt;/b&gt; novo atherosclerotic coronary artery lesion.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Cardiovascular Events - Assessment of myocardial infarction</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Mortality/Death Rates - Assessment of non-cardiovascular mortality</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Therapy Related Outcomes - Assessment of target vessel revascularization (TVR)</EndpointIndex><EndpointIndex>Atherosclerosis - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)</EndpointIndex><EndpointIndex>Atherosclerosis - Protocol Specified Other Endpoints - Assessment of stent related events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Target lesion failure (TLF)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Procedure and Procedure Related Events - Procedural success</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization - Target vessel failure after stent placement</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Stent thrombosis (Definite /Probable /Possible)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Assessment of target lesion revascularization (TLR)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Vascular Indices or Parameters - Target vessel revascularization (TVR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OMEGA: The Omega Clinical Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Atherosclerosis - Subjects Scheduled for Specific Procedures - Subjects scheduled for coronary artery bypass graft surgery (CABG)</PatientSegment><PatientSegment>Atherosclerosis - Subjects with History of/Undergoing Specified Procedures - Subjects with history of/undergoing percutaneous intervention</PatientSegment><PatientSegment>Atherosclerosis - Subjects with comorbid conditions - Subjects with cardiovascular diseases/disorders</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention - On pump coronary artery bypass grafting (CABG)</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - De novo lesion/lesions</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Angiographic Findings - Target lesion measurements by visual estimation in coronary angiogram</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Myocardial Ischemia</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Specified Thrombolysis in Myocardial Infarction (TIMI) Flow Grades - TIMI Flow Grade 2</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Specified Thrombolysis in Myocardial Infarction (TIMI) Flow Grades - TIMI Flow Grade 3</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Stable Coronary Artery Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>48</NumberOfSites><ContactNames><Name>Albert Deibele</Name><Name>Didier Carrie</Name><Name>Edouard Benit</Name><Name>Hans Bauer</Name><Name>Kathleen Allen</Name><Name>Mudassar Ahmed</Name><Name>Peter Maurer, MPH</Name><Name>Pierre Coste</Name><Name>Quang Bui</Name><Name>Thom Dahle</Name></ContactNames></Trial></SearchResults></trialResultsOutput>